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ASSOCIATION OF GLUTATHIONE TRANSFERASE A1, M1, P1 AND T1 
POLYMORPHISM WITH OXIDATIVE STRESS BYPRODUCTS AND 
CARDIOVASCULAR COMPLICATIONS IN PATIENTS WITH END-STAGE 
RENAL DISEASE 
Summary 
Chronic kidney disease is described as a progressive and irreversible deterioration in kidney 
function. When there is less than 10% of nephron function pertained, the patients face end-
stage renal disease where renal replacement therapy is needed. Data show that hemodialysis is 
the most common method used to treat advanced and permanent kidney failure. Increased 
oxidative stress is a hallmark of end-stage renal disease (ESRD). Glutathione transferases 
(GST) are involved in the detoxification of xenobiotics and protection of oxidative damage. 
The role of polymorphic expression of GSTSs in end-stage renal disease development 
enhanced oxidative stress and prognosis of ESRD patients has emerged recently.  
The aim of this study was to test if the genetic polymorphism in antioxidant enzymes GSTA1, 
GSTM1, GSTP1 and GSTT1 is more frequent in ESRD patients than in control group, and if it 
modulates the levels of oxidative stress byproducts and cellular adhesion molecules in these 
patients. The association between GSTM1 and GSTT1 deletion polymorphisms as well as 
SNPs in GSTA1/rs3957357, GSTP1/rs1695 and rs1138272 genes with overall and cause-
specific cardiovascular mortality in patients with end-stage renal disease was also assessed. 
Furthermore, the predictive role of oxidative stress byproducts and adhesion molecules level 
was also tested.  
Individuals with either GSTM1-null or GSTP1*C/*T genotypes were at increased susceptibility 
towards ESRD development than individuals with GSTM1-active or GSTP1*C/*C genotypes 
(OR = 1.6, p = 0.024 and OR = 3.2, p = 0.001, respectively). This risk was even more 
increased when these genotypes were combined with other GST null/low activity genotypes. 
Polymorphic expression of GST gene influences the vulnerability to protein and lipid 
oxidation, as well as the levels of soluble cellular adhesion molecules in plasma of ESRD 
patients. The oxidative stress byproducts were even more increased in terms of combined GST 
 
 
genotypes. Regarding predictive role of GST genotypes, only GSTM1-null genotype in ESRD 
patients was found to be independent predictor of overall and cardiovascular mortality (overall: 
HR = 1.8, p = 0.009; cardiovascular: HR = 2.3, p = 0.006 and myocardial infarction: HR = 
2.3, p = 0.035). Possible predictive role for the byproducts of oxidative stress was found for 
higher concentrations (above the median for each product) of MDA, AOPP, PAB and 
VCAM-1 regarding overall and cardiovascular survival. Comparison of two endothelial cells 
with different GSTM1 genotypes in terms of monocyte adhesion and reactive oxygen species 
production after incubation in uremic serum was not significantly different. 
Taken together, the results presented in this study suggest a possibility for GST genotype-
based stratification of ESRD patients which could improve the attempts towards 
individualization of antioxidant treatment. Besides, determination of oxidative stress 
byproducts may permit the targeting of preventive and early intervention in high-risk patients 
to reduce their cardiovascular risk. 
Keywords: end-stage renal disease; glutathione S-transferases polymorphism; hemodialysis; 
oxidative stress; adhesion molecules 
Research area: Medicine 
Research field: Biochemistry 
 
 
POVEZANOST POLIMORFIZAMA GLUTATION TRANSFERAZA A1, M1, P1 I T1 
SA POKAZATELJIMA OKSIDATIVNOG STRESA I KARDIOVASKULARNIM 
KOMPLIKACIJAMA KOD BOLESNIKA SA TERMINALNOM BUBREŽNOM 
SLABOŠĆU 
Sažetak 
Hronična bubrežna slabost se opisuje kao progresivno i ireverzibilno smanjenje bubrežne 
funkcije. Kada se funkcija bubrega smanji na ispod 10% od normalnih vrednosti, nastupa 
stanje koje se zove terminalna bubrežna slabost kada je neophodna primena terapije neke od 
meoda zamene bubrežne funkcije. Podaci pokazuju da je hemodijaliza najčešće primenjivan 
metod. Povećana produkcija slobodnih radikala i stanje oksidativnog stresa glavna su obeležja 
terminalne bubrežne slabosti. Glutation transferaze (GST) su enzimi koji su uključeni u 
procese eliminacije ksenobiotika i antioksidativne zaštite. Ipak do sada još uvek nije dovoljno 
ispitana njihova uloga u podložnosti za razvoj terminalne bubrežne slabosti, oksidativnog 
stresa kod ovih bolesnika kao i moguća prediktivna uloga. 
Imajući ovo u vidu, cilj ove teze bio je da se ispita veza između polimorfizama gena za GSTA1, 
GSTM1, GSTP1 i GSTT1 u podložnosti za razvoj terminalne bubrežne slabosti, kao i da se 
utvrdi da li polimorfna ekpresija glutation transferaza utiče na vrednosti produkata 
oksidativnog stresa i adhezionih molekula u plazmi bolesnika sa terminalnom bubrežnom 
slabošću. Takođe, jedan od ciljeva bio je i da se ispita da li polimorfizam GST gena može da 
ima prognostički značaj u smislu opšteg ili kardiovaskularnog preživljavanja kod ovih 
bolesnika. Dodatno, ispitan je i prediktivni značaj biohemijskih pokazatelja oksidativnog stresa 
i adhezionih molekula.  
Osobe koje su imale GSTM1-nulti i GSTP1*C/*T genotip imale su veću podložnost za razvoj 
terminalne bubrežne slabosti (OR = 1.6, p = 0.024 and OR = 3.2, p = 0.001, redom), koja je 
još više bila izražena kada su se ovi genotipovi kombinovali sa drugim GST nultim ili 
genotipovima smanjenih aktivnosti. Takođe, polimorfna ekspresija glutation transferaza kod 
bolesnika sa terminalnom bubrežnom slabošću utiče na nivo oksidativnog oštećenja proteina, 
lipida i adhezionih molekula. Produkti oksidativnog stresa su još više izraženi kod bolesnika 
 
 
kod kojih postoji kombinacija GST nultog ili genotipova smanjenih aktivnosti. U ovoj tezi je 
pokazano i da GSTM1-nulti genotip ima značajnu ulogu kao prediktor opšteg i 
kardiovaskularnog uzroka smrti (opšti uzrok smrti: HR = 1.8, p = 0.009; kardiovaskularni 
uzrok: HR = 2.3, p = 0.006 i infarct miokarda: HR = 2.3, p = 0.035). Takođe, pokazano je i da 
više vrednosti (iznad nivoa medijane vrednosti određene za svaki produkt pojedinačno) MDA, 
AOPP, PAB i VCAM-1 imaju prognostički značaj kod opšteg i kardiovaskularnog preživljanja 
u bolesnika sa terminalnom bubrežnom slabošću. Produkcija slobodnih radikala i adhezija 
monocita za endotelne ćelije nije se razlikovala između HUVEC sa GSTM1-aktivnim i GSTM1-
nultim genotipom. 
Rezultati iz ove teze ukazuju da bolesnici sa terminalnom bubrežnom slabošću mogu da se 
stratifikuju prema GST genotipu sa ciljem unapređenja antioksidantne terapije. Takođe, 
merenje produkata oksidativnog stresa može da posluži da se odredi kod kojih bolesnika treba 
započeti rane preventivne mere da bi se smanjio rizik od kardiovaskularnih komplikacija.  
Ključne reči: terminalna bubrežna slabost, glutation transferaze, polimorfizam, hemodijaliza, 
oksidativni stres, ćelijski adhezioni molekuli 
Naučna oblast: Medicina 
Uža naučna oblast: Medicinska biohemija 
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1 INTRODUCTION 
 
1.1 CHRONIC KIDNEY DISEASE AND END-STAGE RENAL DISEASE 
Chronic kidney disease (CKD), is described as a progressive and most frequently 
irreversible deterioration in kidney function in which the body’s ability to maintain metabolic, 
fluid and electrolyte balance fails, resulting in retention of urea and other nitrogenous wastes in 
the blood. Patients with chronic kidney disease have gradual loss of kidney function. 
Definition of CKD and international classification are introduced in National kidney 
foundation Disease Outcomes Quality Initiative criteria (“The National Kidney Foundation 
Kidney Disease Outcomes Quality Initiative (NKF KDOQI),” 2014) According to KDOQI 
criteria, the disease is divided into five stages based on increasing severity and glomerular 
filtration rate (Table 1.). Adverse outcomes of CKD can be prevented through early detection 
and treatment. Early stages can be detected by biochemical analysis including creatinine-based 
estimate of glomerular filtration rate (GFR) (Levey 1999). Criteria for CKD include GFR < 60 
mL/min/1.73 m2 for 3 months, irrespective of the presence or absence of kidney damage. As 
kidney function declines, the end products of protein metabolism accumulate in the blood 
resulting in uremia development. This adversely affects every system in the body. The greater 
the production of waste products, the more severe the symptoms are.  
End-stage renal disease (ESRD) occurs when there is less than 10% of nephron 
pertained function remaining. End-stage renal disease represents severe kidney damage, 
measured by the reduction in the glomerular filtration rate to ˂ 15 ml/min/1.73 m2. At this 
stage affected patients require dialysis or a kidney transplant. All of the normal regulatory, 
excretory and hormonal functions of the kidney are severely impaired. 
Thus at this stage many exogenous and endogenous metabolites are accumulated, 
together with various uremic toxins in that way contributing to redox moiety and impaired 
antioxidant protection in patients on hemodialysis (Mimić-Oka et al., 1999). 
 
 
GST Polymorphisms in ESRD Patients  
 
 
2 
 
Table 1. Stages of chronic kidney disease with glomerular filtration rate (GFR), short 
description and treatment options. 
Stage GFR Description Treatment 
1 > 90 
Normal kidney function but urine findings or structural 
abnormalities or genetic trait point to kidney disease  
Observation, blood 
pressure control 
2 60 - 89 
Mildly reduced kidney function, and other findings (as 
for stage 1) point to kidney disease  
Observation, control of 
blood pressure and risk 
factors.  
3 30 - 59 Moderately reduced kidney function 
Observation, control of 
blood pressure and risk 
factors  
4 15 - 29 Severely reduced kidney function 
Planning for endstage 
renal failure 
5 < 15 Very severe, or end-stage renal failure Dialysis or transplantation 
   Adapted from NKF-NDOQI CKD guidelines (“The National Kidney Foundation Kidney Disease Outcomes Quality  
Initiative (NKF KDOQI),” 2014) 
Chronic kidney disease represents a major public health problem all over the world. In 
U.S. of America every 10th adult is affected with chronic kidney disease (Plantinga et al., 2008) 
while in other countries this problem is of similar magnitude. Worlwide, situation is very 
similar. Namely, around 11% of world population suffers from some stage of chronic kidney 
disease. There are disturbing data showing that incidence of end stage renal disease is 
progressively growing worldwide in the last two decades with over two million affected 
individuals in the world and approximately 650,000 in the Europe (Bello et al., 2005). 
According to the national dialysis register there are almost 6000 people in Serbia treated with 
some type of renal replacement therapy (RRT). Incidence of ESRD in Serbia was also growing 
in the last decade, rising from 107 to 189 patients per million individuals. It is important to 
note that Serbia is among the European countries with higher incidence of ESRD (Ing et al., 
2012). There are at least two reasons for CKD to be considered as a serious condition: the first 
one is that these patients are at greater risk to develop cardiovascular complications, tumors 
and chronic infections; the second one is that majority of CKD patients will develop ESRD, 
the fifth stage of CKD, where renal replacement therapy is needed.  
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1.1.1 Causes of CKD 
The main causes of CKD include: diabetes mellitus, hypertension and glomerulonephritis 
(ERA-EDTA annual reports, 2014). These three conditions are responsible for almost 70% of 
all CKD cases. Among other causes that may affect the renal function are: 
 Hereditary diseases such as polycystic kidney disease, in which large cysts forming in 
the kidneys are damaging renal tissue. 
 Malformations that occur during fetal development. 
 Lupus and other diseases that affect the immune system. 
 Obstructions (kidney stones, tumors or an enlarged prostate gland in men). 
 Repeated urinary infections. 
Apart from these well established causes, other factors may contribute to development and 
progression of renal failure including age, poverty, small gestational mass, and certain ethnic 
groups. Other factors that influence the progression of chronic kidney disease are smoking, 
diabetes, hypertension and obesity.  
1.1.2 Treatment of end-stage renal disease 
When glomerular filtration rate is below 15 ml/min/1.73 m2 a renal replacement 
therapy should be considered. Data from Fresenius medical care network show that 
hemodialysis (HD) is the most common method used to treat advanced and permanent kidney 
failure (Grassman et al., 2005). Namely, from estimated 1.3 million patients in the world who 
received some form of renal replacement therapy, almost 89% received hemodialysis and 11% 
received peritoneal dialysis (Grassmann et al., 2005). 
Hemodialysis is usually performed three times per week in 3-5 hours duration.  
Standard blood drawn rate is about 200-400 ml/min. During the treatment, the patient's entire 
blood volume (about 5 L) circulates through the machine every 15 minutes. Original cotton 
(also called “natural”) dialyzer membranes were replaced with synthetic polysulfone “high 
flux” membranes that showed better biocompatibility. Dialysate acetate-based buffer is now 
replaced with the mixture of bicarbonates and acetic acid which showed many advantages 
regarding acid-base status of patients and impact on metabolism (Desai, 2015).  
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1.2 END STAGE RENAL DISEASE AS A STATE OF REDOX IMBALANCE 
Patients affected with different stages of chronic kidney disease, especially patients with 
end-stage renal disease on chronic hemodialysis treatment, exhibit a huge burden of oxidative 
and inflammatory processes that lead to imbalance in redox homeostasis. This imbalance is 
shown to lead these patients to elevated risk of mortality and morbidity.  
1.2.1 Oxidative stress 
Oxidative stress is commonly defined as “a disturbance in the pro-oxidant–antioxidant 
balance in favor of the former.” (Sies, 1991) (Figure 1). However, since data have shown that 
balance of pro-oxidants and antioxidants cannot be defined by a single entity, a new definition 
which defines oxidative stress as “a disruption of redox signaling and control.” is introduced 
(Jones, 2006).  
 
 
 
 
 
 
 
 
Figure 1. When free radicals production exceeds antioxidant defences, an oxidative stress 
developes. Free radicals attack and oxidise macromolecules such as lipids lipids, proteins, and 
nucleic acids consequently leading to tissue injury and in some cases, the influx of 
inflammatory cells to the sites of injury. Adapted from (Sies, 1991) 
Reactive oxygen species (ROS) are a family of molecules that are produced in all 
aerobic cells. They possess unpaired electrons and are highly reactive. In physiological 
conditions ROS are continuously generated as products of cellular respiration and enzymatic 
reactions (xanthine oxidase, myeloperoxidase, NO synthase, cyclooxygenase, lypooxygenase). 
Oxidative damage
Lipids   proteins  nucleic acids
Tissue injury Inflammation
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Thus, ROS are physiologically produced in mitochondria, but could be synthesized in 
phagocytic cells, as well as, in vascular wall and many other tissues (Valko et al., 2007). ROS 
include radicals such as superoxide ion radical (O2
.-), hydroxyl radicals (OH.), lipid 
hydroperoxides and non-radicals such as singlet oxygen (1O2), hydrogen peroxide (H2O2), 
hypochlorus acid (HOCl), chloramines (RNHCl) and ozone (Bedard and Krause, 2007). 
Besides ROS, reactive nitrogen species (RNS) also occur. They include nitric oxide radical 
(NO.), nitrogen dioxide radical (NO2), peroxynitrite (ONOO-) and dinitrogen trioxide (N2O3). 
Reactive species, both oxygen and nitrogen ones, have many important roles including signal 
transduction, eliminating of invading pathogens, wound healing and tissue repair. 
Although normally produced, amounts of free radical may surmount cellular 
antioxidant capacity resulting in oxidative stress. However, once the production of both ROS 
and RNS exceeds antioxidant defense system these free radicals start to react with 
macromolecules such as proteins, lipids, carbohydrates and nucleic acids resulting in their 
irreversible damage and loss of function. Exogenous factors leading to excessive free radical 
production are pollutants, radiation, cigarette smoking, drugs and xenobiotics. Many clinical 
conditions caused by inflammation are prone to oxidative stress development (Yamakura and 
Kawasaki, 2010) and a growing body of evidence suggests that oxidative stress is involved into 
pathogenesis of numerous diseases with cardiovascular one being the most prevalent (Dhalla et 
al., 2000).  
1.2.2 Evolution of oxidative stress in the course of ESRD development 
Oxidative stress represents a hallmark of end-stage renal disease. As renal disease is 
progressing and ESRD is developing, higher levels of free radical production have been 
reported (Mimic-Oka et al., 1992). An increased redox burden in uremic patients leads to 
oxidation of protein, lipids and carbohydrates. In hemodialysis patients many factors 
contribute to increased production of free radicals on one side and decreased antioxidant 
capacity on the other side, leading to development of well defined concept of oxidative stress. 
Furthermore, these patients have an electrolyte imbalance, high concentrations of cytokines 
and inflammatory mediators. Moreover, these patients are usually under treatment in order to 
correct anemia and different metabolic disorders. However, it is believed that main causes of 
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oxidative stress in hemodialysis patients represent accumulation of uremic toxins, 
bioincompatibility with dialyzer, and dialysate contaminants.  
1.2.2.1 Loss of Antioxidants 
Both in chronic kidney disease and during hemodialysis sessions, a massive production 
of ROS and oxidatively modified lipids and proteins is described, contributing to huge oxidant 
burden in these patients (Locatelli et al., 2003). However, not only the excessive free radical 
production is responsible for systemic redox stress of this population. Patients undergoing 
hemodialysis deal with impaired antioxidant capacity, and the mechanisms leading to such a 
state have been relatively well described (Dursun et al., 2002). It was reported that erythrocyte 
antioxidant capacity increases with the progression of CKD while ESRD patients undergoing 
hemodialysis have defective antioxidant activity (Mimić-Oka et al., 1999). Namely, Karamouzis 
et al. have observed that only in patients with end-stage renal failure the levels of total 
antioxidant enzyme capacity (TAC) are decreased, which is not the case with other stages of 
CKD (Karamouzis et al., 2008). Reduced erythrocyte superoxide dismutase (SOD) and 
glutathione peroxidase (GPX) activity have been reported in patients with ESRD (Yilmaz et 
al., 2006). The GPX and SOD activity are shown to decrease in term of CKD progression with 
the lowest level observed in the fifth stage of CKD (Mimić-Oka et al., 1999). It seems that 
intravenous administration of heparin can displace extracellular SOD from endothelial cells 
(Faraci and Didion, 2004). Since extracellular SOD is an important determinant of nitric oxide 
bioavailability in endothelial cells, any loss of this enzyme would therefore affect normal 
endothelial function (Fukai et al., 2002). Mimic-Oka et al have also described significantly 
lower plasma catalase activity, associated with higher hydrogen peroxide production in ESRD 
patients (Mimić-Oka et al., 1999). 
Even non-enzymatic defense systems are affected in ESRD patients. Namely, dialysis 
procedure itself contributes to the loss of vitamin C, major non-enzymatic antioxidant 
molecules (Deicher et al., 2005). There are evidence that low plasma vitamin C level may be 
useful in prediction of both fatal and non-fatal cardiovascular events among maintenance 
haemodialysis patients (Deicher et al., 2005). Additionally, Takahashi et al have shown that low 
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vitamin C levels can affect endothelium-dependent vasodilatation and contribute to endothelial 
dysfunction and atherosclerosis process (Taddei et al., 1998).  
Regarding glutathione, a major low-molecular-mass thiol compound participating in 
cellular redox reactions and thio-ether formation, it should be emphasized that its content is 
also diminished in HD patients (Ceballos-Picot et al., 1996). Glutathione levels are decreased 
in both plasma (Ross et al., 1997) and erythrocytes in patients affected with ESRD (Francesco 
Galli et al., 1999).  
1.2.2.2 Uremic toxins 
Patients with ESRD have an accumulation of more than hundred uremic solutes with 
potential pro-oxidant activity and toxicity. Knowledge of uraemic toxicity has grown very 
much during past years and the interest for them increased enormously. Based on their 
physicochemical characteristics, uremic retention solutes may be categorized into three groups: 
free water-soluble low molecular weight compounds, middle molecules and protein-bound 
uremic toxins (Duranton et al., 2012; Meert et al., 2007) (Table 2). The first one comprises the 
free water-soluble compounds such as urea, uric acid, myoinositol, oxalate, guanidino 
compounds and polyamines. On the other hand, indoxyl sulfate, indole-3-acetic acid, and p-
cresol represent some of the compounds belonging to the group of protein-bounded uremic 
solutes which have been associated with endothelial dysfunction and cardiovascular disease 
development (Dou et al., 2015, 2004; Gondouin et al., 2013; Schulz et al., 2014). 
Among uremic toxins identified in plasma of HD patients, indoxyl sulfate is mostly 
studied. Like all indolic uremic toxins, it is generated by gut bacteria metabolism of tryptophan 
(Schepers et al., 2010; Vanholder and Glorieux, 2015). Taki et al have shown that serum levels 
of indoxyl sulfate are increased in HD patients, contributing to endothelial dysfunction, and 
atherosclerosis progression (Taki et al., 2007). Furthermore, indoxyl sulfate has been shown to 
increase the expression of ICAM-1 and contributes to development of cardiovascular 
complications (Tumur et al., 2010). Uremic toxins present in the serum of patients with CKD 
alter endothelial cell properties in vitro by accelerating apoptotic processes in a dose dependent 
manner (Zafeiropoulou et al., 2012). 
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Table 2. Classification of uremic solutes/toxins 
Uremic toxins 
Small hydrophilic 
compounds 
Middle molecules 
Protein-bound uremic 
toxins 
 Urea  IL-6, IL-1β  p-cresyl sulfate 
 Uric acid  TNF-α  Indoxyl-sulfate 
 Guanidine  Leptin  Indole-3-acetic acid 
 Oxalate  Resistin  Homocystein  
 ADMA  Endothelin  Pentosidin  
  AOPP  AGEs 
 
Indoxyl sulfate is also able to induce mitochondrial depolarization and cell death (Lee 
WC et al., 2014). A recent study conducted by Dou et al reported that indole-3 acetic acid 
(IAA), another uremic toxin found in serum, is associated with mortality and cardiovascular 
events in patients with CKD. (Dou et al., 2015). They have also demonstrated that IAA is able 
to induce oxidative stress and inflammatory response by activating AhR/p38MAPK/NF-κB 
pathway in vascular endothelial cells in vitro (Dou et al., 2015).  
1.2.2.3 Bioincompatibility of hemodialysis treatment 
Although hemodialysis has many beneficial aspects, process itself is also able to 
provoke inflammatory reactions. An example of this is the inflammatory response due to 
bioincompatibility of dialysis membrane. Indeed, it is believed that bioincompatibility has a 
central role in oxidative stress development. From the first observation in the far 1968 that 
early phase of dialysis leads to significant drop of neutrophil leukocyte count (Kaplow and 
Goffinet, 1968) researchers focused on these phenomena and in years to come found an 
explanation. Craddock et al. suggested the complement activation as the main factor for 
neutrophil aggregation (Craddock et al., 1977) while it was later explained that alternate 
pathway leads to C3a and C5a production (Chenoweth et al., 1983) where these two 
anaphylatoxins stimulate cytokine synthesis and release from monocytes (Fischer et al., 1999). 
In this process a contact of the cells with dialysis membrane leads to activation of L-fucose 
dependent pathway (Betz et al., 1988). Fortunately, synthetic membranes are available in the 
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most dialysis centers around the world and the consequences are minimized nowdays. In 
addition, in some developed countries vitamin E-coated membranes are predominantly used 
place due to proven benefits on patients’ survival and cardiovascular complications have been 
observed with the use of these membranes (Lin et al., 2009; Mune et al., 1999). 
1.2.3 Markers of oxidative stress in patients with end-stage renal disease 
Direct measurement of reactive oxygen and nitrogen species in vivo is very difficult due 
to the highly reactive nature of free radicals. Some techniques such as L-band electron spin 
resonance with nitroxyl probes and magnetic resonance imaging spin trapping are under 
development to measure free radicals directly in animal models (Han et al., 2001; Utsumi and 
Yamada, 2003). However, their application in human studies is still under investigations. Due 
to the fact of very short half-life of ROS, their concentration is changing in seconds, 
additionally compromising their determination. In attempt to overcome these difficulties, 
methods for determination of stable end-products of macromolecules’ oxidation are 
introduced (Table 3). Oxidative modifications of biological macromolecules (proteins, lipids, 
DNA and carbohydrates) are excessively modified by ROS production in vivo. Their 
byproducts’ concentrations are measured in different samples (plasma, serum, cell lysate, tissue 
homogenate) and are able to reflect degree of oxidative stress in different pathologies. 
Table 3. Byproducts of oxidative damage measured in plasma or urine 
Byproducts of oxidative damage 
Proteins Lipids DNA 
 Thiol (-SH) groups  MDA  8-OH-deoxyguanosine 
 Carbonyl groups  MDA-adducts  5-OH-methyl uracil 
 AOPP  F2-isoprostanes  
 Nitrotyrosine  4-HNE  
 AGEs   
AOPP-advanced oxidation protein products; AGEs-advanced glycation end products; MDA-malondialdehyde 
Proteins are very prone to oxidative damage. Indeed, protein modifications by ROS include 
hydroxylation of aromatic and aliphatic amino acids residues, nitrosylayion of sulphhydryl 
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groups, chlorination of aromatic amino acids which result in formation of protein carbonyls, 
nitrotyrosine derivatives and many inter-moleculear cross-links (Galli 2007). Indeed, the most 
important protein oxidative damage byproducts are (a) protein thiol content (b) protein 
carbonyls tyrosine damage byproducts (c) advanced oxidation protein products (AOPP) (d) 
nitrotyrosine (e) advanced glycation end-products (AGEs). The significant byproduct of 
protein oxidative damage is the decrease in thiol (SH-) group content. The SH-groups of 
albumins are considered to be sacrificial targets for reaction with free radicals. The residues of 
amino acids Hcy and Cys are forming disulphides in oxidation reactions and are prone to 
further modifications. Loss of thiols has been described in terms of chronic kidney failure 
(Himmelfarb et al., 2002; Mimic-Oka et al., 1992).  
Direct oxidation of Lys, Arg or Thr by ROS leads to formation of protein carbonyls 
(Stadtman and Levine, 2003), another byproduct of protein oxidative damage. Miyata et al 
have shown that protein carbonyls are related to uremic toxicity and introduced the term 
“carbonyl stress” (Miyata et al., 2001). Several studies confirmed that carbonyls content is 
significantly increased in plasma of hemodialysis patients (Galli et al., 2005; Michelis et al., 
2003) and may cause a significant increase in intercellular adhesion molecule-1 and vascular cell 
adhesion molecule-1 mRNA levels (Pavone et al., 2011). Massive accumulation of carbonyls, 
derived from polyunsaturated fatty acuds, sugars and amino acids, has an important role in the 
genesis of advanced glycation end-products (AGEs) (Himmelfarb and McMonagle, 2001). The 
AGEs content has been increased in patients with end-stage renal disease (Floridi et al., 2002; 
Galli et al., 2005; Noordzij et al., 2008) and it is known to contribute to the higher 
cardiovascular risk and mortality (Miyata et al., 1999; Raj et al., 2000).  
Oxidative modifications of tyrosine include production of 3-chloro-tyrosine, 3-nitro-
tyrosine or di-tyrosine (Figure 2). These are very sensitive byproduct of protein damage and are 
increased in patients on maintain hemodialysis (Himmelfarb and McMonagle, 2001). Di-
tyrosine protein modifications and intraprotein cross-link creation have additional role in 
formation of yet another reliable marker of oxidative stress in ESRD patients-AOPP. In HD 
patients levels of AOPP are in correlation with markers of uremia and oxidative stress (Witko-
Sarsat et al., 1998). This byproduct is also able to induce activation of human neutrophil and 
monocyte oxidative metabolism (Witko-Sarsat et al., 2003). Furthermore, increased AOPP 
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level is shown to increase macrophage infiltration in atherosclerotic plaques and in glomeruli in 
the remnant kidney model (Liu et al., 2006). 
 
 
 
 
 
Figure 2. Nitrotyrosine formation during oxidative stress 
Lipids are also affected by oxidative damage (Figure 3). Determination of the extent of 
lipid peroxidation includes measurement of (a) malondialdehyde (MDA) and other aldehydes 
that represent degradation products of lipid peroxidation and are able to react with 
thiobarbituric acid (b) conjugated dienes in LDL particles and (c) F-2 isoprostanes. MDA is a 
three-carbon, low-molecular weight aldehyde that can be produced by different mechanisms. 
Dahle et al. first described a mechanism of MDA formation based on the fact that only 
peroxides that possessed α or β unsaturated bonds capable of undergoing cyclization to finally 
form MDA (Dahle et al., 1962). There is a lack of MDA distribution in the general population 
and their referent concentrations. However, it has been reported that plasma MDA 
concentration is elevated in various diseases including hemodialysis (Nally, 1997) when 
compared to healthy volunteers. Furthermore, the increased level of MDA have been related 
to increased cardiovascular risk (Rumley et al., 2004; Smith et al., 1993). 
 
 
Figure 3. Mechanism of lipid peroxidation 
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Malondialdehyde is able to bind to proteins and form stable adducts, also termed 
advanced lipid peroxidation end products. These modifications may cause both structural and 
functional changes of oxidized proteins. In addition to the fact that byproducts of oxidative 
damage of macromolecules are elevated, it has been shown that their concentrations in ESRD 
patients are further increasing as disease is progressing and GFR is decreasing. For example, 
GFR shows negative correlation with levels of advanced oxidative protein products, AOPP 
(Witko-Sarsat et al., 1998)., MDA (Yilmaz et al., 2006) and F2-isoprostanes (Cottone et al., 
2009). Furthermore, data suggest that elevated oxidative stress byproducts are associated to 
carotid intima media thickness, as a reflection of the atherosclerosis process (Drüeke et al., 
2002). 
1.3 CARDIOVASCULAR DISEASE IN END STAGE RENAL DISEASE 
PATIENTS 
Although dialysis treatment is shown to improve the quality of life as well as the life 
span in patients with ESRD, attempts to decrease morbidity and mortality in this population 
have failed. Namely, these patients have shorter overall survival in comparison to general 
population (Choi et al., 2014). There are data indicating that within 5 years from the beginning 
of hemodialysis treatment, almost half patients will die (Foley et al., 1998). The main cause of 
death is of cardiovascular origin. Indeed, cardiovascular mortality is increased 20-30-fold in 
hemodialysis patients (Foley and Parfrey, 1998). Therefore patients on hemodialysis are prone 
to the development and progression of cardiovascular disease (Go, 2016). Interestingly, studies 
have shown that there is no statistically significant difference in terms of cardiovascular 
complications between patients treated with hemodialysis and peritoneal dialysis (Siamopoulos 
and Elisaf, 1997).  
Cardiovascular diseases (CVD) can be divided into two groups: ischemic and 
nonischemic CVDs. The ischemic group of cardiovascular diseases comprises coronary artery 
disease, ischemic cardiomyopathy, cerebral vascular insult (CVI or stroke) and peripheral 
vascular disease. In the non-ischemic CVD are arrhythmia and valvular heart disease. It is 
noteworthy to mention that the risk of CVD is already increased even in early stages of CKD 
and increases rapidly in later stages where the renal function severely decreases (Vanholder et 
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al., 2005). It seems that with each decrease of 5 ml/min/1.73m3 of GFR the risk of 
cardiovascular death rises for 22% (Hallan et al., 2007). The similar risk was accounted for 
albuminuria, where it was demonstrated that it has even a stronger association with 
atherosclerosis than GFR (Rodondi et al., 2007). Atherosclerosis represents the main 
pathological mechanism in the development of ischemic heart disease, cerebral vascular disease 
and periphery artery disease (Brevetti et al., 2010; Libby, 2002).  
1.3.1 Oxidative stress-endothelial dysfunction-cardiovascular disease triade in end-
stage renal disease patients 
Well-known cardiovascular risk factors (hypertension, diabetes, smoking and 
metabolism disorders) cannot explain that high prevalence of cardiovascular diseases in this 
population, so other non-traditional risk factors, such as endothelial dysfunction and oxidative 
stress have increasingly been studied (Yao et al., 2004). A term of “accelerated atherosclerosis” 
has been introduced in order to explain high burden of CVD complications in patients with 
ESRD. Many questions arise as to which states contribute to such a bad prognosis and many 
studies conducted by different research groups tend to identify risk factors (Burmeister et al., 
2014; Kotur-Stevuljevic et al., 2012). Indeed, specific metabolic, inflammatory and immune 
factors may contribute in multiplications of risk for cardiovascular diseases and mortality.  
Occlusion of the blood vessel by atheroma leads to myocardial infarction or stroke 
development. Atherosclerosis is now considered not only as a problem of lipid accumulation, 
but also as a result of complex inflammatory and oxidative processes. The pivotal role of 
oxidative stress in cardiovascular disease development and progression has been widely studied 
in the last few decades. Many studies showed that increased ROS production affects initiation, 
progression and clinical consequences of CVD (Csányi et al., 2012; Förstermann and Münzel, 
2006; Sugiyama et al., 2004).  
The endothelium has an important role in controlling vascular function. When intact, 
the endothelium produces regulatory molecules which provide anti-atherogenic environment. 
However, any abnormalities occurring may result in development of atherosclerosis. The 
highly reactive species, such as ROS, alter endogenous vasoactive mediators expression of 
endothelium, contributing to atherogenic processes. In further course, ROS oxidize low 
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density lipoproteins to form their oxidized forms (oxLDL), the process which is accepted as 
the most important one in atherogenesis. The oxLDL causes accumulation of cholesterol 
esters in macrophages (Bobryshev, 2006) (Figure 4). Additionally, oxLDL has cytotoxic effect 
and contributes to inhibition of macrophage motility (Collot-Teixeira et al., 2007; Yu et al., 
2013). At this point endothelial cells are activated and will release many cytokines and express 
various receptors. Importantly, the free radicals are not only produced by endothelial cells, but 
also the smooth muscle cells and the adventitial cells (Madamanchi et al., 2005).  
 
 
 
 
 
 
 
 
 
Figure 4. Oxidative stress in atherosclerosis. Free radicals provoke oxidation of LDL and 
monocyte adhesion and migration to subendothelial space. The oxLDL is taken by 
macrophages which become foam cells. The photo was adapted from (Bonomini et al., 2008). 
Intact vascular endothelium plays an essential role in maintaining adequate vascular 
tone and vascular homeostasis. Furthermore, it prevents platelet aggregation and smooth 
muscle cell proliferation. Any alterations affecting endothelial physiology, also known as 
endothelial dysfunction, are shown to play an important role in early step in the development of 
atherosclerosis (Davignon and Ganz, 2004; Mudau et al., 2012; Sitia et al., 2010). Additionally, 
endothelial dysfunction contributes to plaque progression and the occurrence of 
atherosclerotic complications (Hadi et al., 2005). When ROS production exceeds antioxidant 
mechanisms, an excessive lipid peroxidation and protein oxidation occur. This induces cellular 
response reflected by increased vascular endothelium permeability, over-expression of redox 
genes, intracellular calcium overload and DNA fragmentation, resulting in damage to vascular 
smooth muscle cells (VSMCs) and endothelial cells (Dulak et al., 2000). Additionally, when 
Oxidized 
LDL 
Monocyte adhesion 
Adhesion molecules ICAM-1, 
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redox balance is disturbed and fatty acids are oxidized, MDA formation further contributes to 
LDL modifications (Holvoet et al., 1995).  
When trombocytes encounter activated endothelial cells, they secrete monocyte 
chemoattractant protein-1 (MCP-1) which facilitates monocyte adhesion to endothelium and 
plays a crucial role in initiating atherosclerosis by recruiting macrophages and monocytes to the 
vessel wall (Boring et al., 1998). In further actions, expression of vascular cell adhesion 
molecule-1 (VCAM-1), intercellular adhesion molecule-1 (ICAM-1), and platelet–endothelial 
cell adhesion molecule-1 (PECAM-1) is also increased (Blankenberg et al., 2003; Nakashima et 
al., 1998).  
Although the exact mechanism of atherosclerotic changes in uremic patients has not 
been well documented, it has been accepted that endothelium dysfunction is a prominent 
feature of end-stage renal disease. Chronic kidney disease leads to alteration of endothelium 
structure, its properties and function (Hayakawa and Raij, 1999; Kunz et al., 1999). An increase 
in oxidative stress favors endothelial dysfunction by reducing nitric oxide availability and its 
subsequent beneficial effects on vascular function (Lerman and Burnett, 1992). Even a single 
hemodialysis session may favor endothelial dysfunction due to sequestration of nitric oxide 
(NO) and increased levels of ROS (Errakonda et al., 2011).  
Some authors suggested that in uremic patients, elevated values of AOPPs are able to 
provoke endothelial dysfunction and monocyte activation (Marsche et al., 2004; Witko-Sarsat 
et al., 2003). Indeed, AOPP is not only the oxidative stress byproduct but it also has the ability 
to induce both free radical production and vascular inflammation. Namely, Gou et al have 
shown that oxidized proteins are able to activate endothelial cells via RAGE (receptor for 
advanced glycation end products)-mediated signaling pathway (Guo et al., 2008).  
It has been suggested that in inflammatory and pro-oxidant environment in patients 
with ESRD, endothelium is responding by expressing cellular adhesion molecules (ICAM-1 
and VCAM-1) that facilitate the adhesion of leukocytes to the endothelial cells and their 
migration (Gou et al, 2008). It has been shown that TNF-α, an inflammatory marker, induces 
expression of ICAM-1 and VCAM-1 in cultured endothelial cells (Bevilacqua, 1993). 
Furthermore, increased levels of soluble CAMs are elevated in patients undergoing 
hemodialysis and show a positive correlation with von Wilebrand factor, another proposed 
marker of endothelial activation and thrombotic occurrence (Bolton et al., 2001).  
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1.4 GLUTATHIONE TRANSFERASES 
Glutathione transferases (GSTs) (EC 2.5.1.18) are superfamily of enzymes belonging to 
phase II enzymes that play an important role in the detoxification reactions (Hayes et al., 
2005). GSTs catalyze the conjugation of the tri-peptide glutathione (GSH, γ-glutamylcysteinyl-
glycine) with a hydrophobic co-substrate possessing an electrophilic center, in order to 
produce an inactive hydrophilic conjugate which is easily excreted from the body (Figure 5). 
However, several GSTs do not use GSH as substrates but, as cofactors (in e.g. leukotriene 
biosynthesis). 
Members of large GST enzyme family are able to detoxify numerous toxic compounds 
and possess strong antioxidant activity towards reactive oxygen species and peroxides (Habig 
et al., 1974; Hayes et al., 2005). 
 
Figure 5. GST catalyze the GSH conjugation to a xenobiotic which generate GSH-conjugate. 
Photo adapted from (Simic et al., 2009) 
Apart from conjugation with glutathione, GSTs catalyze hormone biosynthesis, 
peroxide breakdown, tyrosine degradation, dehydroascorbate reduction and many other 
reactions (Hayes et al. 2005). Furthermore, GSTs possess non-catalytic activity and the most 
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important one described so far are the role of GSTP1 and GSTM1 in the inhibition of c-Jun N 
terminal kinase (JNK) (Adler et al. 1999). 
1.4.1 Classification of GSTs 
Glutathione S-transferases are classified into three superfamilies: (i) cytoplasmic 
transferases, (the largest family consisting of dimeric and soluble enzymes), (ii) the 
mitochontrial and (iii) the microsomal GSTs. The microsomal GSTs are integral membrane 
proteins, now designated as membrane-associated proteins in eicosanoid and glutathione 
metabolism (MAPEGs). Microsomal GST enzymes are trimeric and membrane-bound and 
they belong to MAPEG superfamily. A classification of GSTs is based upon their protein 
sequence and structure. Cytosolic GSTs consists of seven major classes designated by the 
names of Greek letters and abbreviated in Roman letters: alpha (GST A; five members), mu 
(GST M; five members), pi (GST P; one member), theta (GST T; two members), zeta (GST Z; 
one member), omega (GST O; two members) and sigma (GST S; one member) (Mannervik et 
al., 2005)(Table 4).  
Each class has one or more protein sequences which are numbered using Arabic 
numerals. Amino acid sequence identity is greater than 40% for members of the same GST 
class while GSTs from different classes share less than 25% identity. 
Table 4. Classification of human glutathione transferases based on amino acid sequence 
identity. The table has been adapted from (Hayes et al., 2005) 
GLUTATHIONE TRANSFERASES (GST) 
Cytosolic GST Mitochondria GST Microsomal GST 
Alpha class: A1-1,A2-2, A3-3, A4-4, A5-5 Kappa class: GST K1-1 MGST1 
Mu class: M1-1, M2-2, M3-3, M4-4, M5-5  MGST2 
Pi class: GST P1  MGST3 
Theta: GST T1, T2-2   
Zeta class: GST Z1-1   
Omega class: O1-1, O2-2   
Sigma class: GST S1-1   
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All GST isoenzymes play an important role in the biotransformation of toxic 
compounds and chemical environmental agents (Luo et al., 2011). However, individual GSTs 
have distinct substrate specificities and catalyze different chemical reactions.  
1.4.2 Structure and substrate specificity 
Soluble GSTs function as 50kD dimmers which are formed from subunits within a 
given GST isoenzyme class (Hayes et al., 2005). Dimeric structure of GSTs increases the 
stability and provides a proper structure of the active site that is required for the efficient 
catalysis (Abdalla et al., 2002; Armstrong, 1997). However, there are some evidence of GSTs 
monomer-dimer equilibrium important for protein : protein interactions, described in mitogen 
activated protein kinases (Adler et al., 1999; Cho et al., 2001). 
 
 
Figure 6. Three-dimensional structure of GST with G- and H-domain depicted (A). 
Interaction of glutathione with ββα motif residues of glutathione transferase (B) (adopted from 
(Wu and Dong, 2012)) 
A single GST unit consists of two important domains: (1) an N-terminal α/β-domain 
(G-domain) and (2) an all-α-helical domain (so called H-domain) (Wu and Dong, 2012). The 
G-domain represents a binding site for tripeptide cofactor glutathione (GSH, γ-glutamyl 
cysteinyl-glycine) and it is conserved throughout all classes (Figure 6). The sulfur from 
glutathione is hydrogen bonded to a catalytic residue in the N-terminal end of the protein 
(Atkinson and Babbitt, 2009). This hydrogen bond represents a crucial role in GST catalysis by 
stabilizing the activated GSH (thiolate anion, GS-) (Atkinson and Babbitt, 2009). Some amino-
acid residues found in different GST classes contribute to their substrate heterogeneity: (a) 
A B ββα  
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tyrosine (alpha, mu, pi and sigma class of GSTs) (b) serine (theta and zheta GST class) (c) 
cysteine (omega GST class) (Armstrong 2010).  
The H-domain is, however, not conserved as G-domain and may vary in shape, size 
and biochemical characteristics, influencing enzyme hydrophobicity and electrophilic substrate 
binding (Oakley, 2011). Thus, alpha GST class is known for its ability to catalyze various 
structurally unrelated compounds, including steroids, benzo(a)pyrene dioal epoxides and 
products of lipid peroxidation (Wu and Dong, 2012). Based on its lack of selectivity towards 
substrate, GSTA1-1 is named “promiscuous” (Table 5). 
Table 5. The list of substrates recognized by cytosolic GSTs (adapted from Hayes 2005) 
GST enzyme Preferred substrates 
GSTA1 BCDE, BPDE, chlorambucil, busulfan, DBADE 
GSTM1 BPDE, CDE, DBADE, styrene-7.8-oxide 
GSTT1 Butadiene epoxides, ethylene oxide, EPNP, BCNU 
GSTP1 Acrolein, base propenals, BPDE, CDE, chlorambucil, EA, COMC-6 
BCDE-benzo-chrysene diol epoxide; BCNU 1.3-bis(2-chloroethyl)-1-nitrosourea; BPDE benzo(a)pyrene diol 
epoxide; CDE chrysene-1,2-diol 3,4-epoxide; DBADE dibenzo(a,h)anthracene diol epoxide; DBPDE 
dibenzo(a,l)prene diol epoxide; EA ethacrynic acid; COMC-6 crotonyloxymethyl-2-cyclohexenone; EPNP 1,2-
epoxy-3-(p-nitrophenoxy)propane 
GST mu class possesses much larger active site that recognizes more electrophilic 
compounds such as aflatoxin B1-epoxides and benzopyrene diols (Wu and Dong, 2012). It is 
important to notify that different GSTs have overlapping substrate specificities, sometimes 
resulting in difficulty to identify isoenzymes based only on their catalytic properties. 
1.4.3 Metabolism of exogenous and endogenous compounds by GST 
The reaction catalyzed glutathione transferases consists of nuclephilic addition of the 
sulfur thiolate of glutathione to a wide range of electrophilic compounds (Dourado et al., 
2008) (Dourado 2008). Once the GSH is activated, its nuclepohilic sulfur atom attacks the 
electrophilic compound present in H-site producing glutathione S-conjugate. This conjugate is 
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water-soluble, usually less toxic than the compound from which it originated. Namely, when 
methylen chloride is catalyzed by theta class of GST, more toxic compound formaldehyde, 
with potential cancerogenicity, is generated during this process (Meyer et al., 1991). Upon 
formation, glutathione conjugate is exported from the cells by ATP-dependent transmembrane 
pumps and metabolized via mercapturic acid metabolic pathway forming S-cysteine conjugates 
(Ballatori et al., 2009). Afterwards, all metabolites are excreted via urine or bile (Egner et al., 
2008; Teichert et al., 2009).  
Besides metabolizing various exogenous compounds, glutathione transferases are 
involved in intracellular binding, transport and catalysis of leukotriens, prostaglandins and 
steroid hormones (Hayes et al., 2005). Furthermore, many endogenously formed byproducts of 
oxidative stress are also inactivated by the action of GST. Especially the alpha class of GST 
takes major place in catalyzing phospholipids, fatty acid and cholesterol hydroperoxydes 
(Seeley et al., 2006). Other substrates for alpha class include degradation products of lipid 
peroxidaion, acrolein and 4-hydroxynonenal (Hubatsch et al., 1998). There is evidence that 
some GST exhibit selenium independent glutathione peroxidase activity that contributes to 
antioxidant protection of the cells along with other antioxidant enzymes (Hayes and McLellan, 
1999). Another important role of glutathione transferases, especially omega class, is the 
catalysis of reaction of S-glutathionylation, implicated in protection against oxidative stress and 
protein structure and function (Tew and Townsend, 2011). In the reaction of S-
glutathionylation the conjugation of GSH to low pKa cysteine sulfhydryl or sulfonic-acid 
occurs as a response to oxidative stress (Tew and Townsend, 2011).  
 
1.4.4 Polymorphism of glutathione transferases 
The term genetic polymorphism refers to the difference in the DNA sequence among 
individuals, groups, or populations. Genetic polymorphism presents the recurrence, within a 
population, of two or more discontinuous genetic variants (alleles) of a specific trait in such 
proportions that they cannot be maintained simply by mutation. Certain form of genetic 
variant is considered an allele if its frequency is more than 1% in general population. Sources 
of polymorphism include single nucleotide polymorphism (SNPs), sequence repeats, 
insertions, deletions and recombination. The most common polymorphisms are SNPs (“snip”) 
GST Polymorphisms in ESRD Patients  
 
 
21 
 
where a single base mutation occurs in the DNA. A result of a SNP can be (i) no alteration of 
amino acid in protein sequencing (so called “synonymous” substitution) or (ii) the substitution 
results in an alteration of the encoded amino acid (“non-synonymous” substitution). Some 
SNPs are found in regulatory regions of genes and therefore responsible of changing the 
amount of a protein's synthesis. However, deletion polymorphisms are not rare. By this type of 
polymorphism it is considered a complete lack of a functional gene which results in an absent 
protein transcript.  
The GST genes located on different chromosomes are described as highly polymorphic 
(Krajka-Kuźniak et al., 2008; Oakley, 2005). Because of their well known xenobiotic-
metabolizing activity, genetic variations in GST genes have gained much of the attention 
recently. Any change in the expression of GST protein level might possibly influence an 
individual’s susceptibility to carcinogens and various diseases. From the clinical point of view, 
deletion and single nucleotide polymorphism of the classes GSTA1, GSTM1, GSTP1, and 
GSTT1 have been widely studied. 
1.4.4.1 Glutathione transferase A1 Polymorphism 
The human alpha class glutathione S-transferase consists of five genes (GSTA1, 
GSTA2, GSTA3, GSTA4 and GSTA5) and seven pseudogenes, clustered on chromosome 
6p12. The GSTA1 and GSTA2 have been known for years and probably the most extensively 
described. They catalyze the conjugation of glutathione with many electrophilic compounds 
and possess glutathione-dependent (selenium-independent) peroxidase activity (Figure 9). The 
alpha class has activity for polycyclic aromatic hydrocarbon, epoxides and alkenyl products of 
lipid peroxidation (4-hydroxynonenal) (Johansson and Mannervik, 2001). Their expression is 
present at high levels in liver, small intestine and kidney and at low levels in a wide range of 
tissues (Coles et al., 2001; Morel et al., 2002).  
Genetic polymorphism has been described for several classes. GSTA1 expression is 
influenced by a genetic polymorphism in the proximal promoter, with three linked base 
substitutions at positions -567, -69 and -52 resulting in two alleles hGSTA1*A (-52G, -69C, -
567T) and hGSTA1*B (-52A, -69T, -567G) (Morel et al 2002). Data suggest that promoter 
activity of hGSTA1*A and hGSTA1*B is mainly under influence of -52G>A base changing. 
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Experiments in vitro have showed high transcriptional activity of GSTA1*A gene (wild 
type) and very lower transcriptional activation with GSTA1*B allele (variant allelle) (Morel et 
al., 2002). It seems that alteration occurring at this position is a result of modified binding of 
the ubiquitous transcription factor Sp1 (Morel et al., 2002) (Figure 7). 
 
 
Figure 7. GSTA1 gene (Savic-Radojevic and Radic, 2014) 
 
Distribution of alleles varies within population. In Caucasians around 38% possess 
GSTA1*A/*A genotype, 48% GSTA1*A/*B genotype and 14% GSTA1*B/*B genotype 
(Magagnotti C at al., 2003) while in African and Asian population distribution is slightly 
different (61% GSTA1*A/*A, 26% GSTA1*A/*B, 13% GSTA1*B/*B and 78% 
GSTA1*A/*A, 19% GSTA1*A/*B, 1% GSTA1*B/*B, respectively) (Coles et al., 2001). 
Expression of GSTA1*B allele results in 4-fold lower enzyme activity, so far linked with many 
disease development such as colorectal carcinoma (Sweeney et al., 2002), prostate cancer 
(Komiya et al., 2005) and bladder cancer (Matic et al., 2013). 
1.4.5 Glutathione transferase M1 gene polymorphism 
Class mu genes are approximately 5 kb in length, and in humans all five genes are 
clustered together on chromosome 1p13.3 (Ross et al., 1993) arranged as 5'-GSTM4-GSTM2-
GSTM1-GSTM5-3' (Xu et al., 1998). Three alleles of GSTM1 class have been identified so far 
GSTM1*A, GSTM1*B and GSTM1*0 with the latter resulting in deletion of the entire gene 
and therefore complete lack of enzyme activity. Since no evidence of functional difference 
between GSTM1*A and GSTM1*B have been reported, these two alleles are considered as 
single functional phenotype (Widersten et al., 1991) (Figure 8). The other four genes belonging 
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to mu subfamily (GSTM2, GSTM3, GSTM4, and GSTM5) possess very similar sequence 
homology and substrate specificity with GSTM1 (Pearson et al., 1993). 
 
 
Figure 8. GSTM1 gene (Pljesa-Ercegovac and Matic, 2014) 
The GST mu class has been recognized to metabolize carcinogens from cigarette 
smoke such as polycyclic aromatic hydrocarbons (PAHs) and aromatic amines (Ketterer et al., 
1992). About 50% of the Caucasians are homozygous for GSTM1*0/GSTM1*0 (GSTM1-null) 
genotype and lack GSTM1 enzyme activity (Benhamou et al., 2002). Individuals with GSTM1-
null genotype have no capability of detoxifying these carcinogens and therefore are possibly 
associated with an increased susceptibility to various types of cancers including lung 
cancer(Sharma et al., 2015; Yang et al., 2015; Zhang et al., 2014), urinary bladder carcinoma 
(Matic et al., 2013) and acute leukaemia (Arruda et al., 2001). Apart from enzymatic activity, 
GSTM1 acts as a modulator of protein kinase (MAPK) signal transduction pathway and 
mediates apoptosis via a mechanism involving protein-protein interactions thus forming 
complexes with apoptosis signal-regulating kinase 1 (ASK1), by inhibiting ASK1 activation 
during cellular stress (Cho et al., 2001; Townsend and Tew, 2003).  
1.4.5.1 Glutathione transferase P1 polymorphism 
Gene for GSTP1 is located on chromosome 11q13. Pi class genes are about 3 kb long 
and contain seven exons. Within GSTP1 gene two SNPs have been described so far: transition 
from Ile to Val at codon 105 and transition of Ala to Val at codon 114. This SNPs result in 
four polymorphic alleles GSTP1*A, GSTP1*B, GSTP1*C, and GSTP1*D. Wild-type allele 
GSTP1*A has isoleucine (Ile) at codon 105 and alanine (Ala) at codon 114. GSTP1*B allele has 
one amino acid substitution (Val105/Ala114), GSTP1*C has two amino acids substitutions 
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(Val105/Val114), while GSTP1*D has Ile at position 105 and Val at 114 (Ile105/Val114) (Ali-
Osman et al., 1997; Watson et al., 1998) (Figure 9). These SNPs are found in the active site of 
the GSTP1-1 protein consequently decreasing the enzyme’s catalytic activity by 5-fold (Harries 
et al., 1997). However, these polymorphism do not change the GSH-binding site, but the 
formation of thioether conjugates between GSH and some small-molecule electrophiles (Ali-
Osman et al., 1997; Zimniak et al., 1994). 
 
 
Figure 9. GSTP1 gene polymorphism. 
Most of the substrates for GSTP1 protein are different diol epoxides, polycyclic 
aromatic hydrocarbon (PAHs) found in a cigarette smoke. Therefore, polymorphic expression 
of GSTP1 has been linked so far with various cancer developments including endometrial 
(Chan et al., 2005), testicular (Harries et al., 1997), hepatocellular carcinoma (Chen et al., 2010). 
As GSTP1 protein is highly expressed in lungs, patients with polymorphic expression of this 
gene were at greater risk for asthma (Kaymak et al., 2016; Lee et al., 2015; Su et al., 2013) and 
bronchial carcinoma (Feng et al., 2013; Ou et al., 2015; Xu et al., 2014). Furthermore, Harries 
et al (1997) suggested that patients homozygous to GSTP1*B allele had increased risk to 
develop testicular cancer (Harries et al., 1997). 
In GSTP1 gene several single nucleotide polymorphisms have been described with 
GSTP1 rs 1695 and GSTP1 rs1138271 being the most relevant one from the clinical point of 
view. In healthy, white populations, the frequencies of the genotype variants of GSTP1 rs1695 
polymorphism are *Ile/*Ile (AA) 51.5%, *Ile/*Val (AG) 39.4% and *Val/*Val (AG) are 9.1%, 
(Garte et al., 2001). The distribution of GSTP1 (rs1138272) genotype in European population 
*Val/*Val (CC) and *Val/*Ala (CT) are 92.1% and 7.9% respectively (Karaca et al., 2015). It 
is interesting that the distribution of variant allele is very low when general population is 
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examined (Karaca et al., 2015). It is common that individuals carrying both variant alleles are 
named with GSTP1-low activity genotype, while those who carry at least on referent allele are 
called GSTP1-active individuals. 
1.4.5.2 Glutathione transferase T1 polymorphism 
The theta class of glutathione transferases consists of two genes, GSTT1 and GSTT1. 
These genes are found at 22q11.2 and the distance between them is about 50 kB (Landi, 2000). 
There are several substrates related to GSTT catalytic activity, including carcinogens PAHs 
found in tobacco smoke and in combustion products (Meyer et al., 1991). Another substrates 
include 1,3-butadiene and ethylene oxide, methyl-bromide, ethylene-dibromide and ethylene-
oxide (Pemble et al., 1994; Wiencke et al., 1995). 
 
 
 
Figure 10. GSTT1 gene polymorphism 
The human GSTT1 gene is 8.1 kb in length (Webb et al., 2016; Coogan et al., 1998) 
and like GSTM1, most commonly exhibits deletion polymorphisms (Figure 10). The complete 
deletion of the gene (homozygotes) represents an absence of both GSTT1*0 alleles (GSTT1-
null genotype), which results in a complete lack of enzyme activity. Heterozygotes with only 
one allele absent may possess lower enzyme activity and are called GSTT1-active genotype 
carriers. In the case of GSTT1, gene homozygous deletion, present in about 20% of 
Caucasians, leads to the lack of GSTT1 enzyme activity (Libetta et al., 2011). Besides deletion 
polymorphism of GSTT1 gene, a single nucleotide polymorphism has also been described. 
This SNP results in forming two alleles GSTT1*A and GSTT1*B with different catalytic 
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properties (Alexandrie et al., 2002) (Figure 13). Subjects carrying GSTT1*A/*A genotype 
possess at least 2-fold higher enzyme activity in erythrocytes toward methyl-chloride compared 
to individuals who have at least one variant GSTT1*B allele (Alexandrie et al., 2002). This loss 
of enzyme activity is due to the conformational changes in enzyme structure which occurred as 
a consequence of amino acid substitution (threonine to proline) (Alexandrie et al., 2002). 
Apart from detoxification of mono-halogen derivatives, GSTT1 is capable of bio-
activation of compounds that have more than one halogen in their structure. During these 
reactions, highly reactive byproducts are formed, capable of reacting with DNA and proteins 
(Guengerich, 2005; Sherratt et al., 1997). In individuals with GSTT1-null genotype, the bladder 
cancer risk can be either decreased or increased, depending on to which substances the 
subjects were exposed (Cantor et al., 2010; Simic et al., 2009). 
1.4.6 Chronic renal failure and GST polymorphism 
Ever since glutathione transferases came into focus of research, a number of studies 
have confirmed or annuled an association between GST polymorphisms and the risk of disease 
developments (Moasser et al., 2014; Piacentini et al., 2012). These disparate findings may be 
due to insufficient power in some studies, differences between disease types, type of study 
populations and study design. In addition to well established mechanisms of oxidative stress 
related to the specific causes of renal failure, dialysis procedure and uremic state, recently the 
role of genetic predisposition to enhanced oxidative damage and consequent worse prognosis 
of MHD patients has started to emerge. In hemodialysis patients who encounter enhanced free 
radical production and accumulation of uremic toxins, up-regulated expression of enzyme 
glutathione transferase in peripheral blood cells is well described (Carmagnol et al., 1981; 
Mimic-Oka et al., 1992). However, as recently shown by Lin et al. (Lin et al., 2009), the 
capacity to evoke the GST response towards oxidative stress in MHD patients seems to be 
genetically determined. Namely, patients with GSTM1-null genotype had enhanced DNA 
damage based on higher lymphocyte level of 8- (OH) deoxy guanosine and higher mortality 
rate than HD patients with active GSTM1 enzyme (Lin et al., 2009). Homozygous deletion of 
GSTM1 allele has attracted much attention in the epidemiologic studies as a result of risk 
linkage with lung and bladder cancer (Matic et al., 2013; Sharma et al., 2015) and increased 
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susceptibility to coronary heart disease among smokers  (Li et al., 2000; Miller et al., 2003). 
Despite the fact that oxidative modifications of proteins and lipids have important role in the 
pathogenesis of cardiovascular complications in these patients, the question of whether 
GSTM1 genotype influences the level of byproducts of protein and lipid oxidative damage in 
patients with ESRD has not been well established as yet. 
In addition to GSTM1, polymorphisms of other GSTs (GSTT1, GSTP1 and GSTA1) 
have also gained a lot of attention in genetic epidemiologic studies. It seems reasonable to 
assume that GSTT1-null or GSTA1 or GSTP1 low activity genotypes might also influence the 
level of oxidative stress in HD patients and thus contribute to endogenous predisposition to 
oxidative damage in the setting of disrupted redox balance. Still, the role of polymorphic 
expression of GSTT1, GSTP1 and GSTA1 genes in increased oxidant-induced protein and 
lipid damage among HD patients has to be established. In this line, it seems reasonable to 
assess whether null or low activity GSTM1, GSTT1, GSTP1 and GSTA1 genotype alone or in 
combination correlate with eight byproductss of oxidative stress including protein thiol, 
carbonyl groups, nitrotyrosine, advanced oxidation protein products, malondialdehyde, 
malondialdehyde adducts, total oxidant status and prooxidant-antioxidant balance in patients 
with end-stage renal disease. 
Many efforts have been made to highlight the pathogenic mechanisms leading to huge 
cardiovascular burden in hemodialysis patients. Thus the prevalence of cardiovascular diseases 
is up to 30 fold higher in the patients with ESRD than in general population. So far there are 
no data related to the link between GST polymorphism and fatal/non-fatal cardiovascular 
diseases in ESRD patients. In the non-ESRD population individuals with GSTM1 and/or 
GSTT1-null genotypes seem to be at higher risk of cardiovascular disease (Nomani et al., 2011; 
Ramprasath et al., 2011). The observed link between GST polymorphism and CVD was 
further strengthened in smokers lacking GSTM1 or GSTT1 genes (Masetti et al., 2003; Wang et 
al., 2008). In addition, it seems that in patients with type 2 diabetes mellitus with GSTT1-null 
genotype and GSTT1*0/GSTM1*0 genotype combination, the susceptibility to advanced 
atherosclerosis is higher than in controls (Taspinar et al., 2012). However, different studies 
have yielded conflicting results. 
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Figure 11. Possible association between glutathione transferase gene polymorphism and 
oxidative stress and cardiovascular disease 
In ESRD patients, only polymorphic expression of GSTM1 was studied with respect 
to prognostic significance. Although the presence of GSTM1-null genotype in ESRD patients 
was associated with lower overall survival compared to those with GSTM1-active gene 
variants (Lin et al., 2009), specific association of this and other common GST 
polymorphisms, which play a key role in antioxidant defense, with cause-specific 
cardiovascular mortality still has to be addressed. 
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2 AIMS 
 
This thesis had several goals to asses: 
 
1. To determine the distribution of glutathione transferase A1, M1, P1 and T1 gene 
polymorphism of in patients with end-stage renal disease and control group 
 
2. To evaluate the association of GSTA1, GSTM1, GSTP1 and GSTT1 polymorphisms 
and byproducts of oxidative stress, as well as the level of adhesion molecules in the 
plasma of patients with end-stage renal disease 
 
3. To assess the predictive value of GST polymorphism, oxidative stress byproducts and 
adhesion molecules level in 5-year overall and cardiovascular survival of ESRD patients 
 
4. To test whether GSTM1 genotype  influences monocyte adhesion to the endothelial 
cells and reactive oxygen species production when exposed to uremic milieu   
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3 MATERIAL AND METHODS 
 
3.1 STUDY SUBJECTS 
This case-control study included a total of 199 patients (84 male and 115 female, mean 
age 60.0 ± 12.1 years) on maintained hemodialysis treatment three times a week in two dialysis 
centers in Belgrade (Center for Renal Diseases, Zvezdara University Medical Center and 
Department of Nephrology and Hemodialysis, University Teaching Hospital Zemun).  
The inclusion criteria were that all recruited patients were stable, age over 21 and with 
hemodialysis treatment vintage over 3 months.. Furthermore, patients had to be HIV, HBV 
and HCV negative.  
Exclusion criteria were previously registered malignancy or infectious co-morbidity 
based on C-reactive protein values and if patients, for any reason, did not want to participate in 
the study.  
Patients did not receive any antioxidant therapy (vitamin C and/or E) at the beginning 
of the study.A total of 35.2% patients received angiotensin-converting inhibitors therapy and 
15.1% received statins. 
The causes of end-stage renal disease (ESRD) were hypertensive nephrosclerosis (n = 
93), glomerulonephritis (n = 32), diabetic nephropathy (n = 25), polycystic renal disease (n = 
19), pyelonephritis (n = 19), Balkan endemic nephropathy (n = 7) and obstructive nephropathy 
(n = 4). Patients were treated with single-use dialysers equipped with low- and high-flux 
polysulphone membranes, with a membrane surface area of 1.3–2.1. m².  
A total of 199 consequtive controls (85 male and 114 female, mean age 59.3 ± 10.9 
years) were recruited from individuals with nephrolithiasis and normal renal function who were 
admitted to the Clinic of Urology, Clinical Center Serbia during the same time period. All the 
participants provided written informed consent. This study protocol was approved by the 
Ethical Committee of Faculty of Medicine, University of Belgrade (No 28/XII-14, date: 
28.12.2005), and the research was carried out in compliance with the Helsinki Declaration (as 
revised in 2013). 
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3.2 DETERMINATION OF GLUTATHIONE TRANSFERASE A1, M1, P1 AND 
T1 GENE POLYMORPHISM 
So far, deletion polymorphisms of GSTM1 and GSTT1 genes, and single nucleotide 
polymorphisms (SNP) of GSTA1 and GSTP1 genes were described as most common type of 
polymorphisms. The GST polymorphisms were determined in extracted DNA. 
3.2.1 DNA extraction 
A total DNA was purified using QIAamp DNA Mini Kit kit (Qiagen, Inc., 
Chatsworth, CA) from the whole blood sample obtained from patients with end-stage renal 
disease and control group, according to manufacturer’s instruction. This spin-column based 
method provides DNA purified of all contaminants and inhibitors. Briefly, in this method cell 
membranes of leukocytes are destroyed by incubation in lysis buffer. Hystones and other 
proteins are removed by enzyme digestion of proteinase K. In the following steps, DNA is 
transferred to the spin-columns, where it selectively binds silica-gel, and purified with adequate 
buffers provided by manufacturer. Purity of DNA sample was confirmed by analysis on Gene 
Quant Pro. If the 260/280 ratio was higher higher 1.8, the quality of isolated DNA was 
considered good.  
Extracted DNA was stored in AE buffer (provided by QIAamp DNA Mini Kit) at -
20oC until further usage. 
3.2.2 Determination of GSTA1 gene polymorphism 
The analysis of the SNP of GSTA1 C-69T (rs3957357) polymorphism was performed 
by polymerase chain reaction–restriction fragment length polymorphism (PCR–RFLP) by 
Coles et al. (Coles et al., 2001) with some modifications. The primers used were GSTA1 C-69T 
forward: 5′-TGTTGATTGTTTGCCTGAAATT-3′ and GSTA1 C-69T reverse: 5′-
GTTAAACGCTGTCACCCGTCCT-3′. The PCR reaction was performed in Mastercycler 
gradient thermal cycler (Eppendorf, Hamburg, Germany) with an initial denaturation step at 95 °C 
for 1 min and then 32 cycles as follows: 50 s at 94 °C, 56 s at 62 °C and 60s at 72°C, with final 
elongation step for 7 min at 72 °C. PCR products were electrophoretically separated on a 1% 
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agarose gel at 150V for 10 minutes and visualized with ethidium bromide in order to determine 
successful amplification. 
In the next step, PCR products were digested with restriction enzyme EarI (Thermo 
Fisher Scientific, Waltham, Massachusetts, USA) overnight at 37°C. Digested products (GSTA1 
AA 481 bp, GSTA1 AB: 385 bp and GSTA1 BB: 96 bp) were separated on 2% agarose gel 
stained with ethidium bromide and visualized on GelLogic2000 Camera (Gel Logic Imaging 
System, Kodak, USA). The presence of restriction site resulting in two fragments (385 bp and 96 
bp) indicated variant genotype (GSTA1*B/*B) also named GSTA1-low activity genotype. If the 
result of restriction was the presence of three fragments (481 bp, 385 bp and 96 bp), it 
indicated heterozygous (GSTA1*A/*B). The presence of only one fragment of 481 bp was for 
referent genotype (GSTA1*A/*A).  
Representative ethidium-bromide stained gel with GSTA1 restriction products is 
presented in Figure 12. 
 
Figure 12. Agarose gel electrophoresis. PCR-RFLP products of the GSTA1 gene. Lanes 4 and 
9 represent GSTA1 *A/*A genotype (481 bp). Lanes 1, 2, 5, 6 and 10 represent GSTA1 
*A/*B genotype (481bp, 385bp and 96bp) while lanes 3, 7 and 8 represent GSTA1 *B/*B 
genotype (385bp and 96bp). M-DNA marker. N-negative control. 
3.2.3 Determination of GSTM1 gene polymorphism 
The analysis of GSTM1 gene deletion polymorphism was performed by multiplex PCR 
(Abdel-Rahman et al., 1996). Primers used were: GSTM1 forward: 5′-
GAACTCCCTGAAAAGCTAAAGC-3′ and GSTM1 reverse: 5′-GTTGGGCTCAAATATA 
CGGTGG-3′. Exon 7 of the CYP1A1 gene was co-amplified and used as an internal control 
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using the following primers: CYP1A1 forward: 5′-GAACTGCCACTT CAGCTGTCT-3′ and 
CYP1A1 reverse: 5′-CAGCTGCATTTGGAAGTGCTC-3′. PCR was carried out for 33 cycles 
in DNA thermal cycler (Mastercycler PCR, Eppendorf, Hamburg, Germany). PCR reaction mixture 
was incubated and initially denatured at 94°C for 4 minutes. After that, the following steps 
were performed: denaturation (94°C, 2 minutes), annealing (1 minute at 59°C) and primer 
extension (1 minute at 72°C). Final extension lasted for 10 minutes at 72°C. PCR products 
were separated on a 2.5% agarose gel at 150V for 10 minutes and stained with ethidium 
bromide. The GSTM1 DNA fragments that were amplified were 215 bp in size. The absence 
of 215bp band was indicative for GSTM1-null genotype. The presence of the GSTM1-active 
genotype (referent genotype) was confirmed by the band at 215bp. The assay does not 
distinguish heterozygous from homozygous referent genotype (Figure 13). 
 
Figure 13. PCR products of the GSTM1 gene deletion polymorphism. Lanes 1, 2, 9, 11 and 12 
are patients with GSTM1-active genotype (both homozygous and heterozygous; 215bp) and 
lanes 3 through 8 with lane 10 represent GSTM1-null genotype. PCR products of CYP1A1 
gene (312 bp) are shown in upper line. M-DNA marker. N-negative control. 
3.2.4 Determination of GSTP1 genes polymorphisms 
Single nucleotide polymorphism of GSTP1 Ile105Val (rs1695) was analyzed using the 
PCR–RFLP method by Harries et al. (Harries et al., 1997). Primers used were: GSTP1 rs1695 
forward: 5′-ACCCCAGGGCTCTATGGGAA-3′ and GSTP1 rs1696 reverse: 5′-
TGAGGGCACAAGAAGCCCCT-3′. PCR was carried out in 35 cycles in PCR thermal cycler 
(Eppendorf Mastercycler, Hamburg, Germany). Reaction mixture for PCR was incubated and initially 
denatured at 94°C for 2 minutes. After that, following steps were performed: denaturation 
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(94°C, 30s), annealing (30s at 55°C) and primer extension (30s at 72°C). Final extension was 
performed for 5 minutes at 72°C. PCR products were separated on a 2.5% agarose gel at 150V 
for 10 minutes and stained with ethidium bromide. The presence of 176bp band indicated the 
presence of amplified GSTP1 gene. The amplification products (20µL) were digested by 2U of 
restriction endonuclease Alw26I at 37°C for 16h. Restriction products were separated on a 3% 
agarose gel. The restriction site resulting in two fragments (91bp and 85 bp) indicated 
GSTP1*Val/*Val (GSTP1-low activity) genotype. The presence of three fragments (176bp, 91bp 
and 85bp) was indicative for GSTP1*Ile/*Val genotype, while the presence of one 176 bp 
band indicated GSTP1*Ile/*Ile genotype (referent genotype) (Figure 14). 
 
Figure 14. PCR-RFLP products of the GSTP1 gene in 3% gel. Lanes 1 and 2 are wild type 
(GSTP1*Ile/*Ile; 176bp), lanes 3, 4 and 5 are heterozygotes (GSTP1*Ile/*Val; 176bp, 91bp and 
85bp) and lane 6 is homozygote (GSTP1*Val/*Val; 91bp and 85bp). M-DNA marker. N-
negative control. 
The GSTP1 rs1138272 polymorphism was determined by qPCR (Applied Biosystem) 
using Applied Biosystem Taqman Drug Metabolism Genotyping Assay (ID C_1049615_20). 
Briefly, DNA isolated from the blood of patients with ESRD was diluted to the concentration 
of 6ng/µL and a 5µL of sample was used. The samples were vaporized at 65°C for about 30 
minutes. After that, 5 µl of solution consisting of Taqman probe and HotStart Master Mix was 
added to each well. According to the thermal protocol for qPCR, the initial denaturation step 
lasted for 4 minutes and was followed by 40 cycles (95°C for 15s and 60°C for 1 minute). 
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3.2.5 Determination of GSTT1 gene polymorphism 
GSTT1 genotyping was performed by multiplex PCR according to Abdel-Rahman et al. 
protocol with some modifications (Abdel-Rahman et al., 1996). Primers used were GSTT1-
forward: 5′-TTCCTTACTGGTCCTCACATCTC-3′ and GSTT1-reverse: 5′-
TCACGGGATCAT GGCCAGCA-3′.  Exon 7 of the CYP1A1 gene was co-amplified using 
the following primers: CYP1A1-forward 5’-GAACTGCCACTTCAGCTGTCT-3’ and 
CYP1A1-reverse 5’-CAGCTGCATTTGGAAGTGCTC-3’. PCR reaction was performed with 
an initial denaturation step at 94 °C for 4 minutes. After initaial denaturation, 33 cycles were 
performed with following thermal protocol: 2 min at 94 °C, 1 min at 61 °C and 1 min at 72 °C. 
Final elongation was done for 6 min at 72 °C. PCR products were electrophoretically separated 
on a 1% agarose gel at 150V for 10 minutes and visualized with ethidium bromide to 
determine successful amplification. 
The assay does not distinguish between heterozygous or homozygous wild-type 
genotypes; therefore, the presence of 480 bp bands was indicative for the GSTT1-active 
genotype. Lack of band was indicative for GSTT1-null genotype. Presence of 312 bp was 
indicative for the presence of CYP1A1 gene, used as a positive control (Figure 15). 
 
Figure 15. PCR products of the GSTT1 gene. Lanes 1, 3, 4 and 5 are patients with GSTT1 
active genotype and lane 2 represents GSTT1-null genotype. PCR products of CYP1A1 gene 
(312 bp) are showed in lower line. M-DNA marker. N-negative control. 
All primers used for PCR reactions are synthesized and bought from Metabion 
International AG (Planegg, Germany) are presented in Table 6.  
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Table 6. A table summarizing all primer sequences and restriction enzymes used to determine 
GST genotype. 
Gene Primer sequence (5'-3') Polymorphism 
Anilling T 
(oC) 
PCR 
product 
Restriction 
enzyme 
GSTA1 F:TGTTGATTGTTTGCCTGAAATT 
R:GTTAAACGCTGTCACCCGTCCT rs3957357 62
oC 481bp Eam1104l 
GSTM1 F:CTGCCCTACTTGATTGATGGG 
R: TGGATTGTAGCAGATCATGC deletion 59
oC 215bp 
- 
GSTP1 F: CCCCAGGGCTCTATGGGAA 
R: TGAGGGCACAAGAAGCCCCT rs1695 55
oC 176bp Alw26I 
GSTT1 F:TTCCTTACTGGTCCTCACATCTC 
R: TCACGGGATCATGGCCAGCA deletion 61
oC 480bp 
- 
CYP1A1 F: ACTGCCACTTCAGCTGTCT 
R: CAGCTGCATTTGGAAGTGCTC positive control  59-61
oC 312bp 
- 
 
3.3 MEASUREMENT OF OXIDATIVE STRESS BYPRODUCTS 
To estimate the redox state of patients with ESRD, byproducts of oxidative stress were 
measured in plasma samples. As markers of lipid peroxidation, malondialdehyde (MDA) and 
malondialdehyde-adducts (MDA adducts) were determined. In assessment of protein oxidative 
damage, protein thiol-groups content, nitrotyrosine, advanced oxidation protein products 
(AOPP) and protein carbonyls were determined. Additionally, prooxidant-antioxidant balance 
(PAB) and total oxidant status (TOS) were also evaluated.  
3.3.1 Plasma separation 
Venous blood samples (app 5 ml) from patients with ESRD were collected in standard 
sterile polystyrene vacuum tubes containing ethylene diamine tetra acetic acid (EDTA) at the 
beginning of the dialysis session prior to the administration of heparin. Blood samples were 
aliquoted for standard biochemical blood analysis, DNA and plasma isolation. For plasma 
separation, samples were centrifuged at 3600 rpm for 10 minutes. Plasma samples were 
aliquoted to avoid frequent thawing/freezing and stored in at -80°C until further usage.  
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3.3.2 Measurement of malondialdehyde levels 
Concentration of malondialdehyde was measured using TBARS (thiobarbituric acid 
reactive substances) colorimetric method (Dousset et al., 1983). This method is based on the 
ability of MDA to conjugate with thiobarbituric acid forming an MDA-TBA compound. This 
red colored compound has a light absorption peak at 532nm and molar absorption coefficient 
of 1.56 x 105 L/ (mol x cm). This method is not specific for MDA exclusively but can detect 
all TBARS. MDA concentrations in plasma of ESRD patients were read from standard curve, 
constructed based on MDA standards. All values for MDA are expressed as mmol/L. 
3.3.3 Determination of MDA protein adducts 
MDA protein adducts were measured by enzyme immunoassay (OxiSelectTM ELISA 
kits, Cell Biolabs). After a standard curve was constructed based on known MDA-BSA 
concentrations, a quantity of MDA adduct in protein samples was calculated. Detection 
sensitivity limit of the kit was 2 pmol/mg of MDA adduct. 
3.3.4 Determination of AOPP (Advanced Oxidation Protein Products) 
AOPP is considered as one of the possible markers of protein oxidative injury, 
especially found in hemodialysis patients. Method for its determination is developed by Witko-
Sarsat et al (Witko-Sarsat et al., 1996) and slightly modified for this purposes. The assay is 
based on the spectroscopic analysis of modified proteins at 340 nm. Namely, when acetic acid 
and potassium-iodide are added into diluted sample, a specific absorbance at 340 nm is read 
providing a concentration of AOPP expressed in Chloramine T equivalents (CT equivalents). 
All measurements are done on STASAR , GILFORD III-Lighting spectrophotometer. EDTA 
plasma was diluted in phosphate buffer (1 : 5).  
3.3.5 Determination of nitrotyrosine concentration 
The nitrotyrosine is produced when oxidative modifications of tyrosine residues are 
introduced in proteins as a result of damage caused by peroxynitrite or other potential nitrating 
agent. Briefly, this assay is based on principle of competitive ELISA. Determination of protein 
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nitrotyrosine concentration in plasma sample (or nitrated BSA standards) is conducted in 
several steps. In the first one, sample is added to a nitrated BSA pre-absorbed EIA plate. After 
a brief incubation, an anti-nitrotyrosine antibody is added, followed by an HRP conjugated 
secondary antibody. The protein nitrotyrosine content in plasma sample was determined using 
a standard curve created from predetermined nitrated BSA standards. 
3.3.6 Prooxidant-antioxidant balance (PAB) 
In order to evaluate the prooxidant–antioxidant balance, the determination of both the 
oxidant and the antioxidant status is achieved. This method is a modification of previously 
described by Alamdari et al (Alamdari et al., 2007). In this assay a total amount of hydrogen-
peroxide in antioxidant moiety is calculated using a chromogen 3,3´5,5´-tetramethylbenzidine 
(TMB) which reacts with both H2O2 and antioxidants (uric acid). These two compounds are 
chosen because they do not interact with each other and do not interfere with the course of 
reactions. Peroxidase catalyzes the reaction between TMB and H2O2 where TMB is oxidized to 
the cation which forms a blue colored compound. In the presence of antioxidants, TMB is 
reduced to form a colorless product. The PAB value is calculated using standard curve made 
on a basis of intensity of predetermined standard solution. The standard solutions were 
prepared by mixing varying proportions (0-100%) of hydrogen peroxide with uric acid. The 
capacity of antioxidants is determined as a value of uric acid concentration expressed in µmol x 
L-1 of uric acid. The capacity of pro-oxidants is determined as a value of H2O2 concentration 
expressed in µmol x L-1.  
The PAB values were of plasma samples were calculated based on the standard curve 
and expressed in arbitrary HK units (the percentage of H2O2 in the standard solutions).  
3.3.7 Total-oxidant status measurement 
Hydrogen peroxide and lipid peroxides represent the main components of total 
oxidant status assay, a method described by Erel in 2005 (Erel, 2005). This assay is based on 
the ability of oxidants present in the sample to oxidize ferrous ion in o-diasinidine complex to 
ferric ion. Molecules of glycerol make this process easier. Ferric ion produced in the reaction 
will react with xylenol orange in an acidic medium to produce colored complex compound 
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which absorbance is measured spectrophotometrically at λ= 560 nm. Different concentrations 
of H2O2 (10-200 μmol/L) were used to plot standard curve where all TOS values of plasma 
samples were obtained.  
3.3.8 Protein thiol groups 
Total content of protein thiol groups in plasma samples from patients with ESRD was 
determined according to method previously described by Jocelyn (Jocelyn, 1987). This method 
is based on reactions of thiols with Ellman’s reagent (5,5'-dithiobis-(2-nitrobenzoic acid) or 
DTNB. Protein thiol groups react with DTNB cleaving the disulfide bond to give 2-nitro-5-
thiobenzoate (TNB−), which will ionize to the TNB2− dianion in water at neutral and alkaline 
pH. This TNB2− ion has a yellow color. Molar extinction coefficient for TNB is 13.6 x 103 
Lmol/1cm at 412 nm wavelength. Since the sunlight can reduce DTNB, all reactions were 
performed in dark place or protected from sunlight.  
3.3.9 Protein carbonyls 
Protein carbonyls were determined by ELISA method (Oxiselect Protein Carbonyl 
Elisa Kit). This immunoassay is based on quantitation of protein carbonyls in protein samples 
by comparing with a standard curve that is prepared from predetermined BSA standards.  
All the protein carbonyls are derivatized to dinitrophenyl (DNP) hydrazone and 
incubated with an anti-DNP antibody, as primary antibody, and after that with secondary HRP 
conjugated antibody. Absorbance was read at 450 nm as primary wavelength and fully reduced 
BSA standards were used as blank. Every measurement was performed in duplicate. Carbonyls 
concentration in plasma samples was expressed as nmol/mg. 
 
3.4 DETERMINATION OF CIRCULATING ADHESION MOLECULES IN 
PLASMA 
Having in mind that early atherosclerotic changes involve recruitment of inflammatory 
cells from the circulation and that this process is predominantly mediated by cellular adhesion 
molecules, predominantly expressed on the vascular endothelium and on circulating leukocytes 
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in response to several inflammatory stimuli, the concentration of soluble cell adhesion 
molecules have been determined in plasma isolated from the patients on hemodialysis. 
3.4.1 Human soluble VCAM-1 measurement 
The human soluble Vascular Cell Adhesion Molecule-1 (sVCAM-1) was determined in 
plasma of ESRD patients using commercial solid-phase sandwich ELISA kit (Novex, Life 
Technologies). In brief, standards or diluted samples were added to antibody coated 96-wells 
plate together with anti-sVCAM-1 Biotin Conjugate solution. After the incubation and plate 
washing, Streptaviridin-HRP was added  to each well. This step was followed by addition of 
chromogen and stop solution after which absorbance was read at 450 nm plate reader. 
Standard curve was designed from values obtained from standards, and values for samples 
were read from standard curve. All values were expressed as ng/ml. 
3.4.2 Human Soluble ICAM-1 Determination 
The human soluble Intercellular Adhesion Molecule 1 (ICAM-1) was determined in 
plasma of ESRD patients using commercial enzyme linked immunosorbent assay (Thermo 
Scientific). This assay was performed using 96-well anti-human sICAM-1 precoated strip plate to 
which standards or diluted samples were added. After 4-times washing of the plate, a 
biotinylated antibody was added to each well, which was followed by another washing and 
addition of Straptaviridin-HRP solution. The reaction was ceased by adding TMB substrate to 
each well after which absorbance was measured at 450 nm and 550 nm. Values measured on 
550 nm were substracted from those on 450 nm to correct for optical imperfections in the 
microplate. Standard curve was designed from values obtained using standards, and ICAM-1 
concentrations were read from standard curve. All values were expressed as pg/ml.  
3.5 OVERALL AND CARDIOVASCULAR SURVIVAL ANALYSIS 
All patients with ESRD were followed for 5 years (from February 2010 to February 
2015) Patients were followed until the death outcome or the end of follow-up period. Both 
overall (all-cause) and cardiovascular mortality was registered during this time. 
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Cardiovascular complications that were prospectively registered were myocardial 
infarction (MI) and cerebral vascular insult (CVI). Diagnosis of MI was performed by 
cardiologist, based on the presence of at least two out of three conditions (specific clinical 
presentation and/or specific changes in electrocardiogram and/or elevation of enzymes). 
Diagnosis of CVI was performed by neurologists, based on scanner findings and specific 
clinical presentation.  
3.6 MOLECULAR CHANGES OF ENDOTHELIAL CELLS 
In order to test if GSTM1 deletion polymorphism has an impact on endothelial cells an 
experiment using primary Human Umbilical Vascular Endothelial Cells (HUVEC, Lonza) was 
performed.  
3.6.1 Cell cultures 
In this thesis two cell cultures were used. The first one was HUVEC and the second 
one were the cell line of human monocytes THP1. 
Primary HUVECs were seeded on previously 0.2% gelatin coated Petri dishes in a 
phenol-red free endothelial growth medium (EGM) supplemented with fetal bovine serum 
(2%), fibroblast growth factor (0.4%), vascular endothelial growth factor (0.1%), heparin 
(0.1%), insulin-like growth factor (0.1%), ascorbic acid (0.1%), epidermal growth factor (0.1%) 
and hydrocortisone (0.04%). The cells were cultivated at 37°C in a humidified atmosphere with 
5%CO2 until they would reach 70-80% confluence when they were subcultured. For all 
experiments the cells at passage 4 were used.  
The THP1 cell line was cultured in flasks in RPMI (Roswell Park Memorial Institute) 
medium enriched with L-glutamine, 10% FBS (fetal bovine serum) and phenol-red. Cells were 
subcultured on every 3 days, or when the color of medium was changed from red to yellow.  
All the reagents used in the experiment (PBS, trypsin, medium were heated in water 
bath before added to cells). Plates were always moved in the number 8-like manner to spread 
evenly the reagents. 
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3.6.2 The treatment of the endothelial cells 
The cells were incubated for 4 hours with 20% human serum obtained from healthy 
volunteers and patients on hemodialysis therapy. As a control, endothelial cells were incubated 
in 20% FBS in EGM (for monocyte adhesion assay only). All experiments were performed in 
24-well plates in triplicates (determination of free radicals) or sextuplicates (monocyte adhesion 
test).  
3.6.3 Cell counting 
After the cells were collected from Petri or 24-well dish, they were transferred into 
separate tubes. The sieve was used to separate cells which formed agglomeration. Cells were 
counted with Beckman coulter Z1 particle counter. A total of 100 µl of sample was diluted in 
10 ml of Z-pak balanced electrolyte solution isoton and measured in triplicates. Mean value 
was used and multiplied with 200 in order to get the number of cells per milliliter.  
3.6.4 The viability assay 
In this study crystal violet test was used to assess the cell viability analysis. This assay 
provides the relative number of living adherent cells. This test is based on ability of crystal 
violet to bind for proteins and DNA of cells. Cells that undergo cell death detach from the 
plates and are subsequently lost from the population of cells, reducing the amount of crystal 
violet staining in a culture. After the treatment, cells were washed with PBS solution and 200 
µL of crystal violet/methanol solution was added. After 15 minutes, wells were washed with 
distilled H2O (500 µL/well, three times) and left upside down over night to dry. During 
following day 150 µL of 1% SDS was added to each well and absorbance was read at plate 
reader at 550 nm. The color intensity corresponded to the number of living adherent cells. The 
results of this assay were presented as % of living cells compared to the control which had 
arbitrary 100% viability.  
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3.6.5 The monocytes adhesion assay 
The HUVECs in passage 3 that were frozen in liquid nitrogen were defreezed and 
seeded in the previously 0.2% gelatin-coated Petri dishes. Cells were diluted in 12 ml of 
previously heated EGM (37°C). The cells were left for three days to reach confluence after 
which they were subcultured to 24-well plate previously coated with gelatin. Approximately 
65,000 cells were seeded per well. The incubation with control and uremic serum was obtained 
once the cells reached confluence. After the 4 hrs of incubation, around 250,000 
monocytes/well were added. The plates were incubated for 15 minutes. After the end of the 
incubation period wells were aspirated and cells were washed 3 times with 400 µl of PBS. After 
this step 100 µl of trypsin/EDTA was added per well. Plates were left at the incubator for 4 
minutes. Plates were tapped with hand or were banged on the table to help the detachment of 
cells. To stop the action of trypsin a total of 200 µl of previously prepared PBS with 10% FBS 
was added per well. Cells were collected and transferred into the corresponding tubes. A 200 µl 
of 4% paraformaldehyde (PFA) was added to each tube. PFA was previously prepared and 
stored at -20°C in 12 ml tubes. One tube was defreezed before used for experiment; PFA was 
kept at 4 after defreezing. Tubes were vortexed and left at 4°C until used for the flow 
cytometer reading the following day. 
Preparation for the flow cytometry readings obtained following steps. Tubes were 
centrifuged for 10 minutes at 1800 rpm (300G) at 20°C and supernatant was aspirated. Then 
the FCR blocking was added (5 µl of the FCR Blocking/tube+35 µl of PBS/BSA/EDTA 
solution). Tubes were vortexed and centrifuged for few seconds before incubated in the dark 
(at room temperature) for 10 minutes (at least). After the incubation period, CD45 and IgG2a 
antibodies were added (1 µl of antibody+ 9 µl of PBS/BSA/EDTA solution).The THP1 
positive staining was CD45 positive, while IgG2a antibodies were used for negative THP1 
staining. For positive HUVEC staining CD45 antibodies were used, while for negative one 
IgG2a antibodies were used. All samples contained CD45 antibodies.  
3.6.6 The measurement of reactive oxygen species production 
To estimate the free radical production in endothelial cells incubated with uremic 
serum, both dihydroethidium (DHE) and dihydrorhodamine (DHR) staining was used. The 
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DHR is a non-fluorescent dye which detects all reactive oxygen species. This dye goes through 
the cell membrane and to react with free radicals found in the cells. Dihydrorhodamine is 
oxidized into rhodamine which has green fluorescence that is detected on flow cytometer in 
FL-1 channel. On the other hand, DHE detects superoxide ion radical. This dye is also cell 
permeable and in the interior of the cells it oxidizes to ethidium which has red fluorescence 
detected in flow cytometer in FL-2 channel.  
Cells from passage 3 were transferred from Petri dish to 24-well plates. Around 50,000 
cells/well were seeded. The treatment with standard medium, control serum and uremic serum 
was obtained once the cells have reached confluence. After the treatment was aspirated from 
the wells, a 300 µL of 10 µM DHE and 2.5 µM DHR were added into wells on corresponding 
plates. Plates were incubated for 30 minutes on 37 °C, after which wells were washed with 
PBS. Cells were detached using 100 µL trypsin/EDTA solution for 4 minutes. To stop the 
reaction of trypsin, 200 µL of 10%FBS in PBS was used. The content was transferred to the 
tubes and cells were centrifuged twice with 500 µl of PBS at 500g for 10 minutes. After this 
step, flow cytometry analysis was performed. 
3.7 STATISTICAL ANALYSIS 
In descriptive statistics, we summarized all continuous variables by means ± standard 
deviations (SD) or median with interquartile range (IQR), depending on normality if variables’ 
distributio. Differences in investigated parameters were assessed by using analysis of variance 
(ANOVA) for continuous variables and χ2 for categorical variables. The associations between 
the genotypes and ESRD risk were calculated by using logistic regression to compute odds 
ratios (ORs) and corresponding 95% confidence intervals (CIs), adjusted according to age and 
gender as potential confounding factors. 
In the first step of statistical evaluation of relationships between byproducts of 
oxidative damage (SH groups, carbonyls, AOPP, nitrotyrosine, MDA, MDA adducts, TOS, 
PAB), adhesion molecules (ICAM-1, VCAM-1) and combined GSTA1, GSTM1, GSTP1 and 
GSTT1 genotypes in ESRD patients, distribution was tested by using the Kolmogorov–
Smirnov test. For normally distributed data, we performed ANOVA and, if necessary, the 
Bonferroni post hoc test for locating differences between multiple groups. For data with a 
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non-normal distribution, we used the Mann–Whitney rank-sum test (for between-two-group 
comparisons) and the Kruskal–Wallis non-parametric test that compared three unpaired 
groups. 
Two-tailed P-values of <0.05 were considered significant. Data were analyzed using the 
Statistical Package for the Social Sciences (SPSS) (version 17.0, Chicago, IL). 
Survival analysis was performed separately in the total cohort and according to the 
cardiovascular cause of death. The Kaplan-Meier method was used to estimate the cumulative 
survival probability. The long-rank test was performed for the assessment of differences in 
survival according to the different categories of variables. 
The predictive value of different GST genotypes in overall and cardiovascular mortality 
was assessed by Cox proportional hazards regression models, adjusted by confounding factors 
in three models. The numbers of patients included in regression models were the same for the 
all tested GST polymorphisms. In Model 1 we adjusted for age and gender. Model 2 included 
the covariates in Model 1 plus an additional adjustment for the current smoking status. Model 
3 included all covariates from Models 1 and 2, plus an additional adjustment for diabetes and 
cholesterol status. The associations are presented as hazard ratios (HR) with their 
corresponding 95% confidence intervals (95% CI). 
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4 RESULTS 
4.1 CLINICAL CHARACTERISTIC OF PATIENTS AND CONTROL GROUP 
Characteristics describing both demographic and clinical features of patients and 
control group are given in Table 7. Although the study previously included 202 patients, it 
turned out that 3 of them had previously registered malignant disease so they were removed 
from further analysis. For the 199 patients on regular hemodialysis and 199 healthy control 
there was no difference in terms of age (60.0 ± 12.1 years in patients vs. 59.3 ± 10.9 yrs in 
control group) or gender (male : female ratio in end-stage renal disease patients was 84 : 115 
and 85 : 114 in control group) distribution. Concentrations of albumin, hemoglobin and serum 
iron were significantly decreased while urea, creatinine and ferritin concentrations were 
significantly increased in patients when compared to individuals from control group. These 
results were in respect with studied illness of these patients. Mean time spent on hemodialysis 
was 6.3 ± 4.4 years. Mean Kt/V value for patients was 1.3.  
The causes of renal failure in our study group were: 26 had diabetes mellitus (13.1%), 
93 had hypertension (46.7%), glomerulonephritis had 27 of them (13.6%), 19 with 
pyelonephritis (9.5%), 18 suffered from polycystic kidney disease (9.0%) and 7 had endemic 
nephropathy (3.5%). For 9 patients (4.5%) the cause of renal failure remained unknown. A 
total of 27 patients (13.6%) had registered previous cardiovascular disease. There were no 
significant correlations between age of the patients/control and any biochemical analysis (data 
not shown).  
4.2 DISTRIBUTION OF GST GENOTYPES 
The distributions of GSTA1, GSTM1, GSTP1 and GSTT1 genotypes in patients and 
controls are presented in Table 8. By the term active genotype we considered the presence of 
at least one allele in the case of GSTM1 and GSTT1. In control group the frequency of GSTA1 
and GSTP1 genotypes were in Hardy-Weinberg equilibrium (p = 0.87 and p = 0.15, 
respectively). 
GST Polymorphisms in ESRD Patients  
 
 
47 
 
Table 7. Clinical characteristics of patients with end stage renal disease (ESRD) and control 
group 
Characteristic ESRD patients Controls 
Gender   
Male  vs female (%) 84 (42) vs 115 (58) 85 (43) vs. 114 (57) 
Age (year; mean ± SD) 60.0 ±12.1 59.3 ± 10.9 
Time on hemodialysis 6.3 ± 4.4 - 
Albumin (g/L; mean ± SD) 39.6 ± 4.0 43.5 ± 2.6* 
Urea 24.4 ± 4.8 5.5 ± 1.2* 
Creatinine 880.2 ± 238.6 84.4 ± 10.3* 
Cholesterol 4.7 ± 1.0  
HDL (mmol/L; mean ± SD) 1.2 ± 0.3 1.3 ± 1.4 
LDL (mmol/L; mean ± SD) 2.6 ± 0.8  
Triacylglycerol (mmol/L; mean SD) 2.1 ± 1.3 1.4 ±0.4* 
Hemoglobin (g/L; mean ± SD) 108.1 ± 15.4 144.0 ± 13.7* 
Serum iron  11.3 ± 5.6 21.1 ± 4.8* 
Ferritin 350.2 ± 278.0 48.0 ± 29.6* 
Hematocrit (%; mean ± SD) 32.1 ± 5.2 29.8 ± 4.9 
 
The frequency of GSTA1, GSTM1, GSTP1 and GSTT1 null/low-activity genotypes was 
higher in patients with end stage renal disease than in control group. In control group 
GSTA1*A/A genotype was found in 39.2% individuals, while GSTA1*B/B genotype was 
found in 13.6% individuals. In contrast, in patients group a total of 35.2% individuals 
possessed GSTA1*A/A genotype while 19.6% had GSTA1*B/B genotype. As far as GSTP1 
genotype is concerned, 23.6% of patients had the GSTP1*Val/Val genotype compared to 
16.6% individuals in controls. Regarding GSTM1 genotype, homozygous deletion was found in 
59.8 % ESRD patients and in 48.7% individuals in control group. The frequency of GSTT1-
null genotype was higher in patients (33.7%) than in controls (28.6%). Significant association 
between the GST genotype distribution and ESRD was found for the GSTM1 genotype. 
Namely, individuals that were homozygous for GSTM1-null allele had 1.6-fold higher 
susceptibility towards ESRD development (OR = 1.6, 95% CI: 1.1 – 2.4, p = 0.024) than 
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individuals carrying at least one GSTM1 referent allele. Very high significant association was 
also found for GSTP1 rs1138272 polymorphism. Individuals who were carriers of at least one 
variant allele (GSTP1*T) had 3.2-fold increased risk for ESRD (p = 0.001) when compared to 
individuals who were homozygous for referent allele (GSTP1*C). In the case of another 
GSTP1 rs1695 polymorphism, it was observed that individuals with GSTP1-Val*Val genotype 
were at increased susceptibility towards ESRD development. However, statistical significance 
lacked (OR = 1.6, 95% CI : 0.9 – 2.7, p = 0.112). Regarding GSTA1 polymorphism, although 
OR was higher in individuals with low activity genotype (OR = 1.6), statistical significance was 
not observed. Grouping individuals who possesses at least one variant GSTA1*B allele did not 
increase susceptibility towards ESRD development. No statistical significance was observed 
for association with ESRD regarding GSTT1 genotype. 
4.3 Combined GST genotypes and ESRD risk 
When combinations of various GST genotypes were analyzed, it was observed that the 
presence of the either variant GSTP1 rs1138272 or GSTM1-null genotype influenced 
significantly the susceptibility towards ESRD development. Namely, the highest susceptibility 
of ESRD development was observed in individuals who carried both GSTP1 (rs1138272)-low 
activity and GSTT1-null genotype (OR = 6.6, 95% CI : 2.1 – 10.5, p < 0.05). The risk was also 
significantly increased in individuals who had combination of GSTP1-low activity (rs1138272) 
genotype with GSTA1-low activity or GSTM1-null genotype (OR = 3.3, 95% CI : 1.7 – 6.6, p < 
0.05 and OR = 5.9, 95% CI : 2.3 – 15.4, p < 0.05, respectively). Individuals who carried both 
GSTP1-low activity genotype combined had almost 3-fold increased risk for ESRD (OR = 2.9, 
95% CI : 1.7 – 5.7, p < 0.05). Interestingly, when GSTP1-low activity genotype was combined 
with either GSTA1-active or GSTP1-active (rs1695) genotype, the ESRD risk development was 
also increased in the studied population (OR = 5.9, 95% CI : 2.3 – 15.4, p < 0.05 and OR = 
3.8, 95% CI : 1.6 – 9.1, p < 0.05, respectively). The presence of GSTM1-null genotype in 
combination with other null or low activity genotypes (apart from GSTP1 rs1138272 
polymorphism) provided the certain risk for those who carried the combinations with this 
genotype. Namely, combination of GSTM1-null with the GSTT1-null or GSTP1-low-activity 
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genotype was also found to be significant (OR = 2.0, 95% CI : 1.1 – 3.7, p < 0.05 and OR = 
1.8, 95% CI : 1.0–3.1, p < 0.05, respectively) (Table 9).  
Table 8. GSTA1, GSTM1, GSTP1 and GSTT1 genotypes in relation to risk of ESRD 
GST genotype Cases n (%) Controls n (%) OR (95%CI) p 
GSTA1     
AA 70 (35.2) 78 (39.2) 1.00  
AB 90 (45.2) 94 (47.2) 1.1 (0.7-1.7) 0.110 
BB 39 (19.6) 27 (13.6) 1.6 (0.9-2.9) 0.746 
AB+BB 129 121 1.2 (0.8-1.8) 0.401 
GSTM1     
*1 active a 80 (40.2) 102 (51.3) 1.00  
*0 null b 119 (59.8) 97 (48.7) 1.6 (1.1-2.4) 0.024 
GSTT1     
*1 active a 132 (66.3) 142 (71.4) 1.00  
*0 null b 67 (33.7) 57 (28.6) 1.2 (0.8-1.9) 0.319 
GSTP1 rs1695     
*Ile/*Ile 75 (37.7) 82 (41.2) 1.00  
*Ile/*Val 77 (38.7) 84 (42.2) 1.0 (0.6-1.5) 0.939 
*Val/*Val 47 (23.6) 33 (16.6) 1.6 (0.9-2.7) 0.112 
Ile/Val + Val/Val 124 117 1.1 (0.8-1.7) 0.531 
GSTP1 rs1138272     
*C/*C 111 (66.9) 182 (86.3) 1.00  
*C/*T 55 (33.1) 29 (13.7) 3.2 (1.9-5.4) 0.001 
Adjusted for age and gender. aActive (present) if at least one active allele present. bNull (inactive) if no active alleles present. 
OR- odds ratio. CI- confidence interval. 
When GSTM1-null and GSTA1-low activity genotypes were combined a certain risk on 
ESRD development was observed although statistically insignificant (OR = 1.8; 95% CI : 0.9 – 
3.3, p = 0.058) (Table 9).  
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Table 9.Combined effects of GSTA1, GSTM1, GSTP1 and GSTT1 genotypes in terms of risk of end-stage renal disease. 
 GSTM1 GSTA1 GSTP1 GSTT1 
 Presenta Nullb Activea Low activityc Activea Low activityc Activea Low activityc 
GSTA1         
Activea         
Ca/Co 29/36 41/42   - - - - 
OR (95%CI) 1.0d 1.2 (0.6-2.3)   
Low activityc         
Ca/Co 48/64 78/55   - - - - 
OR (95%CI) 0.9 (0.5-1.8) 1.8 (0.9-3.3)   
GSTP1 AB         
Activea         
Ca/Co 34/50 41/32 30/33 45/49   - - 
OR (95%CI) 1.0d 2.1 (1.1-4.0)* 1.0 d 1.0 (0.5-2.0)   
Low activityc         
Ca/Co 45/52 78/65 40/45 84/72   - - 
OR (95%CI) 1.3 (0.7-2.4) 1.8 (1.0-3.1)* 1.0 (0.5-1.9) 1.2 (0.7-2.3)   
GSTP1 CD         
Active         
Ca/Co 47/88 20/14 35/71 76/101 45/73 66/99 74/119 38/23 
OR (95% CI) 1.0 2.6 (1.2-5.7)* 1.0 1.5 (0.9-2.5) 1.0 1.1 (0.7-1.7) 1.0 2.6 (1.4-4.7)* 
Low activity         
Ca/Co 64/84 35/13 21/7 34/20 22/9 33/18 37/53 17/4 
OR (95% CI) 1.4 (0.9-2.3) 4.9 (2.4-10.02)* 5.9 (2.3-15.4)* 3.3 (1.7-6.6)* 3.8 (1.6-9.1)* 2.9 (1.7-5.7)* 1.1 (0.7-1.8) 6.6 (2.1-10.5)* 
GSTT1         
Presenta         
Ca/Co 51/73 81/69 48/56 85/85 55/62 77/80   
OR (95%CI) 1.0d 1.7 (1.1-2.8)* 1.0d 1.2 (0.7-1.9) 1.0d 1.1 (0.7-1.7)   
Nullb         
Ca/Co 28/30 38/27 22/22 45/35 20/20 47/37   
OR (95%CI) 1.3 (0.7-2.5) 2.0 (1.1-3.7)* 1.1 (0.5-2.3) 1.5 (0.8-2.7) 1.2 (0.6-2.5) 1.4 (0.8-2.5)   
aActive (present) if at least one active allele present. bNull if no active alleles present. c Low activity if at least one lower activity allele present  dReference group. * 
Statistically significant difference when compared to reference group. OR- odds ratio. CI- confidence interval. 
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4.4 ASSOCIATION BETWEEN GST GENOTYPE AND BYPRODUCTS OF 
OXIDATIVE DAMAGE 
 
The association between polymorphic GST expression and byproducts of oxidatively 
damaged macromolecules (proteins and lipids; prooxidant-antioxidant balance and total 
oxidant status) has been studied in the further course.  
4.4.1 Impact of GST genotype on protein oxidative damage 
In the Table 10 and Figures 16, 17, 18 and 19 are presented the results regarding 
protein oxidative damage measured in the plasma of ESRD patients. All values were stratified 
according to GST genotype. 
Plasma protein thiol groups content was significantly lower in patients with GSTM1-
null, GSTT1-null genotype as well as, GSTP1 *Val/*Val genotype in comparison to 
corresponding reference genotype (p = 0.001, 0.002 and 0.042, respectively) (Figure 16).  
 
 
 
 
 
 
 
 
 
 
 
Figure 16. Plasma thiol groups in terms of GST genotype in ESRD patients. *p < 0.05, **p < 
0.001 
Plasma carbonyl group levels were found to be statistically increased in patients with 
GSTA1 *B/*B or GSTM1-null genotype (p = 0.007 and 0.005, respectively) (Figure 17). The 
GSTP1 rs1695, GSTP1 rs1138272 and GSTT1 gene polymorphism did not significantly 
 AA AB BB    Active  Null        leIle  IleVal  ValVal    CC   CT        Active  Null    
     GSTA1       GSTM1           GSTP1 rs1695  GSTP1 rs1138272   GSTT1 
*
*
* 
* * 
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influence the carbonyls level although modest increased related to the presence of variant allele 
was observed.  
Table 10. Byproducts of protein oxidative damage stratified according to GST genotype in 
ESRD patients. All values are presented as mean ± SD or median with IQR 
Genotype 
SH-groups 
µmol/g 
Carbonyls nmol/g 
Nitrotyrosine 
nmol/L 
AOPP 
µmol/L 
GSTA1-AA 
 
7.1 ± 2.2 
(100%) 
 
2.2 ± 0.2 
(100%) 
 
56.9 [43.3 – 85.1] 
(100%) 
 
65.4 [49.4 - 74.4] 
(100%) 
GSTA1-AB 
 
6.8 ± 1.8 
(96%) 
 
2.3 ± 0.3 
(105%) 
 
62.4 [44.9 – 89.32] 
(110%) 
 
64.3 [45.0 – 75.1] 
(98%) 
GSTA1-BB 
 
6.5 ± 1.9 
(90%) 
 
2.6 ± 0.7* 
(118%) 
 
68.3 [55.0 – 101.2] 
(120%) 
 
61.4 [47.3 – 74.7] 
(94%) 
GSTM1-activea 
 
7.8 ± 2.2 
(100%) 
 
2.1 ± 0.2 
(100%) 
 
64.5 [46.1-93.1] 
(100%) 
 
57.9 [32.8 – 69.4] 
(100%) 
GSTM1-nullb 
 
6.2 ± 1.4** 
(79%) 
 
2.4 ± 0.4* 
(114%) 
 
64.5 [46.1-93.1] 
(100%) 
 
66.3 [52.5 – 86.2]* 
(115%) 
GSTP1-Ile/Ile 
 
7.3 ± 2.2 
(100%) 
 
2.2 ± 0.2 
(100%) 
 
54.5 [39.0 - 78.7] 
(100%) 
 
67.4 [50.3 – 84.5] 
(100%) 
GSTP1-Ile/Val 
 
6.6 ± 1.7 
(90%) 
 
2.3 ± 0.2 
(105%) 
 
75.5 [50.1 – 101.2]* 
(139%) 
 
61.1 [43.9 – 70.5] 
(91%) 
GSTP1 Val/Val 
 
6.4 ± 1.8* 
(88%) 
 
2.3 ± 0.3 
(105%) 
 
72.3 [46.8 – 93.1]* 
(133%) 
 
64.6 [18.7 – 73.7] 
(96%) 
GSTP1 *C/*C 
 
6.9 ± 2.1 
(100%) 
 
2.3 ± 0.3 
(100%) 
 
59.3 [47.1 – 91.2] 
(100%) 
 
64.1 [43.6 – 80.2] 
(100%) 
GSTP1 *C/*T 
 
6.8 ± 1.8 
(98%) 
 
2.3 ± 0.2 
(100%) 
 
62.4 [42.4 – 93.1] 
(105%) 
 
65.6 [46.9 – 76.1] 
(102%) 
GSTT1 activea 
 
7.2 ± 2.0 
(100%) 
 
2.2 ± 0.3 
(100%) 
 
61.1 [44.9 – 93.1] 
(100%) 
 
61.6 [45.1 – 73.7] 
(100%) 
GSTT1-nullb 
 
6.2 ± 1.7* 
(86%) 
 
2.4 ± 0.4 
(109%) 
 
66.5 [49.5 – 101.1] 
(109%) 
 
66.4 [56.7 – 85.4]* 
(108%) 
aActive (present) if at least one active allele present.  bInactive (null) if no active alleles present; *if p < 
0.05, **if p < 0.01 All values are presented as mean ± standard deviation or median with interquartile 
range, depending on normality of distribution 
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Figure 17.  Protein carbonyls in plasma of ESRD patients in terms of GST genotype. *p < 
0.05, **p < 0.01 
The most pronounced effect regarding AOPP content was observed in the ESRD 
patients with GSTM1-null genotype when compared to the patients with GSTM1-active 
genotype (66.3 [52.5 – 86.2] and 57.9 [32.8 – 69.4], respectively). Another significant increase 
in AOPP concentrations has been shown in patients carrying  GSTT1-null genotype (66.4 [56.7 
– 85.4]) in comparison to the ESRD patients with GSTT1-active genotype (61.6 [45.1 – 73.7]). 
 
 
Figure 18. AOPP content in terms of GST genotype in plasma of ESRD patients. *p < 0.05, 
**p < 0.01 
  AA  AB  BB  Active  Null       IleIle IleVal ValVal     CC   CT           Active  Null 
    GSTA1            GSTM1          GSTP1rs1695      GSTP1 rs1138272    GSTT1 
* 
* 
AA  AB  BB        Active  Null       IleIle  IleVal  ValVal     CC   CT               Active  Null       
GSTA1               GSTM1          GSTP1 rs1695       GSTP1 rs1138272        GSTT1 
* * 
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Furthermore, nitrotyrosine, a reliable marker of nitrosative damage of proteins, was 
found to be significantly higher in ESRD patients carrieng at least one variant allele 
GSTP1*Val (rs1695 polymorphism). Namely, the patients with GSTP1*Ile/*Ile genotype had 
54.6 [39.0 – 78.7] nmol/L of nitrotyrosine measured in plasma, while the ESRD patients with 
present variant GSTP1 gene had 75.5 [50.1 – 101.2] if they had GSTP1*Ile/*Val genotype and 
72.3 [46.8 – 93.1] nmol/L of nitrotyrosine if they carried GSTP1*Val/*Val genotype. Other 
GST genotypes did not significantly influence the level of nitrosative oxidative damage in 
ESRD patients (Figure 19).  
 
 
Figure 19. Nitrosative protein damage in terms of GST genotype in ESRD patients. *p < 0.05, 
**p < 0.01 
4.4.2 Impact of GST genotype on lipid oxidative damage 
Malondialdehyde (MDA), a commonly used byproductr of lipid oxidative damage, 
exists both as free and bound to proteins. When bound to proteins, it is designated as MDA 
adduct. Levels of both MDA and MDA adducts were changed in terms of GST genotype and 
these results are presented in Table 11 and Figures 20 and 21.  
Malonidialdehyde levels were significantly changed in terms of GSTP1 genotype 
(rs1695). Namely, patients with GSTP1*Val/*Val genotype had 2.6 [2.0 – 3.2] mmol/l of 
AA  AB  BB        Active  Null       IleIle  IleVal  ValVal     CC   CT               Active  Null       
GSTA1               GSTM1          GSTP1 rs1695       GSTP1 rs1138272        GSTT1 
* 
* 
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MDA compared to 2.1 [1.7 – 2.8] mmol/l in patients with GSTP1*Ile/*Ile genotype (+24 %, p 
< 0.05). Although the increase of MDA concentrations has been observed in patients with 
GSTT1-null genotype when compared to the patients with GSTT1-active genotype, statistical 
significance was not observed. Polymorphisms of other GST genes did not influence 
significantly on the MDA values in patients with end-stage renal disease (Figure 20). 
Table 11. Byproducts of lipid oxidative damage stratified according to GST genotype in ESRD 
patients. All values are presented as mean ± SD or median with interquartile range (IQR). 
Genotype MDA 
mmol/L 
MDA adducts 
pmol/mg 
GSTA1*A/*A 
2.3 [2.0 – 3.0]  
(100%) 
39.8 ± 9.8  
(100%) 
GSTA1*A/*B 
2.4 [1.7 – 3.0]  
(104%) 
39.7 ± 9.1 
(99.7%) 
GSTA1*B/*B 
2.3 [1.7 – 3.1] 
(100%) 
40.2 ± 12.8 
(101%) 
GSTM1-activea 
 
2.3 [1.7 – 3.1]  
(100%) 
 
 
33.0 ± 7.9 
(100%) 
GSTM1-nullb 
2.4 [1.8 – 3.0] 
(104%) 
44.8 ± 8.3** 
(136%) 
GSTP1*Ile/*Ile 
2.1 [1.7 – 2.8] 
(100%) 
36.2 ± 7.7 
(100%) 
GSTP1*Ile/*Val 
2.4 [1.7 – 3.0] 
(114%) 
41.8 ± 10.2* 
(115%) 
GSTP1*Val/*Val 
2.6 [2.0 – 3.2]* 
(124%) 
41.0 ± 7.8* 
(113%) 
GSTP1*C/*C 
2.2 [1.7 – 2.5] 
(100%) 
38.2 ± 9.83 
(100%) 
GSTP1*C/*T 
2.4 [1.8 – 3.2] 
(109%) 
39.3 ± 10.1 
(103%) 
GSTT1 activea 
2.3 [1.7 – 2.8] 
(100%) 
36.7 ± 8.9 
(100%) 
GSTT1-nullb 
2.6 [1.7 – 3.3] 
(113%) 
45.1 ± 9.7** 
(123%) 
aActive (present) if at least one active allele present. bInactive (null) if no active alleles present; *if p < 
0.005, **if p < 0.001 
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Figure 20. Malondialdehyde content in terms of GST genotypes. *p < 0.05, **p < 0.01 
Patients with GSTM1-null genotype had 36% higher concentration of MDA adducts 
when compared to patients with GSTM1-active genotype (44.8 ± 8.3 vs 33.0 ± 7.9). The 
statistically significant increase of MDA adducts level was also observed in GSTP1 rs1695 
polymorphism where patients with heterozygous genotype had 41.8 ± 10.2 pmol/g of MDA 
adducts in comparison with 36.2 ± 7.7 pmol/g in ESRD patients with GSTP1*Ile/*Ile 
genotype. Similarly, the ESRD patients with GSTT1-null genotype had around 23% elevated 
MDA adducts when compared to the patients with GSTT1-active genotype (Figure 21). 
 
 
 
 
 
 
 
 
 
 
Figure 21. MDA adducts content in terms of GST genotypes. *p < 0.05, **p < 0.01 
AA  AB  BB   Active Null   IleIle  IleVal ValVal   CC CT   Active Null 
   GSTA1        GSTM1        GSTP1 rs1695   GSTP1 1138272  GSTT1 
* 
*
* 
* * 
AA  AB  BB        Active  Null       IleIle  IleVal  ValVal     CC   CT               Active  Null       
GSTA1               GSTM1          GSTP1rs1695       GSTP1 rs1138272        GSTT1 
* 
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4.4.3 Impact of GST genotype on TOS and PAB 
Since the effects of different oxidant molecules are additive, total oxidant status and 
prooxidant-antioxidant balance in plasma of hemodialysis patients were determined. Results 
are shown on Table 12 and Figure 22 and Figure 23. 
.Table 12. Total oxidant status and prooxidant antioxidant balance in terms of GST genotype. 
Genotype 
TOS  
µmol of H2O2 equivalents/ml 
PAB 
HK units 
GSTA1*A/*A 
16.2 [12.8 – 38.2] 
(100%) 
119.0 [70.2 – 297.0] 
(100%) 
GSTA1*A/*B 
21.5 [13.9 – 51.5] 
(133%) 
157.4 [75.8 – 232.4] 
(132%) 
GSTA1*B/*B 
17.8 [12.7 – 41.5] 
(110%) 
147.2 [ 72.2 – 230.4] 
(124%) 
GSTM1-activea 
14.2 [11.5 - 21.2] 
(100%) 
124.8 [69.8 – 202.5] 
(100%) 
GSTM1-nullb 
29.5 [15.3 – 64.5]* 
(208%) 
159.4 [75.0 -256.6]* 
(128%) 
GSTP1*C/*C 
17.6 [12.7 – 49.3] 
(100%) 
152.4 [84.6 – 230.4] 
(100%) 
GSTP1*C/*T 
19.1 [13.1 – 42.2] 
(109%) 
148.2 [63.4 - 237.0] 
(97%) 
GSTP1*Ile/*Ile 
16.9 [13.0 – 48.9]  
(100%) 
148.9 [85.4 – 233.8] 
(100%) 
GSTP1*Ile/*Val 
19.5 [12.8 – 44.2] 
(115%) 
154.4 [68.0 – 253.9] 
(104%) 
GSTP1*Val/*Val 
19.7 [14.8 – 48.3] 
(117%) 
139.2 [70.2 - 227.8] 
(93%) 
GSTT1 active 
19.2 [12.8 – 41.5] 
(100%) 
143.0 [66.6 – 232.2] 
(100%) 
GSTT1-null 
18.2 [13.4 – 64.5] 
(95%) 
153.8 [94.6 – 259.4] 
(108%) 
aActive (present) if at least one active allele present. bInactive (null) if no active alleles present; *if p < 
0.005, **if p < 0.001 
Regarding the results on association of GST genotype and total oxidant status, the 
significant increase was observed in patients with GSTM1-null genotype when compared to the 
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patients with GSTM1-active genotype (29.5 [15.3 – 64.5] µmol of H2O2 equivalents/ml vs. 14.2 
[11.5 – 21.2] µmol of H2O2 equivalents/ml, p < 0.05). The patients lacking GSTM1 
antioxidant activity had doubled increased levels of TOS than end-stage renal disease patients 
with at least one present GSTM1 gene. In other analyzed genotypes (GSTA1, GSTP1 
rs1138272, GSTP1 rs1695, GSTT1) no significant increase of TOS level was observed. 
Interestingly, although the GSTA1 heterozygous patients had an increase of TOS for 33% in 
comparison to GSTA1*A/*A genotype carriers, the ESRD patients with GSTA1*B/*B 
genotype had increase of 10% of total oxidant status when compared to the patients carrying 
referent genotype (GSTA1*A/*A: 16.2 [12.8 – 38.2]; GSTA1*A/*B: 21.5 [13.9 – 51.5]; 
GSTA1*B/*B: 17.8 [12.7 – 41.5]) (Figure 22). 
 
 
 
Figure 22. Total oxidant status in terms of GST genotype in ESRD patients. *p < 0.05, **p < 
0.01 
The levels of prooxidant-antioxidant balance assay were significantly increased only in 
ESRD patients with GSTM1-null genotype when compared to the patients with GSTM1-active 
genotype. Namely, the patients with homozygous deletion of GSTM1 gene had 159.4 [75.0 -
256.6] HK units which is around 28% higher than concentration of PAB measured in patients 
with at least one GSTM1 gene present (GSTM1-active genotype, 124.8 [69.8 – 202.5] HK units). 
The presence of variant GSTA1*B allele influced the levels of PAB in ESRD patients by 
AA  AB  BB         Active  Null       IleIle IleVal  Val Val   CC  CT             Active  Null  
GSTA1               GSTM1                GSTP1 rs1695    GSTP1 rs1138272      GSTT1 
 
* 
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increasing them, but although that increase for geterozygous was more than 30%, the result 
remained statistically insignificant (GSTA1*A/*A: 119.0 [70.2 – 297.0]; GSTA1*A/*B: 157.4 
[75.8 – 232.4]; GSTA1*B/*B: 147.2 [ 72.2 – 230.4], p > 0.05). The median concentrations of 
PAB were were not changed in terms of other GST genotypes (GSTT1-null, GSTP1*Val/*Val 
and GSTP1*C/*T) (Figure 23). 
 
 
 
Figure 23. Prooxidant-antioxidant balance in terms of GST genotype in ESRD patients. *p < 
0.05, **p < 0.01 
4.4.4 Impact of GST genotype on circulating soluble adhesion molecules 
concentration 
Giving a thought that oxidative stress contributes to initiation and progression of 
atherosclerosis through a process predominantly mediated by adhesion molecules, one of the 
aims in this thesis was to investigate the association between the concentrations of circulating 
soluble intercellular (sICAM-1) and vascular cellular (sVCAM-1) adhesion molecules, 
determined in plasma of ESRD patients, and GST genotype. These results are presented in 
Table 13 and Figures 24 and 25. 
AA  AB  BB        Active  Null    IleIle  IleVal  ValVal     CC  CT           Active  Null          
GSTA1                GSTM1             GSTP1 rs1695     GSTP1 rs1138272    GSTT1   
 
* 
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Table 13. Association of GSTA1, GSTM1, GSTP1 rs 1138272, GSTP1 rs1695 and GSTT1  
polymorphism with soluble adhesion molecule concentration in plasma of patients with end-
stage renal disease. All results are presented as mean ± SD. 
Genotype sICAM-1 (pg/mL) sVCAM-1 (ng/mL) 
GSTA1*A/*A 
87.1±27.6 
(100%) 
607.5±131.4 
(100%) 
GSTA1*A/*B 
90.9±24.1 
(104%) 
613.9±125.1 
(101%) 
GSTA1*B/*B 
106.8±15.0 
(123%) 
637.4±115.2 
(105%) 
GSTM1-activea 
83.7±27.6 
(100%) 
529.4±134.2 
(100%) 
GSTM1-nullb 
96.0±25.4* 
(115%) 
669.7±82.6** 
(127%) 
GSTP1*Ile/*Ile 
91.1±25.8 
(100%) 
604.7±131.5 
(100%) 
GSTP1*Ile/*Val 
91.8±27.3 
(101%) 
626.9±108.8 
(104%) 
GSTP1*Val/*Val 
89.2±21.6 
(98%) 
616.6±139.3 
(102%) 
GSTP1 *C/*C 
88.5±21.3 
(100%) 
599.0±132.5 
(100%) 
GSTP1*C/*T 
98.9±30.9 
(112%) 
650.3±115.6* 
(109%) 
GSTT1-active 
91.7±22.1 
(100%) 
618.3±129.6 
(100%) 
GSTT1-null 
89.7±30.3 
(98%) 
610.5±116.9 
(99%) 
aActive (present) if at least one active allele present. bInactive (null) if no active  alleles present; *if p < 
0.005, ** if p < 0.001 
Concentration of soluble ICAM-1 was also increased in patients with double deletion 
of GSTM1 gene. Namely, GSTM1-null patients had 96.0 ± 25.4 pg/ml concentration of 
sICAM-1 and GSTM-1-active patients had 83.7 ± 27.6 pg/mL of sICAM-1 (p < 0.05) (Figure 
24). Patients with GSTM1-null genotype had significantly increased values of soluble VCAM-1 
concentration (669.7 ± 82.6 ng/mL) compared to patients with GSTM1-active genotype (529.4 
± 134.2 ng/ml, p < 0.001) (Figure 25). Although the presence of GSTA1 gene polymorphism 
has shown the impact of sICAM-1 concentration, the statistical difference was not observed.  
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Figure 24. Soluble ICAM-1 concentrations in plasma of ESRD patients in terms of GST 
genotype. *p < 0.05, **p < 0.01 
Regarding other GST genes, only GSTP1 rs1138272 gene polymorphism influenced the 
soluble adhesion molecules concentration. Patients who were carriers of variant allele had 
significantly increased levels of sVCAM-1 in comparison with those with referent genotype. 
(GSTP1*C/*T: 650.3 ± 115.6 ng/ml, GSTP1*C/*C: 599.0 ± 132.5 ng/ml, p < 0.05). 
 
 
 
 
 
 
 
 
Figure 25. Soluble ICAM-1 concentrations in plasma of ESRD patients in terms of GST 
genotype. *p < 0.05, **p < 0.01 
Other GST’ gene polymorphism, such as GSTT1 and GSTP1 rs1695, did not show any 
significant influence on circulating levels of CAMs.  
  AA  AB  BB     Active  Null      IleIle IleVal ValVal    CC   CT     Active  Null 
      GSTA1          GSTM1         GSTP1 rs1695     GSTP1rs1138272         GSTT1 
AA  AB  BB  Active  Null    IleIle IleVal ValVal   CC   CT         Acive  Null    
    GSTA1     GSTM1          GSTP1 rs1695    GSTP1 rs1138272   GSTT1 
* 
* * 
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4.4.5 Impact of combined GST genotype on markers of oxidative damage 
 
To assess whether the effects of GST null/low-activity genotypes are more pronounced 
when combined, we compared the level of eight oxidative damage byproducts and two cellular 
adhesion molecules with different combination of GSTA1, GSTM1, GSTP1rs1695 and GSTT1 
genotype (Table 14a and 14b). The level of protein thiols was significantly lowered in terms of 
the presence of variant GST allele. Namely, patients with GSTM1-active/GSTT1-active genotype 
had thiols concentration of 8.2 ± 2.4 µmol/g of protein, while the presence of null or low 
activity genotype had diminishing effect on SH groups concentration. Thus, when GSTM1 and 
GSTT1 genotype were combined, it was observed that patients carrying GSTM1-null genotype 
had significantly lowered the amount of protein thiol groups. Patients with GSTM1-
null/GSTT1-active genotype had 6.5 ± 1.2 µmol/g of protein SH group concentration while the 
presence of GSTT1-null genotype diminished thiols even more (5.5 ± 1.4 µmol/g of protein, p 
= 0.001). When GSTA1-low activity genotype was included in stratification, the effect was even 
more pronounced resulting in losing almost 30% of referent thiol concentration 
(GSTM1/GSTT1/GSTA1 active genotype). The lowest SH-groups concentration was observed in 
patients carrying GSTM1-null/GSTT1-null/GSTA1-low activity/GSTP1-low activity genotype 
where it was determined 5.3 ± 1.2 µmol/g of protein SH group concentration.  
Protein carbonyls, another marker of protein oxidative damage, were significantly 
increased in patients with null or low activity GST genotype present. As presented in Table 
14a, the protein carbonyls concentration gradually increased in terms of GST genotype. Thus, 
patients with both GSTM1- and GSTT1-null genotype had 123.8% increased concentration of 
carbonyls in comparison to ESRD patients with GSTM1-active/GSTT1-active genotype. The 
presence of GSTA1-low activity and GSTP1-low activity genotype further increased carbonyls in 
plasma of ESRD patients. It was determined that patients with all null or low activity GST 
genotype combination ha 126% increased protein carbonyls compared to the patients with all 
active GST genotypes (2.9 ± 0.6 vs. 2.3 ± 0.1, respectively).  
Similar effect was observed in increased AOPP concentration in terms of GST 
genotype combinations. The ESRD patients who carried all null or low activity GST genotypes 
had up to 25% increased AOPP content when compared to appropriate referent group (72.3 
[61.4 - 218.2] and 57.9 [28.3 - 70.0] mmol/L, respectively; p = 0.038).  
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The level of MDA was lowest in ESRD patients with both GSTM1-active/GSTT1-active 
genotype, and then gradually increased with the presence of null or low activity genotypes, 
reaching 2.6 [1.6 - 3.1] mmol/L of MDA concentration in ESRD patients with GSTM1-
null/GSTT1-null genotype combination. However, when GSTA1 and GSTP1 genotypes were 
included in the model, it was observed that the presence of their low activity alleles further 
increases the level of MDA measured in plasma. Thus, the highest level of MDA was 
determined in patients carrying GSTM1-null/GSTT1-nul/GSTP1-low activity genotype although 
statistical significance was not observed.  
As far as MDA adducts were concerned, similar effect was observed. Presence of GST 
null or low activity genotypes was influenced significantly the MDA adducts in ESRD patients. 
The highest concentration was measured in ESRD patients with GSTM1-null/GSTT1-
null/GSTA1-low activity genotype who had almost 2-fold increase of MDA adducts when 
compared to the patients with referent (GSTM1-active/GSTT1-active/GSTA1-active) genotype 
(53.2 ± 8.9 pmol/mg and 31.1 ± 8.3 pmol/mg, respectively; p = 0.001).  
Total oxidant status was further analyzed in terms of combined GST genotypes. When 
GSTM1 and GSTT1 genotypes were combined, it was observed that the presence GSTM1-null 
genotype influenced significantly the increase of TOS level in ESRD patients. Combination of 
GSTA1-low activity or GSTP1-low activity genotype  with GSTM1/GSTT1, gave also higher TOS 
levels when compared to appropriate reference groups, although the statistical significance was 
present only in combination of GSTM1-null/GSTT1-null/GSTA1-low activity genotypes (p = 
0.044). Values of PAB were also increased in favor of null or low activity GST genotype, 
although statistical significance was not present. 
Combined GST genotypes did not influence the sICAM-1 concentration in plasma of 
ESRD patients. On the other hand, significant association of sVCAM-1 concentrations with 
different GST genotypes combinations was observed. Namely, the patients with both GSTM1 
and GSTT1 null genotypes present had significant increase of sVCAM-1 in plasma (49.6 ± 9.6 
vs. 29.4 ± 6.8 in GSTM1-active/GSTT1-active patients, p = 0.001). This trend was continued 
further with the presence of GSTP1-low activity genotype in combination (35% increase in 
concentration, p = 0.001) (Table 14b).  
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Table 14a. Association of combined GST genotypes with byproducts of oxidative stress in plasma of ESRD patients 
 
 
Combined Genotypes 
Thiols 
(μmol/g) 
Carbonyls 
(nmol/mg) 
AOPP 
(mmol/L) 
Nitrotyrosine 
(nmol/L) 
MDA adducts  
(pmol/mg) 
[C] p [C] p [C] p  p [C] p 
GSTM1 active/GSTT1 active 8.2±2.4 
100% 
 2.1±0.3 
100% 
 57.1[28.3-69.4] 
100% 
 60.2[43.7-93.1] 
100% 
 29.4±6.8 
100% 
 
GSTM1active/GSTT1 null 7.1±1.7 
86.6% 
0.029 2.3±0.3 
109.5% 
0.290 64.5[48.8-80.8] 
113% 
0.450 62.4[46.1-93.1] 
104% 
0.279 40.0±5.9 
136.1% 
0.001 
GSTM1 null/GSTT1 active 6.5±1.2 
79.3% 
0.001 2.4±0.0.4 
114.3% 
0.586 61.1[38.5-69.7] 
107% 
0.021 72.3[50.1-101.2] 
120% 
0.168 42.0±6.0 
142.9% 
0.001 
GSTM1 null-GSTT1 null 5.5±1.4 
67.1% 
0.001 2.6±0.5 
123.8% 
0.003 73.9[61.6-213.9] 
129% 
0.001 64.5[48.8-78.7] 
107% 
0.073 49.6±9.6 
168.7% 
0.001 
GSTM1/GSTT1/GSTA1 active 8.8±1.2 
100% 0.001 
2.2±0.2 
100% 0.002 
50.1 [26.7-66.9 
100% 0.001 
62.8[46.1-93.1] 
100% 0.718 
31.1±8.3 
100% 0.001 
GSTM1/GSTT1/GSTA1  null or low 
activity 
5.5±1.2 
62.5% 
2.9±0.5 
131.8% 
77.1[62.6-214.5] 
154% 
75.5[72.3-78.7] 
120% 
53.2±8.9 
171.1% 
GSTM1/GSTT1/ GSTP1 active 8.4±2.8 
100% 0.001 
2.2±0.2 
100% 0.024 
56.4[31.9-70.0] 
100% 0.022 
62.8[46.1-89.3] 
100% 0.040 
30.0±6.4 
100% 0.001 
GSTM1/GSTT1/ GSTP1  null or low 
activity 
5.2±1.2 
61.9% 
2.6±0.5 
118.2% 
72.9[31.9-184.9] 
129% 
59.3[46.8-78.7] 
94% 
49.4±9.9 
164.7% 
GSTM1/GSTT1/GSTA1/GSTP1 active 9.5±2.3 
100% 0.001 
2.3±0.1 
100% 0.037 
57.9[28.3-70.0] 
100% 0.038 
55.4[39.5-72.6] 
100% 0.169 
33.5±6.2 
100% 0.001 
GSTM1/GSTT1/GSTA1/GSTP1 null or 
low activity 
5.3±1.2 
55.8% 
2.9±0.6 
126.1% 
72.3[61.4-218.2] 
125% 
59.3[48.8-75.5] 
107% 
52.6±8.4 
157.0% 
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Combined Genotypes 
MDA 
(mmol/L) 
PAB 
(HK units) 
TOS 
(μmol H2O2 equiv./L) 
sICAM-1 
(ng/ml) 
sVCAM-1 
(ng/ml) 
[C] p [C] p [C] p [C] p [C] p 
GSTM1 active/GSTT1 active 2.2[1.7-2.8] 
100% 
 113.4[67.4-192.2] 
100% 
 14.2[12.2-21.2] 
100% 
 85.5±24.4 
100% 
 595.2±104.3 
100% 
 
GSTM1active/GSTT1 null 2.4[1.8-2.9] 
109% 
0.269 161.2[64.0-264.6] 
142% 
0.127 31.5[16.2-55.7] 
222% 
0.315 95.9±19.7 
112% 
0.115 653.7±66.6 
110% 
0.001 
GSTM1 null/GSTT1 active 2.6[1.8-3.3] 
118% 
0.132 157.4[95.8-269.8] 
139% 
0.08 16.2[12.7-23.9] 
114% 
0.001 80.4±22.3 
94% 
0.547 593.9±94.2 
100% 
0.770 
GSTM1 null-GSTT1 null 2.6[1.6-3.1] 
118% 
0.098 151.4[95.0-244.0] 
133% 
0.181 42.0[14.9-272.2] 
296% 
0.002 96.1±34.1 
112% 
0.290 658.6±59.1 
111% 
0.001 
GSTM1/GSTT1/GSTA1 active 2.2[1.5-2.8] 
100% 0.188 
128.6[66.6-193.4] 
100% 0.402 
14.2[12.1-19.2] 
100% 0.044 
81.8±14.4 
100% 0.067 
526.9±142.3 
100% 0.292 
GSTM1/GSTT1/GSTA1null or low 
activity 
2.5[1.1-2.9] 
114% 
163.4[151.4-175.4] 
127% 
11.5[9.6-13.4] 
81% 
116.0±23.6 
142% 
635.8±26.1 
121% 
GSTM1/GSTT1/ GSTP1 active 2.2[1.7-2.8] 
100% 0.026 
107.8[68.0-186.8] 
100% 0.361 
14.2[12.2-24.2] 
100% 0.068 
88.8±23.5 
100% 0.473 
522.6±129.2 
100% 0.001 
GSTM1/GSTT1/ GSTP1  null or low 
activity 
3.8[3.1-6.9] 
173% 
154.2[127.2-203.4] 
143% 
59.8[15.2-272.8] 
421%% 
101.3±2.8 
114% 
703.7±79.8 
135% 
GSTM1/GSTT1/GSTA1/GSTP1 
active 
2.3[1.5-2.7] 
100% 0.111 
175.8[28.6-232.2] 
100% 0.791 
14.2[11.5-14.8] 
100% 0.096 
87.1±18.5 
100% 0.569 
628.8±76.8 
100% 0.007 
GSTM1/GSTT1/GSTA1/GSTP1 
null or low activity 
2.6[1.8-3.8] 
113% 
137.4[87.8-221.2] 
78% 
20.1[13.4-271.5] 
141% 
99.8±27.9 
115% 
671.7±75.4 
107% 
Table 14b. Association of combined GST genotypes with MDA, PAB, TOS, sICAM-1 and sVCAM-1 from plasma of ESRD patients 
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4.5 PREDICTIVE ROLE OF GST GENOTYPE 
During a five year follow-up death outcomes and cardiovascular complications 
were prospectively registered in order to test predictive role of GST genotype on ESRD 
patients’ outcome. A total of 186 patients were followed to the death or the end of 5 years 
follow up. Overall mortality rate was 51.6% (96 patients) with 58 cardiovascular deaths 
(cardiovascular mortality rate was 30.7%). Around 90 registered deaths were of other 
causes (cachexia, gastro-intestinal bleeding, infections, malignant disease). Within 
cardiovascular deaths, for 36 patients (19%) the myocardial infarction (MI) was the cause, 
while for the 25 (13.2%) the cerebral vascular insult (CVI) was the cause. Three patients 
were with both MI and CVI registered as the causes of death. The mean survival time for 
all patients was 44 ± 20 months. Multivariable Cox regression analysis was used to test the 
independent influence of GST gene polymorphisms on predicting all-cause (overall), 
cardiovascular mortality as well as the death of myocardial infarction and cerebral vascular 
insult (stroke). Three models were used. The first one calculated hazard ratio adjusted for 
age and gender. The second one included smoking status of patients, besides age and 
gender. The third one included everything as the second one with added adjustment for 
diabetes and cholesterol level. Kaplan-Meier survival curve analysis was used to test the 
influence of GST gene polymorphism on ESRD patients’ survival and to estimate mean 
survival time. 
4.5.1 Lack of association between GSTA1 genotype and overall or cardiovascular 
mortality 
Table 15 represents the association of GSTA1 polymorphism with overall, 
cardiovascular mortality as well as the death of myocardial infarction and stroke. Patients 
were dichotomized on those homozygous for variant allele (GSTA1 *B/*B genotype) and 
those who carried at least one reference allele (GSTA1 *A /*A and GSTA1 *A/*B 
genotypes). The GSTA1-low activity genotype did not represent a predictor of higher risk for 
neither overall nor cardiovascular mortality among patients with end-stage renal disease. 
Slightly increase of hazard ratio was observed in Model 3 for cardiovascular mortality, 
although far from being statistically significant. Based on Kaplan-Meier survival curve 
analysis, ESRD patients with GSTA1-low activity genotype did not affect survival of patiens 
with ESRD (Figure 26).  
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Table 15. GSTA1 polymorphism as a predictor for overall and cardiovascular mortality as 
well as death of myocardial infarction and cerebral vascular insult 
Model 1a Model 2b Model 3c 
HR (95% CI) P value HR (95% CI) P value HR (95% CI) P value 
Risk for overall mortality comparing GSTA1*B homozygotes to GSTA1*A carriers 
0.87 (0.53-1.45) 0.598 0.97 (0.56-1.68) 0.92 0.98 (0.56-1.74) 0.969 
Risk for cardiovascular mortality comparing GSTA1*B homozygotes to GSTA1*A carriers  
1.09 (0.55-2.16) 0.808 1.16 (0.56-2.39) 0.697 1.23 (0.58-2.63) 0.593 
Risk for death from MI comparing GSTA1*B homozygotes to GSTA1*A carriers  
1.23 (0.42-3.59) 0.709 0.81 (0.35-1.90) 0.63 0.89 (0.36-2.2) 0.795 
Risk for death from CVI comparing GSTA1*B homozygotes to GSTA1*A carriers 
0.79 (0.36-1.74) 0.56 1.24 (0.42-3.69) 0.69 1.19 (0.40-3.53) 0.75 
Abbreviations: CI, Confidence Interval; HR, Hazard Ratio. aAdjusted for age and gender. bAdjusted 
for the covariates in Model 1 plus smoking status. cAdjusted for the covariates in Model 2 plus 
diabetes and cholesterol level. 
 
Figure 26. Kaplan-Meier survival analysis for overall, cardiovascular, cerebral vascular 
insult and myocardial infarction survival regarding GSTA1 genotype. 
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4.5.2 A significant association of GSTM1 deletion polymorphism with all cause 
and cardiovascular mortality 
The presence of GSTM1-null genotype was independent predictor of overall and 
cardiovascular mortality risk among ESRD patients (Table 16). Patients with GSTM1 
homozygous deletion had a significantly increased risk for overall mortality (Model 1: HR 
= 1.8, 95% CI: 1.1 - 2.8, p = 0.009). Introducing additional parameters into the Cox 
regression model did not alter the risk which remained significantly increased (Model 2: HR 
= 1.8, 95% CI: 1.12 - 2.84, p = 0.015 and Model 3: HR = 1.7, 95%CI: 1.07-2.75, p = 
0.025). Cardiovascular mortality risk was statistically significant increased in all three 
models considered (Model 1: HR = 2.3, 95% CI: 1.28 - 4.29, p = 0.006; Model 2: HR = 
2.1, 95% CI: 1.14 - 3.93, p = 0.018, Model 3: HR = 2.02, 95% CI: 1.08 - 3.80, p = 0.028). 
Additionally, GSTM1-null genotype has shown significant effect on myocardial infarction 
mortality with HR=2.3 (95% CI: 1.06 - 4.83, p = 0.035). However, although HR for 
cerebral vascular insult mortality was high (HR = 2.3) this was shown statistically 
insignificant (95% CI: 0.91 -5.76 p = 0.078).  
Table 16 GSTM1 gene deletion polymorphism as a predictor for overall and cardiovascular 
mortality as well as death of myocardial infarction and cerebral vascular insult 
Model 1a Model 2b Model 3c 
HR (95% CI) P value HR (95% CI) P value HR (95% CI) P value 
Risk for overall mortality comparing GSTM1-null to GSTM1-active carriers  
1.8 (1.15-2.77) 0.009 1.8 (1.12-2.84) 0.015 1.7 (1.07-2.75) 0.025 
Risk for cardiovascular mortality comparing GSTM1-null to GSTM- active carriers  
2.3 (1.28-4.29) 0.006 2.1 (1.14-3.93) 0.018 2.0 (1.08-3.80) 0.028 
Risk for death from myocardial infarction comparing GSTM1-null to GSTM1-active carriers  
2.3 (1.06-4.83) 0.035 2.0 (0.89-4.30) 0.094 1.8 (0.80-3.99) 0.155 
Risk for death from CVI comparing GSTM1-null to GSTM1-active carriers  
2.3 (0.91-5.76) 0.078 2.1 (0.82-5.36) 0.122 2.1 (0.84-5.55) 0.113 
Abbreviations: CI, Confidence Interval; HR, Hazard Ratio. aAdjusted for age and gender. bAdjusted 
for the covariates in Model 1 plus an additional adjustment for smoking status. cAdjusted for the 
covariates in Model 2 plus an additional adjustment for diabetes and cholesterol level. 
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A Kaplan-Meier survival analysis demonstrated shorter overall (Log Rank = 5.718, 
p=0.017) and cardiovascular survival (Log rank = 6.275, p = 0.006) as well as shorter time 
to death of MI (Log Rank = 3.088, p = 0.038) (Figure 27). Mean overall survival time for 
GSTM1-null patients was 41.7 months (38.0 - 45.4), while for GSTM1-active patients it was 
47.5 months (43.1 - 51.9). Patients with homozygous deletion of GSTM1 gene had mean 
cardiovascular survival time of 46.9 months (43.4 - 50.5), while those with GSTM1-active 
genotype lived averagely 53.0 months (49.3 - 56.7). Average survival time for myocardial 
infarction was 52.0 months (48.9 - 55.1) for GSTM1-null genotype patients in comparison 
with GSTM1-active genotype patients who lived 55.0 months (51.6-58.1). Regarding cerebral 
vascular insult survival, Kaplan-Meier survival analysis curve has shown that GSTM1-null 
genotype did not affect it (Log Rank = 3.217, p=0.073) (Figure 27). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 27. Kaplan-Meier survival analysis for overall, cardiovascular, cerebral vascular 
insult and myocardial infarction survival regarding GSTM1 genotype 
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4.5.3 Association of GSTT1 genotype with all cause and cardiovascular 
mortality 
 
Table 17 summarizes the association of GSTT1 gene deletion polymorphism with 
overall, cardiovascular mortality as well as the death of myocardial infarction and cerebral 
vascular insult (stroke). No association was found for any cause of the death regarding 
GSTT1-null genotype in patients with end-stage renal disease. Namely, patients lacking 
GSTT1 activity had no increased risk for either overall (HR = 1.1, 95% CI: 0.705 - 1.67, p 
= 0.712) or cardiovascular mortality (HR = 1.2, 95% CI: 0.68 - 2.2, p = 0.906). 
Homozygous deletion of this gene was not shown to be significant for special causes of 
death, including myocardial infarction (HR = 1.1, 95%CI: 0.56 - 2.28, p = 0.733) and 
cerebral vascular insult (HR = 1.1, 95% CI: 0.46 - 2.50, p = 0.879).  
Kaplan-Meier survival analysis showed no impact of GSTT1-null genotype of 
ESRD patient’s survival considering overall, cardiovascular, cerebral vascular insult and 
myocardial infarction cause of death (Figure 28). 
Table 17. GSTT1 gene deletion polymorphism as a predictor for overall and cardiovascular 
mortality as well as death of myocardial infarction and cerebral vascular insult among 
ESRD patients by Cox proportional hazards regression models 
Model 1a Model 2b Model 3c 
HR (95% CI) P value HR (95% CI) P value HR (95% CI) P value 
Risk for overall mortality comparing GSTT1-null  to GSTT1-active carriers 
1.1 (0.71-1.67) 0.712 1.1 (0.59-1.70) 0.712 1.1 (0.66-1.69) 0.811 
Risk for cardiovascular mortality comparing GSTT1-null to GSTT1-active carriers 
1.2 (0.68-2.03) 0.569 1.4 (0.79-2.43) 0.250 1.3 (0.74-2.41) 0.332 
Risk for death from MI comparing GSTT1-null to GSTT- active carriers 
1.1 (0.56-2.28) 0.733 1.5 (0.74-3.14) 0.250 1.5 (0.72-3.27) 0.270 
Risk for death from CVI comparing GSTT- null to GSTT1-active carriers 
1.1 (0.46-2.49) 0.879 1.1 (0.45-2.53) 0.880 1.0 (0.40-2.50) 0.98 
Abbreviations: CI, Confidence Interval; HR, Hazard Ratio. aAdjusted for age and gender. bAdjusted 
for the covariates in Model 1 plus an additional adjustment for smoking status. cAdjusted for the 
covariates in Model 2 plus an additional adjustment for diabetes and cholesterol level. 
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Figure 28. Kaplan-Meier survival analysis for overall, cardiovascular, cerebral vascular 
insult and myocardial infarction survival regarding GSTT1 genotype 
4.5.4 Association of GSTP1 genotype with all cause and cardiovascular mortality 
The Cox proportional hazard model was applied to assess whether polymorphism 
in both GSTP1 gene examined in this thesis is associated with poor outcome of the 
patients on hemodialysis. These results are presented in Table 18.  
As far as GSTP1 rs1695 polymorphism is concerned, patients were dichotomized 
into those with active genotype (GSTP1 *Ile/*Ile+*Ile/*Val) and low activity genotype 
(GSTP1 *Val/*Val genotype). Although the risk was increased (HR = 1.4, 95% CI: 0.70-
2.79), GSTP1 low-activity genotype was not significant predictor of overall death (p = 0.337). 
This genotype was not associated with neither cardiovascular cause of death (HR = 1.4, 
95% CI: 0.79 - 2.47, p = 0.248) nor cerebral vascular cause of death (HR = 1.3, 95% CI: 
0.53 - 3.04, p = 0.602). The GSTP1 Val/Val genotype was associated with doubled 
myocardial infarction risk of death (HR = 2.24, 95%CI: 1.06 - 4.76, p = 0.063) in tested 
Model 2 which was adjusted to age, gender and smoking status. Kaplan-Meier survival 
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analysis showed that patients GSTP1*Val/*Val genotype had significantly shorter 
myocardial infarction survival in comparison to those with GSTP1-active genotype (Log 
rank = 6.08, p = 0.014) (Figure 29). Mean survival time for these patients was 49.2 months 
(43.6 - 54.9), while the ESRD patients who carried at least one GSTP1*Ile allele lived 
averagely 54.5 monts (52.1 – 56.9). 
Table 18. GSTP1 rs1695 and GSTP1 rs1138272 polymorphism as a predictor for overall 
and cardiovascular mortality as well as death of myocardial infarction and cerebral vascular 
insult among ESRD patients by Cox proportional hazards regression models 
Model 1a Model 2b Model 3c 
HR (95% CI) P value HR (95% CI) P value HR (95% CI) P value 
Risk for overall mortality comparing GSTP1*Val homozygotes to GSTP1 Ile carriers  
1.2 (0.78-1.94) 0.378 1.4 (0.84-2.29) 0.203 1.4 (0.81-2.30) 0.248 
Risk for cardiovascular mortality comparing GSTP1*Val homozygotes to GSTP1 Ile carriers 
1.4 (0.79-2.47) 0.248 1.7 (0.9-3.1) 0.103 1.6 (0.84-3.09) 0.151 
Risk for death from myocardial infarction comparing GSTP1*Val homozygotes to GSTP1 Ile carriers 
1.9 (0.97-3.80) 0.063 2.2 (1.06-4.76) 0.035* 2.0 (0.88-4.45) 0.097 
Risk for death from CVI comparing GSTP1*Val homozygotes to GSTP1 Ile carriers 
1.3 (0.53-3.04) 0.602 1.7 (0.69-4.25) 0.25 2.0 (0.78-5.00) 0.15 
Risk for overall mortality comparing GSTP1*C  homozygotes to GSTP1 *T carriers  
0.8 (0.51-1.32) 0.421 0.7 (0.44-1.31) 0.313 0.8 (0.45-1.40) 0.428 
Risk for cardiovascular mortality comparing GSTP1*C homozygotes to GSTP1 *T carriers 
1.1 (0.60-1.92) 0.811 1.0 (0.3-1.7) 0.489 1.2 (0.58-2.24) 0.694 
Risk for death from MI comparing GSTP1*C homozygotes to GSTP1 *T carriers 
1.3 (0.61-2.62) 0.522 1.3 (0.55-2.87) 0.588* 1.6 (0.65-3.71) 0.326 
Risk for death from CVI comparing GSTP1*C homozygotes to GSTP1 *T carriers 
0.9 (0.38-2.26) 0.874 1.0 (0.38-2.52) 0.428 1.0 (0.38-2.72) 0.962 
Abbreviations: CI, Confidence Interval; HR, Hazard Ratio. aAdjusted for age and gender. bAdjusted 
for the covariates in Model 1 plus an additional adjustment for smoking status. cAdjusted for the 
covariates in Model 2 plus an additional adjustment for diabetes and cholesterol level. 
Regarding the impact of GSTP1 rs1138272 polymorphism on patients’ survival, 
results have shown that this SNP does not change the risk of death outcome in none of the 
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causes of death in any of three models considered. Patients with GSTP1*C/*T genotype 
had 1.6 increased risk of fatal outcome, but still statistically insignificant (p = 0.326). The 
risk was even slightly decreased when overall and cerebral vascular causes of death were 
considered but without reaching statistical significance in any of Models. Kaplan Meier 
analysis of survival is presented in Figures 29 (GSTP1 rs1695 polymorphism) and Figure 30 
(GSTP1 rs1138272 polymorphism).  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 29. Kaplan-Meier survival analysis for overall, cardiovascular, cerebral vascular 
insult and myocardial infarction survival regarding GSTP1 genotype (rs1695). 
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Figure 30. Kaplan-Meier survival analysis for overall, cardiovascular, cerebral vascular 
insult and myocardial infarction survival regarding GSTP1 rs1138272 genotype 
4.6 PREDICTIVE ROLE OF OXIDATIVE STRESS BYRODUCTS 
In order to assess the potential predictive role of oxidative stress byproducts, “case 
only” study was performed. A total of 199 patients with ESRD was included in the study 
and followed during 5-years. To examine predictive role of oxidative stress byproducts and 
cellular adhesion molecules, a Cox hazard ration calculations and Kaplan-Meier survival 
analysis were performed. Patients were dichotomized on those with low (below the median 
(med)) and high values (above the median) of the parameter that was considered. The 
predictive role of each byproduct was tested in three Models, each of them being adjusted 
for specific parameters that have been linked to mortality in previous studies (Model 1 was 
adjusted for age and gender; Model 2 adjustment included age, gender and smoking status; 
Model 3 included age, gender, smoking status, cholesterol levels and presence of diabetes 
adjustment parameters). 
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4.6.1 Protein oxidative stress byproducts as possible predictors of patients’ 
outcome 
End-stage renal disease patients with low levels of thiols (above the median) had 
1.7-fold greater risk for CV death in Model 2 (HR = 1.7; 95% CI: 0.96-3.04, p = 0.067). 
Patients with low thiols had almost doubled risk for MI death when compared to those 
with high levels (above the median)(Model 1: HR = 1.9; 95% CI: 0.96 - 3.99, p = 0.064). In 
Model 2 and Model 3 certain increase of MI risk was observed in ESRD patients with low 
thiol levels, but with no statistical significance (Model 2: HR = 1.9; 95% CI: 0.89 - 4.03, p 
= 0.098; Model 3: HR = 1.7; 95% CI: 0.80 - 3.71, p = 0.167). Furthermore, patients with 
thiol concentration below the median level had no shorter survival in comparison with 
those with higher values of thiol content. Kaplan-Meier survival analysis showed that 
ESRD patients with lower thiols concentration have shorter survival of fatal myocardial 
infarction survival (Log-Rank = 3.756, p = 0.053) (Figure 31A).  
The dichotomization of patients based on the median levels of carbonyls showed 
no significant association with increased risk for fatal overall and cardiovascular outcome in 
this group of patients with ESRD (Table 19a). Concentration of carbonyls above the 
median level in plasma of patients with ESRD did not have prognostic level in terms of 
overall and cardiovascular survival, as it has been shown in Kaplan-Meier survival analysis 
(Figure 31B). 
Advanced oxidation protein products (AOPP) level was a significant predictor of 
fatal cardiovascular and myocardial infarction outcome in all three models tested in the 
study. Increase in AOPP concentration above the median level was associated with an 
increased risk for cardiovascular death (Model 1: HR = 2.4; 95% CI: 1.31 - 4.50, p = 0.005; 
Model 2: HR = 2.2, 95%CI: 1.13 - 4.17, p = 0.020; Model 3: HR = 2.1, 95%CI: 1.10 - 4.12, 
p = 0.024). The risk was even more increased when only myocardial infarction death was 
considered. Namely, patients with values of AOPP higher than 64.29 µmol/ L had 3 times 
greater risk for MI compared to the ESRD patients with lower values of AOPP (Model 1: 
HR = 3.3; 95% CI: 1.41 - 7.93, p = 0.006; Model 2: HR = 2.5, 95%CI: 1.01 - 6.17, p = 
0.047) (Table 19b). Although the patients with higher AOPP concentration were at greater 
risk for all-cause and fatal CVI outcome, this increase was not statistically significant. 
Kaplan-Meier survival analysis revealed that patients with high AOPP levels had poorer 
cardiovascular and MI survival than those with low AOPP levels (Log Rank =7.0, p = 
GST Polymorphisms in ESRD Patients  
 
 
76 
 
0.003 and Log Rank = 7.1, p = 0.008, respectively) (Figure 32A). Dichotomization of 
patients based on the median levels of nitrotyrosine showed no significant association with 
any cause of death in these patients. Kaplan-Meier survival analysis did not show shorter 
survival of the patients with higher nitrotyrosine concentration (Table 19b and Figure 32B). 
Table 19a. Protein oxidative byproducts (protein thiols and carbonyls) as predictors for 
overall and cardiovascular mortality as well as death of myocardial infarction and cerebral 
vascular insult among ESRD patients by Cox proportional hazards regression models. 
Model 1a Model 2b Model 3c 
HR (95% CI) P value HR (95% CI) P value HR (95% CI) P value 
Protein thiol gropus (med = 6.7 µmol/ g) 
Risk for overall mortality  
1.3 (0.88-2.01) 0.171 1.4 (0.90-2.15) 0.137 1.3 (0.96-2.07) 0.196 
Risk for CV mortality  
1.6 (0.94-2.79) 0.081 1.7 (0.96-3.04) 0.067 1.6 (0.91-2.89) 0.103 
Risk for death from MI  
1.9 (0.96-3.99) 0.064 1.9 (0.89-4.04) 0.098 1.7 (0.80-3.71) 0.167 
Risk for death from CVI  
1.1 (0.48-2.33) 0.889 1.1 (0.50-2.62) 0.747 1.1 (0.49-2.58) 0.782 
Carbonyls (med = 2.2 nmol/ g) 
Risk for overall mortality 
0.9 (0.44-1.90) 0.813 1.2 (0.56-2.57) 0.635 1.1 (0.51-2.44) 0.779 
Risk for CV mortality 
1.1 (0.47-2.73) 0.786 1.4 (0.57-3.58) 0.453 1.4 (0.53-3.53) 0.523 
Risk for death from MI 
1.0 (0.32-3.17) 0.988 1.3 (0.39-4.27) 0.687 1.3 (0.39-4.54) 0.655 
Risk for death from CVI 
1.9 (0.59-6.11) 0.282 2.2 (0.66-7.32) 0.200 2.5 (0.67-9.09) 0.173 
Abbreviations: CI, Confidence Interval; HR, Hazard Ratio. aAdjusted for age and gender. bAdjusted 
for the covariates in Model 1 plus an additional adjustment for smoking status. cAdjusted for the 
covariates in Model 2 plus an additional adjustment for diabetes and cholesterol level. 
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Table 19b. Protein oxidative byproducts AOPP and nitrotyrosine as a predictor for overall 
and cardiovascular mortality as well as death of myocardial infarction and cerebral vascular 
insult among ESRD patients by Cox hazard regression model. 
Model 1a Model 2b Model 3c 
HR (95% CI) P value HR (95% CI) P value HR (95% CI) P value 
AOPP (med = 64.3 µmol/L) 
Risk for overall mortality  
1.5 (0.97-2.36) 0.075 1.5 (0.92-2.42) 0.104 1.5 (0.91-2.41) 0.119 
Risk for CV mortality  
2.4 (1.3-4.5) 0.005 2.2 (1.13-4.17) 0.020 2.1 (1.10-4.12) 0.024 
Risk for death from MI  
3.3 (1.41-7.93) 0.006 2.5 (1.01-6.17) 0.047 2.4 (0.94-5.93) 0.066 
Risk for death from CVI  
1.5 (0.65-3.43) 0.351 1.8 (0.73-4.39) 0.203 1.8 (0.73-4.44) 0.198 
Nitrotyrosine (med = 64.5 nmol/L) 
Risk for overall mortality 
1.2 (0.77-1.86) 0.432 1.1 (0.70-1.81) 0.611 1.1 (0.70-1.82) 0.618 
Risk for cardiovascular mortality 
1.7 (0.90-3.05) 0.104 1.6 (0.83-3.03) 0.164 1.6 (0.83-3.13) 0.523 
Risk for death from MI 
1.8 (0.80-3.98) 0.160 1.8 (0.73-4.38) 0.200 2.0 (0.79-5.13) 0.142 
Risk for death from CVI 
1.6 (0.65-3.73) 0.318 1.5 (0.60-3.50) 0.404 1.4 (0.57-3.29) 0.490 
Abbreviations: CI, Confidence Interval; HR, Hazard Ratio. 
aAdjusted for age and gender. bAdjusted for the covariates in Model 1 plus an additional adjustment 
for smoking status. cAdjusted for the covariates in Model 2 plus an additional adjustment for 
diabetes and cholesterol level 
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Figure 31. Kaplan-Meier survival curves for overall, cardiovascular, CVI and MI survival 
of ESRD patients dichotomized by median levels of thiol groups (А) and carbonyls (B). 
A 
B 
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Figure 32. Kaplan-Meier survival curves for overall, cardiovascular, CVI and MI survival 
of ESRD patients dichotomized by median levels of AOPP (A) and nitrotyrosine (B) 
A 
B 
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4.6.2 The possible predictive role of malondialdehyde 
Patients with ESRD were dichotomized based on median levels of 
malondialdehyde (median was 2.3 mmol/L) measured in plasma of these patients. 
Univariate Cox’s proportional hazards regression analysis showed that high values of MDA 
(above median) are strong predictor of mortality in ESRD patients (Table 20). Namely, 
overall mortality of hemodialysis patients was significantly increased in patients with MDA 
concentration above median level (Model 1: HR = 1.5, 95%CI = 1.00 - 2.28, p = 0.049, 
Model 2: HR= 1.6, 95% CI = 1.05 - 2.52, p = 0.029). Patients with high MDA levels were 
at greater risk for cardiovascular mortality and this risk was even increased when data were 
adjusted to additional parameters considered in Model 2 and Model 3 (Model 1: HR = 1.9, 
95%CI: 1.11 - 3.28, p = 0.019, Model 2: HR = 2.4, 95% CI: 1.33 - 4.20, p = 0.003; Model 
3: HR = 2.2, 95% CI: 1.18 - 3.93, p = 0.012). Malondialdehyde has shown possible 
predictive role for cerebral vascular insult and myocardial infarction fatal outcome as well. 
Thus the risk for death of cerebral vascular insult was up to three times higher in patients 
with MDA levels above the median (HR = 3.0, 95%CI: 1.21-7.39, p = 0.018). Regarding 
fatal myocardial infarction outcome, the highest observed risk was seen in Model 2 (HR = 
2.6, 95%CI: 1.21-5.44, p = 0.014).  
Kaplan-Meier survival analysis has shown shorter cardiovascular and cerebral 
vascular insult survival for patients with high malondialdehyde levels (Log Rank = 4.41. p 
= 0.036 and Log Rank = 5.21, p = 0.022, respectively) (Figure 33A). Mean cardiovascular 
survival time for patients with MDA concentrations in plasma above the median levels was 
46.7 months (42.5 – 50.9) while the patients with low MDA levels lived averagely 52.1 (49.0 
– 55.2). Mean CVI survival time for patients with MDA concentrations in plasma above 
the median levels was 52.7 months (49.4 – 56.1) while the patients with low MDA levels 
lived averagely 56.8 (54.5 – 59.1). 
Stratified malondialdehyde adducts (MDA adducts median was 39.1 pmol/g) level 
did not show any association with increased risk for overall, cardiovascular, myocardial 
infarction or cerebral vascular insult mortality of patients with end-stage renal disease in 
any of the three Models that were considered in the study. 
 Kaplan-Meier analysis has shown that high MDA adducts levels did not have any 
influence on ESRD patients’ survival (Figure 33B). 
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Table 20. Lipid oxidative stress byproducts, malonidaldehyde and MDA adducts, as 
predictors for overall and cardiovascular mortality as well as death of myocardial infarction 
and cerebral vascular insult among ESRD patients by Cox proportional hazard regression 
models. 
Model 1a Model 2b Model 3c 
HR (95% CI) P value HR (95% CI) P value HR (95% CI) P value 
MDA (med = 2.3 mmol/L) 
Risk for overall mortality  
1.5 (1.00-2.82) 0.049 1.6 (1.05-2.52) 0.029 1.5 (0.97-2.42) 0.068 
Risk for cardiovascular mortality  
1.9 (1.11-3.28) 0.019 2.4 (1.33-4.20) 0.003 2.2 (1.18-3.93) 0.012 
Risk for death from MI  
1.9 (0.96-3.74) 0.064 2.6 (1.21-5.44) 0.014 2.5 (1.11-5.40) 0.026 
Risk for death from CVI  
2.9 (1.20-7.14) 0.018 3.0 (1.21-7.39) 0.018 2.9 (1.18-7.39) 0.021 
MDA adducts (med = 39.1 pmol/ mg) 
Risk for overall mortality 
1.0 (0.63-1.73) 0.871 1.0 (0.60-1.69) 0.970 1.0 (0.60-1.73) 0.931 
Risk for CV mortality 
1.1 (0.58-2.34) 0.631 1.1 (0.56-2.17) 0.771 1.2 (0.60-2.41) 0.609 
Risk for death from MI 
1.4 (0.58-3.49) 0.448 1.4 (0.56-3.49) 0.474 1.5 (0.56-3.75) 0.440 
Risk for death from CVI 
1.1 (0.42-3.11) 0.787 1.1 (0.42-3.14) 0.788 1.3 (0.45-3.60) 0.642 
Abbreviations: CI, Confidence Interval; HR, Hazard Ratio. 
aAdjusted for age and gender. bAdjusted for the covariates in Model 1 plus an additional adjustment 
for smoking status. cAdjusted for the covariates in Model 2 plus an additional adjustment for 
diabetes and cholesterol level 
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Figure 33. Kaplan-Meier survival curves for overall, cardiovascular, CVI and MI survival 
of ESRD patients dichotomized by the median levels of MDA (A) and MDA adducts (B). 
A 
B 
GST Polymorphisms in ESRD Patients  
 
 
83 
 
4.6.3 Prooxidant-antioxidant balance level as a predictor of overall and 
cardiovascular mortality 
 
The Table 21 summarizes the association between prooxidant-antioxidant balance 
and total oxidant status values with different models of overall (all-cause) and 
cardiovascular survival, as well as fatal myocardial infarction and cerebral vascular insult 
outcome.  
Multivariate Cox regression analysis revealed that PAB is a strong predictor of 
hemodialysis patients’ outcome. Namely, patients with PAB levels above the median value 
(148.6 HK units) were at increased risk for fatal all-cause and cardiovascular outcome, 
specifically cerebral vascular insult death. Thus the risk for overall mortality was up to 2.4 
times higher in Model 2, adjusted for age, gender and smoking status (HR = 2.4, 95%CI: 
1.45 - 3.87, p = 0.001). When cardiovascular cause of death was isolated, the mortality risk 
was even slightly higher than for all-cause moratlity (Model 1: HR = 2.5, 95%CI: 1.33 - 
4.59, p = 0.004; Model 2: HR = 2.4, 95%CI: 1.27- 4.52, p = 0.007; Model 3: HR = 2.3, 
95%CI: 1.22-4.41, p = 0.011). High values of PAB (above the median) were strong 
predictors of CVI death as well with the highest risk of 2.6 observed in Model 1 (HR = 2.6, 
95%CI: 1.04 - 6.53, p = 0.04). Regarding MI cause of death, the risk was up to 1.9 times 
higher but without statistical significance (Model 1: HR = 1.9, 95%CI: 0.83 - 4.10, p = 
0.131). Kaplan-Meier survival method based on median levels of PAB has showed that 
patients with high values have shorter cumulative overall, cardiovascular and cerebral 
vascular insult survival (Log Rank = 10.4, p = 0.001; Log Rank = 9.0, p = 0.003; Log Rank 
= 5.4, p = 0.020, respectively)(Figure 34). Mean overal survival time for ESRD patients 
with high PAB values was 37.0 months (32.0 – 42.0) wile for the patients with low PAB 
values it was 48.7 (44.8 – 52.7). Based on the Kaplan-Meier analysis results, ESRD patients 
with PAB above the median levels lived approximately 9 months shorter compared to the 
patient with low PAB values when cardiovascular survival was considered (44.1 (39.2 - 
49.0) and 53.0 (49.6 – 56.4), respectively) and 5 months shorter when cerebral vascular 
insult was observed (51.4 (47.2 – 55.5) and 56.2 (53.4 – 59.0), respectively). 
When patients were stratified based on median values of total oxidant status (20.0 
µmol H2O2 equivalents) results have shown that patients with high TOS values (above the 
median) were not at greater risk for overall or cardiovascular death. The risk was at 
marginal statistical significance for CVI death when Model 1 was considered (HR = 2.3, 
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95%CI = 0.97 - 5.32, p = 0.058). Kaplan-Meier survival analysis has shown shorter CVI 
survival for patients with high levels of TOS but without reaching statistical significance 
(Log Rank = 3.2, p = 0.075) (Figure 34). 
Table 21. The median levels of prooxidant-antioxidant balance (PAB) and total oxidant 
status (TOS) as a predictor for overall and cardiovascular mortality as well as death of 
myocardial infarction and cerebral vascular insult among ESRD patients by Cox 
proportional hazards regression models. 
Model 1a Model 2b Model 3c 
HR (95% CI) P value HR (95% CI) P value HR (95% CI) P value 
PAB (med = 148.6 HK units) 
Risk for overall mortality  
2.2 (1.40-3.53) 0.001 2.4 (1.45-3.87) 0.001 2.3 (1.42-3.83) 0.001 
Risk for cardiovascular mortality  
2.5 (1.33-4.59) 0.004 2.4 (1.27-4.52) 0.007 2.3 (1.22-4.41) 0.011 
Risk for death from MI  
1.9 (0.83-4.11) 0.131 1.7 (0.72-3.83) 0.236 1.6 (0.67-3.74) 0.297 
Risk for death from CVI  
2.6 (1.04-6.53) 0.040 2.5 (0.99-6.47) 0.052 2.5 (0.97-6.36) 0.058 
TOS (med = 20.00 µmol H2O2 equivalents/L) 
Risk for overall mortality 
1.0 (0.67-1.59) 0.884 1.1 (0.70-1.73) 0.687 1.1 (0.66-1.68) 0.819 
Risk for cardiovascular mortality 
1.4 (0.82-2.50) 0.211 1.5 (0.81-2.61) 0.212 1.3 (0.73-2.45) 0.343 
Risk for death from MI 
1.2 (0.58-2.51) 0.611 1.2 (0.54-2.60) 0.676 1.1 (0.48-2.48) 0.829 
Risk for death from CVI 
2.3 (0.97-5.32) 0.058 2.2 (0.93-5.34) 0.070 2.2 (0.90-5.27) 0.086 
Abbreviations: CI, Confidence Interval; HR, Hazard Ratio.aAdjusted for age and gender. bAdjusted 
for the covariates in Model 1 plus an additional adjustment for smoking status. cAdjusted for the 
covariates in Model 2 plus an additional adjustment for diabetes and cholesterol level. 
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Figure 34. Kaplan-Meier survival curves for overall, cardiovascular, CVI and MI survival 
of ESRD patients dichotomized by the median levels of PAB (A) and TOS (B). 
A 
B 
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4.6.4 Soluble ICAM-1 and ICAM-1as potential predictors of all-cause and 
cardiovascular death 
On the Table 22 are summarized results on the predictive role of soluble ICAM-1 
and VCAM-1 concentrations measured in plasma of end-stage renal disease patients on 
overall and cardiovascular death outcome. Levels of cell adhesion molecules were 
dichotomized based on the median values and were 649.6 ng/ml for sVCAM-1 and 90.4 
ng/ml for sICAM-1.  
Multivariate Cox regression method has shown that end-stage renal disease patients 
with high sICAM-1 values had no statistically significant increase in risk for either overall 
or cardiovascular death, as well as for CVI or MI death.  
Kaplan-Meier survival analysis revealed shorter overall survival for patients with 
sICAM-1 values above the median (Log Rank = 4.6, p = 0.032) (Figure 35 A). The ESRD 
patients with high sICAM-1 levels lived approximately seven months shorter in 
comparison with the patients with sICAM-1 concentrations bellow median levels when 
overall survival was considered (41.0 months (34.6 – 47.4) and 48.0 months (42.1 – 53.9), 
respectively). High sICAM-1 levels did not influence cardiovascular survival of ESRD 
patients (Log Rank = 2.821, p = 0.093).  
Regarding the predictive role of sVCAM-1 values, Cox regression analysis has 
shown that the end-stage renal disease patients with sVCAM-1 values above the median 
have increased all-cause mortality risk. Thus sVCAM-1 was a strong predictor of overall 
mortality in the model adjusted for age and gender (Model 1: HR = 1.9, 95%CI: 1.2-3.1, p 
= 0.007). When additional parameters were introduced, such as smoking (for Model 2) and 
cholesterol and diabetes (Model 3), the risk was slightly higher (Model 2: HR = 2.0, 95%CI: 
1.25 - 3.31, p = 0.004 and Model 3: HR = 2.0, 95%CI: 1.22 - 3.26, p = 0.006). Values of 
sVCAM-1 above the median increased the risk of cardiovascular and myocardial infarction 
death in ESRD patients, but without reaching statistical significance (Table 22). The 
sVCAM-1 concentration above the median level showed as a poor predictor of cerebral 
vascular insult death.  
Kaplan-Meier survival analysis curve showed that patients with high sVCAM-1 
level have significantly shorter overall survival (Log Rank = 6.2, p = 0.013) compared to 
the patients with low sVCAM-1 levels (Figure 35 B). Mean overall survival time for ESRD 
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patients with high sVCAM-1 values was 41.3 months (37.2 – 45.3) while for the patients 
with low sVCAM-1 concentration it was 47.5 (42.9 – 52.2).  
Table 22. The median levels of sICAM-1 and sVCAM-1 as a predictor for overall and 
cardiovascular mortality as well as death of myocardial infarction and cerebral vascular 
insult among ESRD patients by Cox proportional hazards regression models. 
Model 1a Model 2b Model 3c 
HR (95% CI) P value HR (95% CI) P value HR (95% CI) P value 
ICAM-1 (med = 90.4 ng/ml) 
Risk for overall mortality  
1.6 (0.78-3.19) 0.209 1.5 (0.68-3.16) 0.323 1.3 (0.53-2.95) 0.601 
Risk for cardiovascular mortality  
1.6 (0.67-3.76) 0.288 1.4 (0.66-5.03) 0.485 1.0 (0.29-2.58) 0.790 
Risk for death from MI  
1.6 (0.50-5.30) 0.420 1.2 (0.61-11.67) 0.786 1.4 (0.58-2.42) 0.304 
Risk for death from CVI  
0.9 (0.23-3.61) 0.888 0.9 (0.20-3.71) 0.835 0.57 (0.11-3.04) 0.508 
VCAM-1 (med = 649.6 ng/ml) 
Risk for overall mortality 
1.9 (1.20-3.05) 0.007 2.0 (1.25-3.31) 0.004 2.0 (1.22-3.26) 0.006 
Risk for cardiovascular mortality 
1.7 (0.92-3.10) 0.089 1.7 (0.91-3.20) 0.093 1.7 (0.91-3.21) 0.097 
Risk for death from MI 
1.9 (0.86-4.23) 0.150 1.8 (0.79-4.19) 0.157 1.8 (0.76-4.09) 0.189 
Risk for death from CVI 
1.3 (0.54-3.17) 0.554 1.3 (0.51-3.18) 0.608 1.3 (0.52-3.29) 0.561 
Abbreviations: CI, Confidence Interval; HR, Hazard Ratio. aAdjusted for age and gender. bAdjusted 
for the covariates in Model 1 plus an additional adjustment for smoking status. cAdjusted for the 
covariates in Model 2 plus an additional adjustment for diabetes and cholesterol level. 
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Figure 35. Kaplan-Meier survival curves for overall, cardiovascular, CVI and MI survival 
of ESRD patients dichotomized by the median levels of ICAM-1 (A) and VCAM-1 (B)
A 
B 
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4.7 Effect of human umbilical vein endothelial cells incubation in uremic serum 
In order to test whether polymorphic expression of GSTM1 gene in human umbilical 
vein endothelial cells (HUVEC) influences their susceptibility to oxidative stress and 
atherogenic potential in terms of monocyte adhesion in uremic milieu, two primary cell 
cultures that differ with respect to GSTM1 were incubated in uremic serum. The HUVECs 
were treated with control serum obtained from healthy volunteers and uremic serum from 
patients on hemodialysis. The 2% FBS and 20% FBS serums were used as a vehicle. 
4.7.1 Viability of endothelial cells after incubation in uremic serum 
Incubation of HUVECs in 20% uremic serum in EGM for 4 hrs did not change 
viability of endothelial cells (Figure 36). Namely, the cell viability was decreased less than 
10% compared to the cells that were exposed to 2% FBS (standard EGM).   
 
Figure 36. Endothelial cell viability assay when exposed to 2% FBS, 20% FBS, 20% 
control serum and 20% uremic serum. 
 
4.7.2 Effect of monocyte adhesion to endothelial cells after incubation in uremic 
serum 
In this study we have expected that endothelial cells with different GSTM1 
genotype will react differently with to monocyte adhesion, when exposed to uremic milieu. 
When endothelial cells are exposed to uremic serum, toxins with pro-oxidant activities 
activate endothelial cells, consequently provoking its dysfunction. These first cellular 
changes on endothelial cells can be detected by monocyte adhesion assay. A small number 
of monocytes adhered to untreated HUVECs, incubated with 2% FBS (standard medium) 
and 20% FBS (Figure 37). 
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Figure 37. Representative Figures from flow cytometry analysis (A) Monocyte adhesion to 
HUVECs incubated in 2% FBS (B) Incubation in 20% FBS (C) Incubation in 20% control 
serum (D) Incubation in uremic serum. M1-marker for endothelial cells M2-marker for 
monocytes. 
Two cell cultures with different GSTM1 genotypes were tested for the difference 
between the relative monocyte adhesions. The HUVEC with GSTM1-active genotype had 
RMA of 21.05 ± 0.99 when incubated in control serum obtained from healthy volunteers. 
When these cells were exposed to 4-hour long incubation in uremic serum, the RMA 
increased up to 60.96 ± 13.50 (∆ 39.91, p < 0.001). On the other hand, GSTM1-null 
HUVECs had RMA of 38.29 ± 9.76 after exposure to control serum. After incubation with 
uremic serum, the relative monocyte adhesion increased up to 71.57 ± 14.20 (∆ 33.28, p < 
0.001). Although the increase of RMA after exposure to uremic toxins was statistical 
significant in both cell cultures, the comparison solely of GSTM1-active HUVEC with 
GSTM1-null HUVEC after 4 hr treatment with 20% uremic serum was not statistically 
significant (∆ 10.61, p = 0.248) (Figure 38).  
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Figure 38. Comparison of monocyte adhesion test in two endothelial cells, one of them 
with GSTM1-active (light grey color) and the other one with GSTM1-null genotype (dark 
grey color). 
 
4.7.3 Reactive oxygen species production in endothelial cells after incubation in 
uremic serum 
In order to test whether GSTM1 gene deletion may influence the reactive oxygen 
species production in uremic cells exposed to 4 hrs incubation in uremic serum, two 
endothelial cell cultures with different GSTM1 genotype were cultivated to passage 4. After 
incubation period, fluorescence of DHE and DHR dyes was measured using flow 
cytometry. A total ROS production in HUVECs with GSTM1-active genotype was +15% 
after incubation in uremic serum in comparison to the endothelial cells incubated in control 
(healthy) serum. When endothelial cells with GSTM1-null genotype were incubated in 
uremic serum, an increase of 20% of total ROS production was observed after uremic 
treatment when compared to the incubation in control serum. Comparison of two 
endothelial cell culture total ROS production after uremic exposure did not differ 
significantly (Figure 39).  
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Figure 39. A total reactive oxygen species (A) and superoxide anion production (B) in 
endothelial cells in terms of GSTM1 genotype after incubation in 20% uremic serum. The 
ROS production in endothelial cells incubated in 20% FBS was determined as 1. 
In the next line, it was tested whether this increase of reactive oxygen species is a 
result of elevated superoxide anion production. The increase of superoxide anion 
production in GSTM1-active endothelial cells was 25% when compared to the control, while 
in GSTM1-null endothelial cell this increase was 45%. Although the endothelial cells with 
homozygous deletion of GSTM1 gene produced more superoxide anion radical after 
uremic serum stimulation, statistical significance between two cell cultures in terms of 
GSTM1 genotype was not observed. 
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5 DISCUSSION 
 
In this doctoral thesis the association between GSTA1, GSTM1, GSTP1 rs1695, 
GSTP1 rs1138272 and GSTT1 gene polymorphism and susceptibility for end-stage renal 
disease was analyzed. Additionally, influence of GST gene polymorphism, both individual 
and combined effect, on oxidative damage byproducts was also tested. A total of eight end-
products of oxidative stress and two cellular adhesion molecules from ESRD patients 
plasma were analyzed in terms of GST genotype. Potential predictive role of GST gene 
polymorphisms, oxidative stress byproducts and soluble CAMs was also assessed. And 
finally, the influence of GSTM1 gene polymorphism on monocyte adhesion to endothelial 
cells and their production of reactive oxygens species was tested in human umbilica ;vein 
endothelial cells. 
In this thesis it was shown that GSTM1-null and GSTP1*C/*T genotype increased 
the susceptibility for end-stage renal disease development when compared to the control 
group of healthy individuals. This effect was even more pronounced if the GST null/low 
activity genotypes were combined. Furthermore, concentrations of protein and lipid 
byproducts of oxidative stress correlate with GST null or low activity genotypes. Additionally, 
GSTM1-null genotype and GSTP1*C/*T were associated with higher levels of soluble 
VCAM-1 in plasma of patients with ESRD, what is shown for the first time. Predictive role 
of GSTM1-null genotype in 5-year overall and cardiovascular death outcome was also 
shown to be significant.  
There is mounting evidence for the presence of elevated oxidative stress in patients 
who undergo maintenance hemodialysis compared to healthy matched controls (Miyata et 
al., 1999; Tarng et al., 2000; Witko-Sarsat et al., 1996) that may contribute to poor 
cardiovascular and global outcome (Locatelli et al., 2003). 
High levels of reactive oxygen species that occur in the course of CKD are 
associated with the disease pathogenesis, its progression and complications (Libetta et al., 
2011; Kao et al., 2010). Based on this premise, it was reasonable to expect that variations in 
detoxifying and antioxidant activities of glutathione transferases modulate individual 
susceptibility towards ESRD development, regardless of its specific cause. Among five 
common GST polymorphisms analyzed in this thesis, only GSTM1-null and GSTP1*C/*T 
genotypes (rs1138272) have shown a significant association with increased ESRD 
susceptibility. The ESRD risk was even more pronounced if any of other three null/ low 
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activity GST genotypes (GSTA1, GSTT1 or GSTP1 rs1695) were combined. The results on 
association between GSTM1-null genotype and increased susceptibility of ESRD 
development are in accordance with several studies performed in Indian population 
(Agrawal et al., 2007; Datta et al., 2010a and 2010b). However, there are several studies 
which results are not in line with GSTM1-null genotype as a risk factor for ESRD 
development, such as the study among Taiwan Chinese (Yang et al., 2004), population of 
Taipei (Lin et al., 2009) and Asian Indians ESRD patients (Tiwari et al., 2009). Regarding 
GSTT1-null genotype, several studies suggested that GSTT1-null genotype increases the 
susceptibility for ESRD development (Datta et al., 2010a; Nomani et al., 2016; Yang et al., 
2004). The role of low activity GSTP1-*Val/*Val polymorphism was addressed in only 
three studies (Agrawal et al., 2007; Nomani et al., 2016; Tiwari et al., 2009), in which it has 
shown conflicting results. In this thesis it was found that individuals with 
GSTP1*Val/*Val genotype are at increased risk (OR = 1.8) although statistical significance 
lacked. On the other hand, GSTP1 rs1138272 polymorphism significantly altered the 
susceptibility to ESRD development. Thus, individuals carrying variant GSTP1 allele were 
at 3-fold increased risk for ESRD when compared to subjects who were homozygous for 
referent allele (OR = 3.2, p < 0.05). So far this polymorphism has been assessed in several 
studies regarding malignant and non-malignant disease development, however with no 
results on its distribution and effects in population of chronic kidney disease patients 
(Ghatak et al., 2016; Qi et al., 2015). Taken together, these conflicting data may suggest the 
existence of ethnic-specific GST genetic susceptibility towards ESRD susceptibility. It is 
noteworthy of mentioning that GSTs genes distribution is also ethnic specific (Garte et al., 
2001; Karaca et al., 2015). To our knowledge, this is the first investigation that addressed 
the susceptibility to ESRD in European Caucasians in association with common GST 
polymorphisms.  
In further course of the thesis it was explored whether combination of GST genes 
additionally influences the ESRD risk. The results suggest that there is an increase of 
ESRD susceptibility when GST genes are combined. These results are in accordance with 
previous studies of Datta et al. and Agrawal et al. who concluded that GSTM1/GSTT1 and 
GSTM1/T1/P1 genotype combinations are increasing ESRD risk in in Northern Indian 
patients although the magnitude of this association was higher when compared to our 
population (Agrawal et al., 2007; Datta et al., 2010a). Variances in susceptibility to end-
stage renal disease development in different populations might not only be the 
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consequence of ethnicicity where significant variety of GSTs distributions is observed, but 
also due to the different etiology of ESRD in various regions. Since ESRD among our 
patients had distinct etiology and could hardly be associated with environmental agents 
metabolized by GST enzymes, except for Balkan endemic nephropathy, weak association 
obtained for GSTM1-null and GSTP1*C/*T genotypes and its absence with other GST 
forms is not unexpected. It is reasonable to assume that GST polymorphic expression may 
be much more important in the course of chronic kidney disease progression, since 
accumulated end products of endogenous and exogenous origin and ROS in these patients 
act as GST substrates (Klemm et al., 2001). This is a situation in which gene interaction 
with disease specific mechanisms influences further course of disease. 
Numerous studies showed significant redox imbalance in patients with end-stage 
renal disease. Various oxidative stress byproducts are measured in order to determine the 
level of oxidative damage in patients on hemodialysis, and eventually, to introduce a proper 
antioxidant therapy. Frequently are measured lipid hydroperoxides (Chao et al., 2002), 
sulfhydryl groups (Himmelfarb et al., 2002), carbonyl groups (Miyata et al., 2001), advanced 
oxidation protein products (Witko-Sarsat et al., 1996) mostly in plasma or serum, but there 
is a broad specter of new potential biomarkers of oxidative damage developing each day. 
Since the GST genes are very important in antioxidant reactions, it was reasonable to 
assume that lack or low activity GST gene variants will contribute to increased susceptibility 
to oxidative and carbonyl stress in ESRD patients. Additionally, taken that oxidative stress 
parameters correlate with cardiovascular complications and mortality, interaction between 
the uremic state and particular GST genotype would represent a potential mechanism 
explaining the inter-individual differences in terms of cardiovascular outcome in these 
patients. 
This was conducted in the next phase of this thesis, in which the influence of 
polymorphic GSTA1, GSTM1, GSTP1 and GSTT1 genes was analyzed with respect to 
oxidative phenotype, as well as to the level of soluble adhesion molecules. A total of eight 
oxidative stress byproducts and two cellular adhesion molecule concentrations were 
measured in plasma of ESRD patients and correlated with GST genotypes. Among 
oxidative stress parameters, the measurement of total oxidant status and prooxidant-
antioxidant balance was also conducted. We found that individual GST polymorphisms 
influence vulnerability to both protein and lipid oxidation, with GSTM1-null gene variant 
having the most pronounced effect. Moreover, ESRD patients with GSTM1-null genotype 
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had increased levels of both sICAM-1 and sVCAM-1 in plasma. Interestingly, GSTP1 
rs1138272 polymorphism correlated only with increased sVCAM-1 levels in plasma of 
these patients. Besides, our results have shown a strong combined effect of null or low 
activity GSTM1, GSTT1, GSTA1 and GSTP1 genotypes in terms of susceptibility towards 
oxidative and carbonyl stress in patients with ESRD. The data concerning genetic 
predisposition to worse oxidative phenotype in patients with ESRD are limited. Lin et al. 
showed that hemodialysis patients with GSTM1-null genotype are more vulnerable to 
oxidative DNA damage when compared to those who possess GSTM1-active genotype (Lin 
et al., 2009). Our results confirmed similar findings presented in patients with benign 
prostate hyperplasia in which combined GSTM1-null/GSTT1-null genotype was associated 
with increased plasma MDA level (Nomani et al., 2016). Results from this thesis are also 
consistent with the results of Tang et al.(Tang et al., 2010), who showed that coronary 
artery disease patients with GSTM1-null/GSTT1-null genotype have lower total antioxidant 
capacity than those with both active genotypes. Besides, several studies have suggested that 
this particular genotype combination was associated with enhanced DNA damage observed 
in cancer patients (Butkiewicz et al., 1999; Kato et al., 1995; McCarty et al., 2009; Rojas et 
al., 2000). In the light of the role that GST enzymes have in detoxification and as 
antioxidant enzymes, results of this and other studies on association between null/low 
activity GSTM1, GSTT1, GSTP1 and GSTA1 genotypes and increased oxidant damage of 
proteins and lipids are biologically plausible. Results regarding GSTM1 gene deletion and 
CAMs association from this thesis are in accordance with the cross-sectional ARIC study 
performed in larger cohort of smokers where the evidence on modulating effect of GSTM1 
polymorphism in terms of inflammation was confirmed (Miller et al., 2003). According to 
the presence of various GST gene variants in combination, ESRD patients may be stratified 
in terms of level of oxidative and carbonyl stress. Since oxidative stress parameters 
correlate with cardiovascular complications and mortality (Bayes, 2005; Descamps-Latscha 
et al., 2005; Köse et al., 2011; Lin et al., 2009), it may be speculated that interaction 
between uremic state and combined GST genotype would represent at least one of 
potential mechanisms explaining inter-individual differences in terms of cardiovascular 
outcome in these patients.  
Oxidative stress in ESRD patients is considered the cornerstone of atherosclerotic 
process. Carotid artery intima-media thickness in chronic hemodialysis patients correlates 
with lipid peroxidation byproducts (Dursun et al., 2008), while serum MDA is strong 
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predictor of prevalent CVD in these patients (Boaz et al., 1999). Besides, the content of 
AOPP independently predicts atherosclerotic cardiovascular (CV) events in non-diabetic 
pre-dialysis patients (Descamps-Latscha et al., 2005). It is important to note that GST 
family members play a dual role in defense mechanisms that counteract complex 
biochemical changes present in uremic state. Namely, all products of analyzed GST genes 
possess both glutathione conjugating and antioxidant enzymatic activity (Hayes and 
Strange, 1995; Simic et al., 2009). However, according to the results presented in this thesis, 
the level of protection against both oxidative and carbonyl stress in uremic syndrome is 
influenced by common GST polymorphisms which determine the quantity and/or activity 
of GST protein ”echelons” that act upon organic hydroperoxides and accumulated harmful 
compounds.  
In this study, we addressed the most relevant classes of oxidative protein and lipid 
damage byproducts encountered in ESRD, as well as, total oxidant status and pro-
oxidant/antioxidant balance in relation to GSTA1, GSTM1, GSTP1 and GSTT1 genotypes.  
The ESRD patients with homozygous deletion of GSTT1 allele or carriers of 
GSTP1-low activity (*Val/*Val) genotype were significantly more susceptible to increased 
level of oxidative damage byproducts, but not as much as GSTM1-null patients. However, 
the effect modification with regard to oxidative phenotype in hemodialysis patients is most 
pronounced if GSTM1- and GSTT1-null as well as low activity GSTA1 and GSTP1 
genotypes are present in combination. Similar result was obtained in few previous studies 
which have shown that the presence of both GSTM1- and GSTT1-null genotypes 
influenced significantly on the level of MDA in the plasma of chronic kidney disease 
patients (Datta et al., 2010b; Nomani et al., 2016). To our best knowledge this is the first 
study that encountered association between common GST polymorphisms and oxidative 
stress byproducts. Taken together these results suggest a possibility for GST genotype 
based stratification of ESRD patients which could improve the attempts towards 
individualization of antioxidant treatment. The suggested therapeutic interventions aimed 
at reducing oxidative stress in hemodialysis patients include biocompatible membranes, 
administration of antioxidants and substances indirectly affecting oxidative stress (Libetta 
et al., 2011). Recently, vitamin E-bonded membranes for hemodialysers have been 
developed, which have a wide spectrum of positive effects on antioxidant status in dialysis 
patients (F. Galli et al., 1999; Kalantar-Zadeh et al., 2006). The results obtained in this 
study suggest that the use of dialysers with vitamin E bonded membranes would be of 
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most benefit for patients with combined GST null or low activity genotypes. According to 
results of this and other investigations, the susceptibility to oxidative stress in hemodialysis 
patients depends at least partly on GST genotype.  
During a five year follow-up death outcomes and cardiovascular complications 
were prospectively registered in order to test predictive role of GST genotype on ESRD 
patients’ outcome. Data obtained in this study have shown that GSTM1-null genotype in 
ESRD patients is a significant independent predictor of overall and cardiovascular 
mortality. Besides, patients with GSTP1-low activity genotype (GSTP1*Val/*Val) exhibited 
an increased risk of cardiovascular mortality, specifically myocardial infarction where it 
reached statistical significance. For general cardiovascular mortality and cerebral vascular 
insult, although the increased hazard ratio was observed, it did not reach statistical 
significance in any of three models tested.  
Several lines of evidence indicate an association between the GSTM1-null genotype 
and faster progression of kidney disease as well as worse outcome of dialysis patients. Very 
recently Chang et al. have shown that GSTM1-null allele influences the course of kidney 
disease progression in participants of the African American Study of Kidney Disease 
(AASK) trial (Chang et al., 2013). Patient groups with and without the common GSTM1-
null allele, differed significantly in the time to a glomerular filtration rate event or dialysis, or 
death. Similarly, Lin at al. (Lin et al., 2009) showed that dialysis patients with the GSTM1-
null genotype exhibit higher mortality rate when compared to those with the active enzyme. 
Our results confirmed these findings regarding the deleterious effect of GSTM1-null 
genotype on overall mortality in ESRD patients. It is interesting to mention that studies 
regarding the role of GST gene polymorphism in cancer risk and prognosis have suggested 
that individuals with referent, or so called active genotype, are at greater risk, but have 
poorer survival rate (Li et al., 2012; Liu et al., 2014).A possible explanation of this is that 
individuals with the GSTs variant genotypes are less able to detoxify the metabolites of 
drugs and carcinogens which make them prone to certain cancers development. It is 
reasonable to assume that these individuals (because of the lack of detoxifying enzymes) 
have therefore better respond to chemotherapeutic drugs, resulting in a survival advantage.  
Furthermore, by the cause-specific analysis of the association between GSTM1 and 
cardiovascular causes of death, such as MI and stroke, we provided a direct proof of the 
role of GSTM1 protein in prevention of oxidative stress related cardiovascular 
complications. Namely, patients lacking GSTM1 protein (GSTM1-null genotype) 
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demonstrated a significantly higher risk of cardiovascular death. When ESRD patients were 
further stratified according to the specific cause of death (MI or stroke), Kaplan Meier 
analysis demonstrated a significantly shorter time to death from both cardiovascular causes 
in patients with GSTM1-null genotype in comparison to those with the active enzyme. The 
independent significant association between GSTM1-null genotype remained in all three 
models tested for overall and cardiovascular survival as shown by Cox regression analysis. 
Risk for CVI death for ESRD patients with GSTM1-null genotype was increased, but 
statistical significance lacked out. To our knowledge this is the first study suggesting a 
significant association between GSTM1-null genotype and the fatal outcome from either 
overall or specific-cause cardiovascular mortality in end-stage renal disease patients. These 
results are biologically plausible given the role of GSTM1 in antioxidant protection and the 
progression of carotid atherosclerosis in pro-oxidant environment. Oxidized lipids are GST 
substrates while GSTM1 directly regulates intracellular levels of lipid peroxidation by 
product 4-hydroxynonenal (4-HNE) in vascular smooth muscle cells. A prospective study 
in Netherlands confirmed an increased progression of atherosclerosis among smokers 
lacking the enzyme GSTM1 (de Waart et al., 2001). Specifically, de Waart et al 
demonstrated that the male smokers with the GSTM1 null genotype had a higher mean 2-
year progression of the common carotid artery intima-media thickness compared to those 
with GSTM1-active (de Waart et al., 2001). In contradiction to other studies is a report from 
Cora et al. who suggested that GSTM1-null genotype may protect against coronary artery 
disease development (Cora et al., 2013). 
The question arises about the association between GSTM1-null genotype and 
cerebral vascular insult being stronger than death from myocardial infarction. Data from 
recent meta-analysis suggested that the individuals with homozygous deletion of GSTM1 
gene is associated with an increased risk of ischemic heart disease (OR=1.38; 95%CI=1.01-
1.87). Although it has been shown that the presence of GSTM1-null genotype was 
associated with hypertriglyceridemia and low HDL-cholesterol levels in healthy humans 
(Danielski et al., 2003; Maciel et al., 2009), it has not been shown directly that the GST 
activity is actually changed during cardiac or coronary vascular disease. However, Noce et 
al have shown that the erythrocyte GST activity displays increased activity in uremic 
diabetic patients and represent potential predictor of disease outcome (Noce et al., 2014, 
2012) 
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Taken together, our data suggest that patients with GSTM1-null genotype are at 
higher risk for all-cause and cardiovascular death in ESRD patients, while those with 
GSTP1-low activity were at increased risk for myocardial infarction. Results from this thessis 
implicate that GSTM1-null genotype could be considered as a potenitail biomarker of 
increased susceptibility towards ESRD development and violated redox balance in these 
patients. This deletional polymorphism may also be useful in targeting the high-risk 
patients for early prevention preventive and eventual intervention in order to reduce their 
cardiovascular risk. However, in order to accomplish that, prospective clinical trials with 
thousands subject included in different CKD stages are required. Further studies will 
provide reliably data of the antioxidant therapy effects in individuals with polymorphic 
GST expression. Data from this thesis suggest that the ESRD patients with GSTM1-null 
genotype could represent potential candidates for antioxidant therapy with the aim of MI 
or CVI prevention. Although there are no clear evidence that antioxidant therapy reduces 
the risk of major cardiovascular events in people with CKD (Coombes and Fassett, 2012; 
Jun et al., 1996)  it may be speculated that some patients with particular genotypes will have 
benefits from such therapy. 
In order to assess the potential predictive role of oxidative stress byproducts, we 
assessed to Cox hazard ration calculations and Kaplan-Meier survival analysis. Patients 
were dichotomized on those with low (below the median) and high values (above the 
median) of the parameter that was considered. The predictive role of each byproduct was 
tested in three Models, each of them being adjusted for specific parameters that have been 
linked to mortality in previous studies (Model 1 for age and gender; Model 2 for age, 
gender and smoking status; Model 3 for age, gender, smoking status, cholesterol levels and 
presence of diabetes). An increasing body of evidence supports a role for oxidative stress in 
the pathogenesis of cardiovascular diseases. As previously mentioned, oxidative stress in 
end-stage renal disease has multifactorial origin and it is considered to be the cornerstone 
of atherosclerotic process. However, its implication in prognosis of chronic renal failure is 
still lacking.  
Due to the relatively lack of extracellular antioxidants, albumins are prone to 
oxidative damage and represent the main source of various protein byproducts (Capeillère-
Blandin et al., 2004). In the plasma of hemodialysis patients the level of advanced oxidation 
protein products has been observed and described as one of the mediators of oxidative 
stress and monocyte respiratory burst (Witko-Sarsat et al., 1998, 1996). The AOPPs 
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represent dityrosine-containing, crosslinked protein products that are produced in the 
reaction of plasma proteins with chlorinated oxidants, originating from neutrophils that 
possess myeloperoxidase, the only enzyme that is able to generate a chlorinated oxidant 
(Witko-Sarsat et al., 1998). Its levels are increased in both acute and chronic renal failure, as 
well as in kidney injury (Lentini et al., 2010). Although the AOPP accumulation represents 
not only a result of redox imbalance in ESRD patients, but also a significant contributor to 
many cellular and molecular processes, (Guo et al., 2008; Wei et al., 2009; Zhou et al., 
2009), the studies describing its prognostic relevance are rare. A study by Kaneda et al. has 
shown that accumulation of AOPP has been associated with ischemic cardiovascular 
disease development and that increased levels of AOPP may present independent 
predictors of cardiovascular disease in patients with chronic kidney disease (Kaneda et al., 
2002). In this thesis AOPP levels above the median (64.29 µmol /L) were significant 
predictors of cardiovascular mortality in ESRD patients. Their prognostic significance 
remained even after additional adjustment for covariates relevant for cardiovascular disease 
development. Risk for myocardial infarction death was also increased in patients with high 
AOPP levels in Model 1 and 2, but lost on significance in Model 3. No association between 
AOPP levels and the risk of CV was observed in this cohort of ESRD patients. Based on 
our knowledge, this is the first study that describes potential prognostic relevance of 
AOPP. A relatively recent study by Zhou et al. suggested that accumulation of AOPP in 
hemodialysis patients was independently associated with ischemic heart disease 
development (Zhou et al., 2012), but the authors did not consider lethal outcome. It seems 
that AOPP levels are even increased in patients with normal renal function and may 
indicate early atherosclerosis even in relatively healthy population (Ashfaq et al., 2006). 
During oxidative stress, polyunsaturated fatty acids (PUFA) are very prone to 
reactive oxygen species attack. When oxidatively modified, PUFA form lipid 
hydroperoxides which rapidly decompose to secondary products. Malondialdehyde is one 
of the products which serves as a reliable marker of lipid peroxidation and has been 
associated with broad specter of chronic and malignant diseases (Bakan et al., 2002; 
Dierckx et al., 2003; Kolanjiappan et al., 2002; Polidori et al., 2002). Its prognostic 
relevance, however, has not been widely studied, especially in patients on hemodialysis. So 
far it has been shown that MDA levels measured in red blood cells correlate with severity 
of hypertension and that its level is increased in acute myocardial infarction (REF). The 
levels of MDA in plasma are also increased in patients with coronary artery disease 
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(Sakuma et al., 1997). A PREVENT study that comprised a cohort of more than 600 
patients revealed that serum levels of MDA were strongly predictive of cardiovascular 
events in patients with stable coronary artery disease, independently of traditional risk 
factors and inflammatory markers (Walter et al., 2004). In this thesis it was shown a 
possible predictive role of increased MDA concentration (above 2.3 µmol/L) in plasma of 
ESRD patients. Thus overall and cardiovascular death outcome risk was significantly 
increased in patients with extensive lipid peroxidation. Additionally, fatal cerebral vascular 
insult and myocardial infarction were also associated with high MDA levels, where the risk 
was almost tripled in comparison with the patients whose concentration of MDA was 
bellow median level. This result is not in accordance with Terrier-Lenglet et al who did not 
find any association between plasma levels of MDA and overall/cardiovascular mortality in 
patients with CKD (Terrier-Lenglet et al., 2011). However, in a study where oxidative 
modifications of lipids associated with LDL (MDA-LDL) were tested for possible 
cardiovascular predictive value, a significant correlation between increased MDA-LDL 
levels and cardiac events was found (Kotani et al., 2015). Besides binding to lipoproteins, 
MDA is able to generate cross-links with DNA molecule and proteins (Del Rio et al., 
2005). When reacting with lysine on proteins, a stable lipid peroxidation protein adducts are 
formed, so called MDA adducts, which are found in atherogenic lesions (Fu et al., 1998; 
Heinecke, 1998; Holvoet et al., 1995; Stocker and Keaney, 2004). The MDA adducts are 
highly immunogenic and pro-inflammatory and represent a great threat to endothelial cells 
since they are a part of pathological processes involved in formation of atherosclerotic 
plaque (Matsuura and Lopez, 2008). We hypothesized that MDA-adducts measured in 
plasma of ESRD patients could have prognostic value. However, the results from this 
thesis have shown no association of increased MDA values with overall or cardiovascular 
mortality.  
It is important to note that malondialdehyde in biological samples is measured as 
thiobarbituric acid reactive substances, a method that is very unspecific to MDA and 
compromises its exact determination (Knight et al., 1988). This problem is overcome with 
several modern techniques for MDA determination, with HPLC being accepted as the 
most common and relevant one. In this study, however, we have used 
spectrophotometrical method, which due to the lack of specificity and sensitivity, may 
overestimate actual MDA values and therefore this might be considered as limitation in the 
study.  
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Besides determining single oxidative stress byproducts, a prognostic value of 
prooxidant-oxidant status and total oxidant status was also tested. The PAB assay 
simultaneously measures prooxidants and antioxidants in the sample, determining the 
balance that exists between them. Previous studies have shown that PAB levels are 
increased in patients with coronary artery disease when compared to healthy controls, 
although the statistical significance was not observed (Rahsepar et al., 2011). Similarly, PAB 
values are increased in patients 12h after suffered myocardial infarction indicating its 
possible role in prognosis of cardiovascular disease, although data on this issue are very 
limited in the literature (Ghayour-Mobarhan et al., 2009). In this thesis it is reported that 
patients with PAB values above the median levels (148.6 HK units) were at increased risk 
of all-cause and cardiovascular mortality. It was not observed that increased PAB values 
may serve in the prognosis of acute myocardial infarction. In case of cerebral vascular 
insult, a possible predictive role of higher PAB levels is noted, although the statistical 
significance was seen only in Model 1, adjusted for age and gender only. Earlier study in 
stroke patients, however, was not able to confirm its 6-months predictive value (Parizadeh 
et al., 2011).  
Soluble ICAM-1 and VCAM-1 measured in serum of patients, have been 
considered markers of endothelial activation (Nakai et al., 1995) and represent an early 
manifestation of atherosclerothic processes (Cybulsky and Gimbrone, 1991). They 
represent mediators of leucocyte adhesion and migration in the process of ischemic 
cardiovascular disease development (Blann et al., 1996). Although the prognostic value of 
inflammation in dialysis patients has been investigated extensively, their prognostic value 
has still been contradictory and various studies have yielded different conclusion. Dong et 
al have shown that sICAM-1, but not sVCAM-1, predicts mortality in peritoneal dialysis 
patients (Dong et al., 2014). Indeed, patients with cardiovascular diseases have significantly 
increased serum sICAM-1 levels compared to patients with no evidence of CVD 
(Papayianni et al., 2002) and may serve as predictors of CVD mortality in hemodialysis 
patients (Papagianni et al., 2003). Partially in contrast with the above mentioned results, in 
this thesis has been shown that the ESRD patients with the sICAM-1 levels above the 
median (90.4 ng / ml) were not at increased risk for neither all-cause nor cardiovascular 
mortality in any of the observed Models. On the other hand, the results of this thesis 
suggest that sVCAM-1 could be a potential predictor of overall mortality. Namely, the risk 
of overall death outcome was doubled in all of the three models used in this study with 
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high statistical significance. Although the risk of cardiovascular mortality was increased in 
ESRD patients with high levels of sVCAM-1, statistical significance lacked. No association 
between sVCAM-1 levels and myocardial or cerebral vascular insult cause of death was 
observed. A study performed by de Caterina et all has shown that VCAM-1 correlates with 
atherosclerothic processes and may serve as a potential in vivo biomarker of endothelial 
dysfunction (De Caterina et al., 1997). Thus the aortic expression of VCAM-1 correlates 
with cardiovascular risk factors (Mu et al., 2015). The result from this thesis is in 
accordance with the study performed by Papagianni et al who showed that that patients 
with higher sVCAM-1 levels had higher 5-year all-cause and CVD mortality (Papagianni et 
al., 2008). However, there are more studies indicating no association between this CAM 
and higher mortality in CKD patients (Dong et al., 2014; Tripepi et al., 2005; Wang et al., 
2005). This apparent result’s discrepancy between different studies is probably based on 
differences in study population (chronic renal failure versus hemodialysis patients or 
peritoneal dialysis) and on differences in covariates used in statistical modelling. Although 
the expression of both ICAM-1 and VCAM-1 is upregulated in atherosclerotic lesions, it 
seems that VCAM-1 has a more important role in the development of atherosclerosis 
(Cybulsky et al., 2001). Still, it remains unclear why sVCAM-1 values are better predictor 
than sICAM-1 of cardiovascular death outcome in hemodialysis patients and further 
studies should elucidate this problem.  
This study was performed in a relatively large cohort of ESRD patients with a long-
term follow-up period and was adjusted for multiple confounding factors that influence 
cardiovascular disease development. The consistency in hemodialysis treatment of our 
ESRD patients was also favored and represents an advantage in the study. 
In order to test whether polymorphic expression of GSTM1 gene in human 
umbilical vein endothelial cells (HUVEC) influences their susceptibility to oxidative stress 
and atherogenic potential in terms of monocyte adhesion in uremic milieu, two primary cell 
cultures that differ with respect to GSTM1 were incubated in uremic serum.  
One of the main steps in early steps of atherogenesis represents adhesion of 
monocyte to the endothelium of arterial vessels. Monocyte adhesion promotes the 
remodeling of endothelial cell membrane into specific features that serve as docking sites 
for leucocyte transmigration and are further implicated in endothelial dysfunction (Hordijk, 
2006; Wittchen, 2009). The link between uremic toxins and endothelial dysfunction and 
cardiovascular disease development in end stage renal disease has been well established 
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during last several years. There is a growing body of studies trying to elucidate specific 
mechanism and particular factors contributing to the endothelial activation and dysfunction 
in uremic patients. In this thesis it was firstly shown that GSTM1-null genotype is associated 
with increased susceptibility towards ESRD and redox imbalance in these patients. In 
addition, this genotype was associated with increased plasma levels of soluble VCAM-1, 
protein which overexpression occurs within atherogenesis. In later course, it was revealed 
that patients with homozygous deletion of GSTM1 gene are at increased risk of fatal overall 
and cardiovascular outcome. In the last stage of thesis it was reasonable to assume that we 
will be able to confirm this association on cellular level. Two human umbilical vein 
endothelial cell cultures, one with GSTM1-active and the other with GSTM1-null genotype, 
were incubated for 4 hours in uremic serum obtained from patients on regular 
hemodialysis. Both GSTM1-active and GSTM1-null genotype HUVECs have shown 
increased relative monocyte adhesion to endothelial cells. However, in the present 
experimental conditions we did not succeed to observe the GSTM1 gene deletion effect on 
monocyte adhesion to endothelial cells (p = 0.248). It is interesting dough that HUVEC 
with GSTM1-null genotype when exposed to healthy serum incubation had higher 
monocyte adhesion when compared to endothelial cells with GSTM1-active genotype. In 
this study it was shown that GSTM1-null endothelial cells did not have increased reactive 
oxygen species production.  
To our knowledge this is the first study where association between GSTM1 gene 
deletion and endothelial dysfunction has been tested. In the view of the fact that oxidative 
stress byproducts correlate with the cardiovascular complications and mortality, it may be 
speculated that interaction between uremic state (with all its accompanying phenomena) 
and particular GST genotype would represent at least one of potential mechanisms that 
would explain inter-individual differences in terms of cardiovascular outcome in these 
patients. 
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6 CONCLUSIONS 
 
Based on the results and discussion presented in this thesis it may be concluded: 
 The distribution of glutathione transferases A1, M1, P1 and T1 gene variants differs 
between patients with end-stage renal disease and control group.  
 Individuals with GSTM1-null confer 1.6 times higher risk of ESRD 
development in comparison to GSTM1-active subjects 
 Carriers of GSTP1*C/*T genotype have higher risk of ESRD development.  
 GSTA1, GSTM1, GSTP1 and GSTT1 polymorphisms are associated with increased 
levels of oxidative stress byproducts and the level of cellular adhesion molecules levels. 
 Regarding individual polymorphisms, most pronounced association between 
genotype and byproducts of oxidative stress in ESRD was found for GSTM1 
null. The presence of GSTT1-null or GSTP1-low-activity (Val/Val and Ile/Val) 
genotypes in ESRD patients also significantly influences the level of oxidative 
damage byproducts, but not as much as GSTM1-null.  
 Strong combined effect of null/low activity GSTA1, GSTM1, GSTP1 and GSTT1 
genotypes in terms of susceptibility towards oxidative and carbonyl stress was 
found in ESRD paients.  
 GSTM1-null genotype in ESRD patients was associated with increased level of 
soluble ICAM-1 and VCAM-1, while the GSTP1*C/*T genotype influenced the 
concentration of soluble VCAM-1 in plasma of these patients 
 GST polymorphisms, oxidative stress byproducts and cellular adhesion molecules levels 
influence 5-year overall and cardiovascular survival 
 GSTM1-null genotype has been confirmed as the risk factor for overall (HR = 
1.8) and cardiovascular death (HR = 2.4), as well as myocardial infarction death 
(HR = 2.3) in ESRD patients  
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 Malondialdehyde concentration above median level in plasma of ESRD patients 
were prognostic in terms of overall (HR = 1.6) and cardiovascular mortality 
(HR = 2.4), as well as for fatal cerebral vascular insult outcome (HR = 3.0)  
 Advanced oxidation protein products are also significant predictors of 
cardiovascular (HR = 2.4) and myocardial infarction mortality (HR = 3.3) 
 Prooxidant-antioxidant balance above median level in plasma of ESRD patients 
were prognostic in terms of overall (HR = 2.4) and cardiovascular mortality 
(HR = 2.5), as well as for fatal cerebral vascular insult outcome (HR = 2.6)   
 Soluble vascular cell adhesion molecule 1 in plasma of patients with ESRD are 
associated with overall mortality (HR = 2.0).  
 These genetic markers may permit the targeting of preventive and early 
intervention on high-risk patients to reduce their cardiovascular risk. 
 In vitro incubation of human umbilical vein endothelial cells in uremic serum resulted 
in increased monocyte adhesion to these cells and elevated production of free radicals. 
This response was not influenced by GSTM1 genotype  
 
 Taken together, the results presented in this study suggest a possibility for GST 
genotype-based stratification of ESRD patients which could improve the attempts 
towards individualization of antioxidant treatment. Besides, determination of oxidative 
stress byproducts may permit the targeting of preventive and early intervention in high-
risk patients to reduce their cardiovascular risk. 
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